

In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register.

The following guiding principles have been applied to the disclosure:

- Information will be excluded in order to protect the privacy of patients and all named persons associated with the study*
- Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the **GSK Clinical Study Register**.*

- Aggregate data will be included; with any direct reference to individual patients excluded*
- *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered*

The GlaxoSmithKline group of companies

Division: Worldwide Development**Retention Category:** GRS019**Information Type:** Worldwide Epidemiology Study Report**Control:** No Treatment

Title:	Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™ Study Report
---------------	--

Phase: IV**Compound Number:** GW582892**Effective Date:** 28-MAY-2013**Subject:** Physician and pharmacist survey of the understanding of the risk of urinary retention with POTIGA, Risk Evaluation and Mitigation Strategy (REMS)**Author(s):** [REDACTED] (GlaxoSmithKline); [REDACTED]
(Concentrics Research)**Indication Studied:**

Initiation Date: 25 Feb 2013

Completion Date: 10 Apr 2013

Early Termination Date: NA

Date of Report: 24 May 2013

Earlier CSRs: NA

Sponsor Signatory: [REDACTED], MD
Safety Physician
GlaxoSmithKline

This study was performed in compliance with Good Clinical Practices and GlaxoSmithKline Standard Operating Procedures for all processes involved, including the archiving of essential documents.

Copyright 2013 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited.

Table of Contents

	Page
TITLE PAGE	1
ABBREVIATIONS.....	3
ETHICS AND GOOD CLINICAL PRACTICE.....	4
1. INTRODUCTION	5
2. STUDY OBJECTIVES	6
3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE.....	6
4. INVESTIGATIONAL PLAN	6
4.1. Study Design	6
4.2. Discussion of Study Design	7
4.3. Selection of Study Population	8
4.3.1. Inclusion/Exclusion Criteria	8
4.3.2. Withdrawal Criteria	8
4.4. Study Assessments and Procedures.....	9
4.4.1. Administration of Survey.....	9
4.4.2. Data Collected at Screening.....	9
4.4.3. Data Collected During the Survey	9
4.4.4. Safety Assessments.....	10
4.5. Data Quality Assurance	10
4.6. Statistical Analyses.....	10
5. STUDY POPULATION RESULTS	11
5.1. Subject Disposition	11
5.2. Protocol Deviations.....	12
5.3. Protocol Amendments	12
5.4. Demographics and Baseline Characteristics	12
5.4.1. Physician Practice History	13
5.4.2. Pharmacist Practice History	13
6. SURVEY RESULTS	15
6.1. Organization of Results	15
6.2. Healthcare Providers Understanding of Risks Associated with POTIGA.....	15
6.3. Healthcare Provider Profiling Questions	22
6.4. Adverse Event Reporting.....	28
7. DISCUSSION AND CONCLUSIONS.....	28
7.1. Discussion	28
7.1.1. Healthcare Provider Demographics.....	28
7.1.2. Healthcare Providers' Understanding of Risks of POTIGA.....	28
7.2. Conclusions	31
8. REFERENCES	33
9. POST-TEXT TABLES AND FIGURES	34

ABBREVIATIONS

AE	Adverse Event
AED	Anti-Epileptic Drug
CCA	Confidentiality & Consent Agreement
DEA	Drug Enforcement Administration
DHCP	Dear Healthcare Provider (Letter)
FDA	Food and Drug Administration
GSK	GlaxoSmithKline
HCPs	Healthcare Providers
IC	Informed Consent
IRB	Institutional Review Board
REMS	Risk Evaluation and Mitigation Strategy
US	United States

Trademark Information

Trademarks of the GlaxoSmithKline group of companies
LAMICTAL
LAMICTAL ODT
LAMICTAL XR
POTIGA
TREXIMET

Trademarks not owned by the GlaxoSmithKline group of companies
None

ETHICS AND GOOD CLINICAL PRACTICE

Physician agreement to participate was obtained for each physician by electronically signing a Confidentiality & Consent Agreement (CCA) prior to the survey.

Privacy issues were addressed and respected at each stage of the study. Physician data from the screening and survey responses were stored confidentially in password protected systems maintained by Concentrics Research.

In all cases, subject identifiers were not collected or transmitted to GSK according to GSK policy. All physicians were given a numeric subject identifier.

1. INTRODUCTION

GlaxoSmithKline (GSK) conducted a survey to inform healthcare professionals' of the risk of urinary retention and the symptoms of acute urinary retention in patients taking POTIGA. POTIGA was approved with a FDA requirement for a Risk Evaluation and Mitigation Strategy (REMS). The REMS was comprised of a communication plan for healthcare professionals that was designed to disseminate information about the risk of urinary retention with POTIGA and highlight this potential risk and the need to inform patients to seek immediate medical attention for symptoms of urinary retention, inability to urinate, and/or pain with urination.

There were two elements of the communication plan: (1) A Dear Healthcare Professional (DHCP) Letter designed to disseminate information about the risk of urinary retention with POTIGA; letters were disseminated within 4 weeks of first retail availability (actual – May 7, 2012) and annually for the next two years (2) a REMS Program Website (available at time of launch; actual -April 16, 2012).

The target audience for these communications was: (1) Prescribing physicians i.e., Epileptologists, Neurologists and Neurosurgeons, (2) Pharmacists dispensing POTIGA tablets and the Medication Guide.

As a condition of approval, FDA required that GlaxoSmithKline (GSK) assess the effectiveness of the communication plan. Accordingly, a survey was conducted among a sample of prescribing physicians to evaluate whether they could recall the risk of urinary retention with POTIGA. In addition, the survey evaluated where HCPs prefer to seek information for POTIGA, for example Dear HCP letters, website, or product labeling. The survey concentrated on the risks described in the DHCP letter for POTIGA, though it was recognized that the DHCP letter was not the only source of information concerning risks associated with medication use. The design for this study was based on previous experience of risk management programs for GSK products.

A survey was also conducted among a sample of pharmacists to evaluate whether they can recall the risk of urinary retention with POTIGA.

Although the Marketing Application was approved June 10, 2011, initial retail availability did not commence until after the Drug Enforcement Administration (DEA) had completed rule making placing POTIGA into Schedule V under of the Controlled Substances Act. The drug did not become available to patients until early May 2012 (first distribution to wholesalers April 19, 2012). FDA has agreed that with such delayed retail availability of POTIGA, an assessment of HCP understanding submitted on June 10, 2012 would provide little meaningful information. Therefore, the first assessment of the REMS survey will be included with the report due on June 10, 2013.

Originally, ER physicians and urologists were planned to be included in the survey as well. Given the survey targeted prescribers only, ER physicians and urologists were no longer targeted in the survey per FDA feedback received on January 25, 2013.

2. STUDY OBJECTIVES

The objectives of this survey were to assess prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA as evaluated by a survey instrument.

3. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

This study, sponsored by GSK, was conducted with one dedicated market research center. Concentrics Research was responsible for oversight of the site and to conduct data management and analysis. Site oversight also included a 100% quality check of the web survey programming prior to live implementation.

4. INVESTIGATIONAL PLAN

4.1. Study Design

This was a cross-sectional, non-interventional observational survey of individuals who prescribe POTIGA or dispense AEDs. The study was limited to a survey of physicians and pharmacists and did not include any treatment intervention.

This cross-sectional study assessed prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA as evaluated by a survey instrument.

Table 1 Events Table

Procedures	Telephone, Email or Fax Screening	Survey
Inclusion/Exclusion Criteria	X	
Physician specialty	X	
Medications prescribed to treat epilepsy (past 12 months) (Physicians)	X	
Dispensed an AED medication within past 3 months (Pharmacists)	X	
Demography (Age, gender, clinical specialty, years of clinical practice, etc.)	X	
Confidentiality & Consent Agreement (CCA)		X
Understanding Evaluation of Key Safety Messages		X
POTIGA Prescribing and Dispensing History		X
Additional Practice Characteristics not captured at Screening		X

A listing of physicians eligible to complete the survey was compiled at one research center, utilizing a custom database of approximately 500,000 geographically and therapeutically diverse physicians and over 168,000 pharmacists from all 50 states.

Pharmacists and physicians in the targeted specialties were contacted initially via multiple methods, including, telephone, e-mail, and/or fax, with an invitation to participate in the study. Interested physicians were asked to contact the market research center staff on the study, who then completed a telephone screening process to determine if the physician met all of the study protocol-defined eligibility criteria and, to confirm their interest in participating in the survey if they did meet the eligibility criteria. Eligible physicians who agreed to participate were scheduled for either an appointment with an interviewer to complete the survey via telephone or were provided an email containing a link to an on-line survey for completion along with their unique access passcode.

A total of three hundred and seventy-three (n=373) prescribing physicians and pharmacists participated in the survey on the understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA.

4.2. Discussion of Study Design

Cohort	Description	Number of Subjects
1	Prescribing Physicians (Neurologists, Neurosurgeons, Epileptologists) who have prescribed POTIGA within the past 12 months	168
2	Pharmacists who have dispensed an AED within the previous three months	205

The final study design was based on experience from risk management studies previously completed by GSK. Therefore, this study was a cross-sectional, non-interventional observational survey of individuals who prescribe POTIGA or dispense AEDs did not include any treatment intervention.

Prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA was assessed using the survey instrument.

Prior to start of the survey, physicians and pharmacists were asked to sign a Confidentiality & Consent Agreement, which described the purpose of the study, data handling, storage and security, expectations of confidentiality of study data and participation, honoraria for study participation, and rights as a survey subject. The individual completing the survey was required to confirm that he/she was the same individual who was screened previously to help safeguard against delegation of participation to other colleagues or staffs in the physician's office or pharmacy. The design of the survey instrument included closed-ended questions, including True/False and multiple choice questions.

4.3. Selection of Study Population

Using the database described previously, physicians and pharmacists were recruited from a demographically representative population who prescribe POTIGA (neurologists, neurosurgeons, epileptologists), and dispense POTIGA (pharmacists).

4.3.1. Inclusion/Exclusion Criteria

Recruiters used the approved screener questions and qualified physicians and pharmacists if they met the following inclusion and exclusion criteria:

Inclusion criteria

1. Prescribing physicians and pharmacists:
 - a. Practicing physician or pharmacist who sees and treats, or fills prescriptions for, patients with epilepsy, currently (within the past 12 months).
 - b. Prescribed POTIGA within the past 12 months (prescribing physicians)
 - c. Filled a prescription for at least one AED within the previous three months (pharmacists).
2. Able to read, speak, and understand English.
3. Willing to take the online survey or have the survey administered via a telephone interview, including electronically signing a Confidentiality & Consent agreement and completing all study protocol-specified procedures.

Exclusion criteria

1. The physician or pharmacist was currently employed by, or was a representative of any of the following:
 - a. A pharmaceutical company or manufacturer of medicines or healthcare products.
 - b. Contributor/editor to published guideline committees for epilepsy or UR.
2. The physician or pharmacist has a visual impairment that would prevent him or her from being able to read independently.
3. The physician or pharmacist participated in the Pilot REMS study for POTIGA.
4. The physician or pharmacist was an employee of GSK or Concentrics Research.

4.3.2. Withdrawal Criteria

Physicians and pharmacists could withdraw from the study at any time during the interview or survey.

4.4. Study Assessments and Procedures

4.4.1. Administration of Survey

The survey proceeded in several parts. There were 30 closed-end questions included in the POTIGA survey. Questions were as follows:

- Understanding Evaluation of Key Safety Messages of POTIGA based on the US Prescribing Information & Practices
- Demographics and Practice/Prescribing History of each Physician
- Demographics and Dispensing History of each Pharmacist
- Personal experience, Awareness, Receipt and Dissemination of information about POTIGA

4.4.2. Data Collected at Screening

The following items were recorded in the screening questionnaire:

- Inclusion/Exclusion criteria
- Demographics: Gender, race, ethnic origin, age
- Interest in study participation

4.4.3. Data Collected During the Survey

The following baseline assessments were recorded in the study questionnaire:

- Awareness of information about POTIGA: General awareness of sources for POTIGA information, and preference of resources to learn about the risks associated with POTIGA in the future.
- Physician Demographics: Years of clinical practice, size of practice (total and epilepsy patient population), age range of current patient population, how long prescribing AEDs, how many months prescribing POTIGA, within a month, how many POTIGA (including new prescriptions and refills) prescriptions written in the past 12 months, how many patients have been prescribed POTIGA within the past 12 months.
- Pharmacist Demographics: Years as practicing pharmacist, number of years dispensing/answering questions on AEDs, have dispensed POTIGA within the past 12 months, have answered patient questions related to POTIGA within the past 12 months, how many months dispensing POTIGA, number of patients have dispensed POTIGA to within the past 12 months, within a month, number of prescription for AEDs (including new prescription and refills) have been filled within the past 12 months.

4.4.4. Safety Assessments

This survey did not investigate adverse events associated with the use of POTIGA. If during a phone survey the physician described an adverse event experienced personally or experienced by a patient, that was purported to be associated with the use of the aforementioned medicines or any other GSK product to the survey administrator, the survey administrator was instructed to complete an adverse event reporting form and submit the completed form via fax to GSK Global Clinical Safety and Pharmacovigilance at [REDACTED] within 24 hours of receiving the information. No adverse events were reported during the course of the survey.

4.5. Data Quality Assurance

The physician screening information was captured on paper and then data entered into an online form. The online survey captured all physician questionnaire responses. Physicians responded directly via the web survey, and telephone interviews were conducted so that interviewers read the questionnaire text from the web survey and directly entered the physician's responses into the online forms. This way, all data were captured in one location. All screening information, demographic data, and questionnaire response data was exported from the online survey database into SPSS using a pre-defined protocol for exporting survey data. Data were aggregated and tabulated into summary tables in SPSS. All data were stored confidentially in the appropriate validated systems maintained by Concentrics Research.

In all cases, physician identifiers were not collected or transmitted to GSK according to GSK policy. Physicians were given a numeric subject ID.

4.6. Statistical Analyses

Baseline assessments including demographics and geographic location, HCP speciality and prescribing/dispensing history of POTIGA and other AEDs were summarized using descriptive statistics for continuous data and proportions (%) for categorical data.

The primary outcome in the study was the proportion (%) of HCPs answering each question of understanding of the risks associated with POTIGA correctly. Point estimates for the proportion with correct responses, and associated 95% confidence intervals, were calculated for each question about the awareness of risks of POTIGA. In the case of multiple choice questions, the number and proportion of subjects reporting each response were also provided.

GSK considers a proportion (%) of correct responses of at least 80% for each individual question to represent sufficient subject understanding of the risks associated with POTIGA. This is based on previous studies by GSK including the risk management program for LAMICTAL and TREXIMET. This threshold was imposed for prescribers and pharmacists. Prescribers and pharmacists were the HCPs who play an important role in re-enforcing the safety messages for POTIGA.

The proportion of correct answers to survey questions was summarized overall and by demographic subgroups within the tabulated data. Although the sample size in some subgroups may be relatively small and have low precision, data was grouped into 2-3 sub-categories as appropriate to identify potential trends in subject understanding including:

- Demographics (geographic location)
- Type of HCP
- POTIGA prescribing/dispensing (yes or no, months prescribing POTIGA)
- Other practice/prescribing characteristics (years in practice, years prescribing AEDs, size of patient population)


This study was descriptive; hence no formal statistical testing was completed.

5. STUDY POPULATION RESULTS

5.1. Subject Disposition

A total number of 1028 healthcare providers were screened in the study in order to achieve 373 completed surveys as presented in [Figure 1](#).

Figure 1 Summary of Screening - Total Population



* One physician was removed from the study due to inconsistencies between indicated primary specialty on screener and questionnaire.

**The most common reason for termination of physicians at time of screening was not prescribing Potiga, therefore, recruitment was suspended by GSK.

Over a thousand physicians and pharmacists (n=1,028) responded to the recruitment information and were screened for the study. The most common reason for not meeting the inclusion criteria was that physicians did not prescribe POTIGA (n=587).

Physicians and pharmacists were recruited into the study without strict quotas across demographic characteristics.

5.2. Protocol Deviations

There were no protocol deviations during the course of this study.

5.3. Protocol Amendments

Throughout the course of the study, two protocol amendments were made and documented within the final protocol (see Modular Appendix)

- Amendment 01 – The survey will focus on POTIGA prescribers and pharmacists only:
 - The screener was amended after the study began to ask physicians a subset of epilepsy drugs at Q7 instead of the full list previously included. This subset still allowed for masking of the drug to be studied (POTIGA), but shortened the burden on the physician to respond to the full listing during recruitment. This revision was made based on qualitative feedback during recruitment where physicians were not continuing with screening due to frustration with the length of this question. After reviewing data gathered to date, the most common responses to the drugs prescribed were included in the remaining listing, along with POTIGA.
- Amendment 02- Honoraria has been increased for POTIGA prescribers:
 - For prescribing physicians, the honorarium for completing the survey was \$125. The honorarium for the prescribing physicians was increased from \$100 to \$125 after the start of the study, due to recruitment being significantly lower than expected.

5.4. Demographics and Baseline Characteristics

Physician and pharmacist demographic and baseline characteristics are presented in [Table 2](#).

Physicians stated their primary specialty was in Neurology (64%, n=108) or Epileptology (36%, n=60). Pharmacists stated their primary specialty was in Community/Retail (55%, n=113), and Hospital/Clinic (45%, n=92).

Table 2 Summary of Demographic Characteristics

Demographics	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Primary Specialty		
Neurology	108 (64.3)	--
Neurosurgery	--	--
Epileptology	60 (35.7)	--
Pharmacy (Community/Retail)	--	113 (55.1)
Pharmacy (Hospital/Clinical)	-	92 (44.9)

Columns may not sum to 100% due to rounding.

(--) Indicates a percentage that does not round to 1 or is zero.

** This question was asked at screening and a second primary specialty question was asked after agreement to participate that resulted in slightly different answers. While this data is reported as it relates to screening, the final assessment of specialty is based off the questionnaire data.*

5.4.1. Physician Practice History

A summary of prescribing physician practice history is presented in [Table 3](#). The largest practice history grouping of physicians surveyed was the category of practicing medicine for 5 to 15 years (41%, n=69) followed by those physicians that have been practicing for more than 16 to 25 years (36%, n=61). Approximately 43% (n=72) had prescribed AEDs for 5 to 15 years (as reflected in the table below), and most (33%, n=55) reported having prescribed POTIGA within the past 3 months. Fifty-two percent (52%, n=87) of physicians have prescribed POTIGA for only 1-2 patients in the past 12 months; however, over the past year, 60% (n=101) of physicians reported they have written more than 50 prescriptions for AEDs per month on average. Prescribing physicians treat patient populations across all age ranges, and most reported a patient population size of over 1,000 patients, with an epilepsy patient population size of more than 100 patients.

5.4.2. Pharmacist Practice History

The largest practice history grouping of pharmacists surveyed was the category of practicing pharmacy for 5 to 15 years (29%, n=60). Approximately 31% (n=64) had dispensed or answered patient questions regarding prescribed AEDs for more than 5 years (as reflected in the table below), and most (83%, n=171) reported not having answered patient questions related to POTIGA in the past 12 months. Seventy-seven percent (77%, n=158) have not dispensed POTIGA in the past 12 months. Of those pharmacists who have dispensed POTIGA within the past 12 months (44%, n=14), most reported having dispensed POTIGA for only 1-3 months and for approximately 1-2 patients within that timeframe. Pharmacists reported having dispensed an average of 50+ AED prescriptions per month over the past year.

Table 3 Summary of Physician and Pharmacist Practice History

Healthcare Provider Practice History	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Q14(Q22) Practicing Medicine/Pharmacy		
Less than 5 years	8 (4.8)	30 (14.6)
5-15 years	69 (41.1)	60 (29.3)
16-25 years	61 (36.3)	49 (23.9)
26-35 years	25 (14.9)	45 (22.0)
More than 35 years	5 (3.0)	21 (10.2)
Q15(Q23) Prescribing/Dispensing Anti-Epileptic Drugs (AEDs)		
Less than 5 years	6 (3.6)	35 (17.1)
5-15 years	72 (42.9)	64 (31.2)
16-25 years	59 (35.1)	48 (23.4)
26-35 years	26 (15.5)	41 (20.0)
More than 35 years	5 (3.0)	17 (8.3)
Q24 Answered Patient Questions related to POTIGA in past 12 months		
Yes	-- (--)	21 (10.2)
No	-- (--)	171 (83.4)
Don't know/don't remember	-- (--)	13 (6.3)
Q25 Dispensed POTIGA in past 12 months		
Yes	-- (--)	32 (15.6)
No	-- (--)	158 (77.1)
Don't know/don't remember	-- (--)	15 (7.3)
Q16(Q26*) Months Prescribing/Dispensing POTIGA		
Less than 1	16 (9.5)	3 (9.4)
1 – 3	55 (32.7)	14 (43.8)
4 – 6	50 (29.8)	5 (15.6)
7 – 9	19 (11.3)	1 (3.1)
10 – 12	12 (7.1)	5 (15.6)
More than 12 months	11 (6.5)	1 (3.1)
Don't know/don't remember	5 (3.0)	3 (9.4)
Q17(Q27*) Patients Prescribed/Dispensed POTIGA in past 12 months		
1 – 2	87 (51.8)	21 (65.6)
3 – 10	66 (39.3)	8 (25.0)
11 – 20	12 (7.1)	1 (3.1)
More than 20	3 (1.8)	1 (3.1)
Don't know/don't remember	-- (--)	1 (3.1)
Q18(Q28) Prescriptions for AEDs written/filled per month on average over past year		
1 – 10	5 (3.0)	4 (12.5)
11 – 30	24 (14.3)	8 (25.0)
31 – 50	38 (22.6)	7 (21.9)
More than 50	101 (60.1)	13 (40.6)
Q19 Range of Patient Population (multiple response)		
Pediatric (Under 18)	53 (31.5)	-- (--)
18-34	155 (92.3)	-- (--)
35-64	157 (93.5)	-- (--)
65 +	143 (85.1)	-- (--)

Healthcare Provider Practice History	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Q20 Size of Total Patient Population		
Less than 100 patients	1 (0.6)	-- (--)
101 – 500 patients	19 (11.3)	-- (--)
501 – 1000 patients	56 (33.3)	-- (--)
More than 1000 patients	92 (54.8)	-- (--)
Q21 Size of Epilepsy Patient Population		
Less than 10 patients	-- (--)	-- (--)
10 – 50 patients	3 (1.8)	-- (--)
51 – 100 patients	25 (14.9)	-- (--)
101+ patients	140 (83.3)	-- (--)
I do not treat patients with epilepsy	-- (--)	-- (--)

Columns may not sum to 100% due to rounding.

(--) Indicates a percentage that does not round to 1 or is zero

*These questions were only asked of pharmacists who had dispensed Potiga in the past 12 months.

6. SURVEY RESULTS

6.1. Organization of Results

Responses from physicians who have prescribed POTIGA at least once within the past 12 months and pharmacists who have filled a prescription for at least one AED within the previous 3 months are presented in this section.

6.2. Healthcare Providers Understanding of Risks Associated with POTIGA

Healthcare providers understanding of the primary objectives are presented in [Table 4](#) below, as well as the tabulated data appended at the end of the report.

Of the 13 primary objectives, 5 were related specifically to urinary retention and symptoms of acute urinary retention risks associated with POTIGA. Of these risk objectives, 3 were correctly answered by more than 80% of physicians based on the point estimate. The urinary retention objectives that met the pre-defined threshold with a point estimate of at least 80% included:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (85.1%, n=143).
- Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (82.7%, n=139).
- Correct Response: Patients with benign prostatic hyperplasia (BPH) (85.7%, n=144), patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients) (79.8%, n=134) and patients who use concomitant

medications that may affect voiding (e.g. anti-cholinergics) (82.1%, n=138) are recommended to have closer monitoring for urinary retention.

The remaining 2 primary risk objectives related to urinary retention and symptoms of urinary risks with POTIGA did not meet the targeted threshold within the physician population:

- True: It is known from controlled clinical studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA (73.8%, n=124).
- Correct Response: Pain when urinating (22.6%, n=38), difficulty starting urination (58.3%, n=98) and inability to urinate (76.8%, n=129) are all urinary symptoms that patients taking POTIGA should be specially advised to watch out for.
 - Only 23 (14%) physicians correctly responded that they should specially be advising patients to watch out for pain when urinating, difficulty starting urination and the inability to urinate.
 - Thirty-four out of 92 Neurologists (37%) reported “urinary retention as a symptom to watch for/an AE/potential side effect” of POTIGA. Seventeen out of 51(33%) Epileptologists provided the same response.

The following three primary objectives, not specifically related to the risk of urinary retention, were correctly answered by more than 80% of physicians based on the point estimate. These objectives that met the pre-defined threshold of 80% were:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (97.6%, n=164).
- False: According to U.S. prescribing information, POTIGA can be used as monotherapy (91.1%, n=153).
- Correct Response: Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=147).

The remaining primary objectives for POTIGA had a point estimate that fell below the 80% targeted threshold:

- Correct Response: According to the U.S. prescribing information, POTIGA can be taken with or without food (69.0%, n=116).
 - Thirty percent (n=52) of total physicians did not know or did not recall the correct response to this objective and almost 25% (n=42) stated they were not sure or uncertain of the appropriate response.

- Correct Response: According to the U.S. prescribing information, 1,200 mg is the maximum recommended daily maintenance dose of POTIGA for the General Population (67.9%, n=114).
 - Almost 15% (n=8) of physicians who provided an incorrect response stated their response were based on “general recall/memory/best recall from PI/from literature/dosing directions”. Thirteen percent (n=7) of physicians either reported they were “not aware of the maximum dose/uncertain or maximum dose” or “do not know/recall” the correct maximum dosing.
- Correct Response: According to the U.S. prescribing information, the youngest age at which POTIGA can be used is 18 (61.9%, n=104).
 - Twelve percent (n=8) of total physicians stated that “persons 12 years of age/adolescents/FDA approved for 12 years” is the youngest age at which the medicine can be used. Five out of the 30 physicians (17%) who stated their specialty was Epileptology provided the same response to the follow-up question.
- Correct Response: According to the U.S. prescribing information, when increasing a dose, 150mg/day is the maximum total daily dose at which POTIGA can be increased once every 7 days (59.5%, n=100).
 - Twenty percent (n=9) Neurologists provided their response was based on the “label/indications/package inserts/prescribing literature” and 21% (n=4) of Epileptologists stated their response was based on “general recall”. Eight (12%) of the total physicians stated the maximum daily dose at which POTIGA could be increased once every 7 days was 150mg.
- False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week (54.8%, n=92).
 - 15 of the 75 total physicians (20%, n=15) stated that 150mg/day as an initial dosage was true and based their response on the “label/indications/package inserts/prescribing literature”, while 12 (16%) physicians stated their rationale to this objective was based on “general recall”.
- Correct Responses:
 - No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe asthma (63.1%, n=106).
 - Yes, the label for POTIGA recommends caution when prescribing for patients over the age of 65 years (55.4%, n=93).

- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe Crohn's disease (51.8%, n=87).
- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe glaucoma (47.0 %, n=79).

None of the primary objectives for the pharmacist cohort achieved the pre-defined 80% threshold; however, when stratified by those pharmacists who had dispensed POTIGA, four objectives met the established threshold:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (90.6%, n=29).
- Correct Response: Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=28).

The following 2 objectives, that met the threshold when stratified, were specifically related to urinary retention risks when using POTIGA:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (81.2%, n=26).
- Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (81.2%, n=26)

Rationale provided for some of the additional POTIGA objectives that failed to meet the target threshold were:

- Almost three-fourths (73%, n=38) of retail pharmacists were not able to provide a correct response to the objective related to POTIGA can be taken with or without food because of their lack of familiarity of POTIGA. Over 42% (n=14) of hospital pharmacists provided an incorrect response to this objective because of their lack of familiarity with the drug and 15% (n=5) stated they simply did not know/did not recall the correct dosing directions.
- Sixty-two percent (n=39) of retail pharmacists and 46% (n=18) of hospital pharmacists stated a "lack of familiarity/never heard of POTIGA/never dispensed POTIGA/no experience with POTIGA" at the objective concerning the recommended maximum daily maintenance dose of POTIGA.
- Over half (55%, n=36) of retail pharmacists and 41% (n=21) of hospital pharmacists stated a lack of familiarity with POTIGA, while 15% of total pharmacists were not aware of the minimum dosing age.
- About half (53% of retail and 48% hospital) of total pharmacists stated their lack of POTIGA knowledge as the rationale for providing an incorrect response to the

objective that 150mg/day is the total daily dose POTIGA can be increased by over the course of 7 days. Approximately the same percentage (50% retail and 46% hospital) provided the same rationale to the objective testing the recommended initial dose of POTIGA as 150mg/day is “False”.

- Most of the pharmacists (n=173; 84%) reported not having dispensed POTIGA in the past 12 months or being unsure if they had, which, likely resulted in the high rate of uncertainty.

Table 4 Summary of Physician and Pharmacist Risk Questions

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
Q1	According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?				
	Migraine	2	1.2	1	0.5
	*Partial-onset seizures	164	97.6	127	62.0
	Generalized tonic clonic seizures	9	5.4	6	2.9
	None of the above	--	--	--	--
	I don't know	2	1.2	74	36.1
Q2	True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.				
	True	8	4.8	29	14.1
	*False	153	91.1	82	40.0
	I don't know	7	4.2	94	45.9
Q3	According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?				
	*Urinary retention	143	85.1	117	57.1
	Pancreatitis	9	5.4	5	2.4
	Ischemic colitis	3	1.8	1	0.5
	I don't know	19	11.3	85	41.5
Q4	According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?				
	600 mg	11	6.5	10	4.9
	900 mg	13	7.7	4	2.0
	*1200 mg	114	67.9	105	51.2
	2000 mg	1	0.6	--	--
	None of the above	4	2.4	6	2.9
	I don't know	27	16.1	84	41.0
Q5	According to U.S. prescribing information, which of the following statements, if any, is true?				
	The oldest age at which POTIGA can be used is 65	6	3.6	2	1.0
	There are no lower age limits for POTIGA	11	6.5	4	2.0
	The youngest age at which POTIGA can be used is 12	22	13.1	11	5.4

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
	*The youngest age at which POTIGA can be used is 18	104	61.9	85	41.5
	None of the above	9	5.4	10	4.9
	I don't know	25	14.9	94	45.9
Q6	According to U.S. prescribing information, which of the following statements, if any, is true?				
	POTIGA should always be taken with food	6	3.6	5	2.4
	POTIGA should always be taken on its own, without food	2	1.2	3	1.5
	*POTIGA can be taken with or without food	116	69.0	120	58.5
	None of the above	2	1.2	1	0.5
	I don't know	42	25.0	77	37.6
Q7	Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?				
	*Pain when urinating	38	22.6	47	22.9
	*Difficulty starting urination	98	58.3	97	47.3
	Renal colic	17	10.1	10	4.9
	*Inability to urinate	129	76.8	88	42.9
	None of the above	1	0.6	1	0.5
	I don't know	12	7.1	73	35.6
Q8	If a patient on POTIGA experiences inability to pass urine, what would you advise them to do?				
	Report the issue at their next doctor's appointment	6	3.6	25	12.2
	Drink more water	6	3.6	6	2.9
	*Seek immediate medical attention	139	82.7	138	67.3
	Stop taking POTIGA	68	40.5	26	12.7
	None of the above	2	1.2	1	0.5
	I don't know	3	1.8	44	21.5
Q9	According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?				
	Total daily dose increased by 50mg/day	21	12.5	26	12.7
	*Total daily dose increased by 150mg/day	100	59.5	88	42.9
	Total daily dose increased by 200mg/day	8	4.8	--	--
	Total daily dose increased by 300mg/day	13	7.7	2	1.0
	None of the above	4	2.4	1	0.5
	I don't know	22	13.1	88	42.9
Q10	True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.				
	True	54	32.1	24	11.7
	*False	92	54.8	102	49.8
	I don't know	22	13.1	79	38.5

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
Q11_1	Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	*Yes	147	87.5	133	64.9
	No	8	4.8	9	4.4
	I don't know	13	7.7	63	30.7
Q11_2	Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	18	10.7	20	9.8
	*No	87	51.8	62	30.2
	I don't know	63	37.5	123	60.0
Q11_3	Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	6	3.6	12	5.9
	*No	106	63.1	72	35.1
	I don't know	56	33.3	121	59.0
Q11_4	Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	*Yes	93	55.4	90	43.9
	No	39	23.2	22	10.7
	I don't know	36	21.4	93	45.4
Q11_5	Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	20	11.9	31	15.1
	*No	79	47.0	52	25.4
	I don't know	69	41.1	122	59.5
Q12	True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.				
	*True	124	73.8	94	45.9
	False	8	4.8	8	3.9
	I don't know	36	21.4	103	50.2
Q13	Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?				
	*Patients with benign prostatic hyperplasia (BPH)	144	85.7	137	66.8
	*Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	134	79.8	99	48.3
	*Patients who use concomitant medications that may	138	82.1	129	62.9

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
	affect voiding (e.g. anti-cholinergics)				
	Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	13	7.7	33	16.1
	Patients who are obese	4	2.4	12	5.9
	None of the above	1	0.6	2	1.0
	I don't know	11	6.5	57	27.8

Columns may not sum to 100% due to rounding.

(--) Indicates a percentage that does not round to 1 or is zero

6.3. Healthcare Provider Profiling Questions

Following the understanding questions, physicians and pharmacists were asked a series of profiling questions to gain an understanding of how they learned about the risks associated with POTIGA and how they would prefer to learn about risk associated with the use of POTIGA in the future. Physician and pharmacist responses are presented in [Table 5](#).

Over half of the physicians reported interest in GSK-sponsored Education Meetings (55%, n=92), followed by GSK sales representatives (46%) and POTIGA product labeling or other healthcare professionals (36%, respectively). Pharmacists preferred to receive information from the POTIGA product labeling (49%, n=101), along with GSK-sponsored educational meetings (36%) and from GSK sales representatives (35%).

Most physicians reported learning about the risks associated with POTIGA from the product labeling (78%) or from a GSK sales representative (60%). Most pharmacists reported learning about the risks associated with POTIGA from the product labeling (46%) or from other healthcare professionals (22%).

The majority of both physicians (82%, n=137) and pharmacists (91%, n=186) did not learn about the risks associated with POTIGA from a Dear HCP Letter and relatively few healthcare professionals reported learning information on POTIGA from GSK medical information, promotional materials, websites for both GSK and POTIGA or GSK-sponsored education meetings.

Physicians and pharmacists were then asked how they would prefer to learn about the risks associated with POTIGA in the future. Over half of the physicians reported interest in GSK-sponsored Education Meetings (55%, n=92), followed by GSK sales representatives (46%) and POTIGA product labeling or other healthcare professionals (36%, respectively). Pharmacists preferred to receive information from the POTIGA product labeling (49%, n=101), along with GSK-sponsored educational meetings (36%) and from GSK sales representatives (35%).

Table 5 Healthcare Provider Profiling Questions

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
Q29_1	POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	14	8.3	10	4.9
	No	137	81.5	186	90.7
	Don't know	17	10.1	9	4.4
Q29_2	GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	58	34.5	21	10.2
	No	98	58.3	177	86.3
	Don't know	12	7.1	7	3.4
Q29_3	GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	67	39.9	28	13.7
	No	90	53.6	171	83.4
	Don't know	11	6.5	6	2.9
Q29_4	GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	39	23.2	41	20.0
	No	118	70.2	159	77.6
	Don't know	11	6.5	5	2.4
Q29_5	GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	100	59.5	9	4.4
	No	64	38.1	190	92.7
	Don't know	4	2.4	6	2.9
Q29_6	GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	30	17.9	4	2.0
	No	130	77.4	195	95.1
	Don't know	8	4.8	6	2.9
Q29_7	POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	131	78.0	95	46.3
	No	30	17.9	104	50.7

		Physicians		Pharmacists	
Total Responding:		168		205	
Q#	Objective	n	%	n	%
	Don't know	7	4.2	6	2.9
Q29_8	Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?				
	Yes	74	44.0	45	22.0
	No	85	50.6	154	75.1
	Don't know	9	5.4	6	2.9
Q30	How would you prefer to learn about the risks associated with the use of POTIGA in the future? (Select up to 3 options).				
	GlaxoSmithKline-sponsored Educational Meeting	92	54.8	74	36.1
	GlaxoSmithKline Sales Representatives	77	45.8	71	34.6
	POTIGA Product Labeling (including Prescribing Information, Medication Guide)	60	35.7	101	49.3
	Other Healthcare Professionals	60	35.7	36	17.6
	GlaxoSmithKline Medical Information	41	24.4	48	23.4
	GSK Website: POTIGA.com	37	22.0	61	29.8
	GlaxoSmithKline Promotional Materials	28	16.7	60	29.3
	POTIGA Dear HCP Letter	21	12.5	64	31.2

Table 6 Summary of Pharmacist Risk Questions by POTIGA Dispensing History

		Pharmacists who Have Dispensed POTIGA		Pharmacists who Have Not Dispensed POTIGA	
Total Responding:		32		173	
Q#	Objective	n	%	n	%
Q1	According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?				
	Migraine	1	3.1	--	--
	*Partial-onset seizures	29	90.6	98	56.6
	Generalized tonic clonic seizures	3	9.4	3	1.7
	None of the above	--	--	--	--
	I don't know	2	6.2	72	41.6
Q2	True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.				
	True	9	28.1	20	11.6
	*False	20	62.5	62	35.8
	I don't know	3	9.4	91	52.6
Q3	According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?				
	*Urinary retention	26	81.2	91	52.6
	Pancreatitis	3	9.4	2	1.2
	Ischemic colitis	1	3.1	--	--
	I don't know	4	12.5	81	46.8
Q4	According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?				
	600 mg	4	12.5	6	3.5
	900 mg	2	6.2	2	1.2
	*1200 mg	24	75.0	81	46.8
	2000 mg	--	--	--	--
	None of the above	--	--	6	3.5
	I don't know	4	12.5	80	46.2
Q5	According to U.S. prescribing information, which of the following statements, if any, is true?				
	The oldest age at which POTIGA can be used is 65	1	3.1	1	0.6
	There are no lower age limits for POTIGA	1	3.1	3	1.7
	The youngest age at which POTIGA can be used is 12	5	15.6	6	3.5
	*The youngest age at which POTIGA can be used is 18	18	56.2	67	38.7
	None of the above	1	3.1	9	5.2
	I don't know	7	21.9	87	50.3
Q6	According to U.S. prescribing information, which of the following statements, if any, is true?				
	POTIGA should always be taken with food	2	6.2	3	1.7
	POTIGA should always be taken on its own, without	3	9.4	--	--

		Pharmacists who Have Dispensed POTIGA		Pharmacists who Have Not Dispensed POTIGA	
Total Responding:		32		173	
Q#	Objective	n	%	n	%
	food				
	*POTIGA can be taken with or without food	24	75.0	96	55.5
	None of the above	--	--	1	0.6
	I don't know	4	12.5	73	42.2
Q7	Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?				
	*Pain when urinating	14	43.8	33	19.1
	*Difficulty starting urination	24	75.0	73	42.2
	Renal colic	3	9.4	7	4.0
	*Inability to urinate	22	68.8	66	38.2
	None of the above	--	--	1	0.6
	I don't know	2	6.2	71	41.0
Q8	If a patient on POTIGA experiences inability to pass urine, what would you advise them to do?				
	Report the issue at their next doctor's appointment	6	18.8	19	11.0
	Drink more water	2	6.2	4	2.3
	*Seek immediate medical attention	26	81.2	112	64.7
	Stop taking POTIGA	6	18.8	20	11.6
	None of the above	--	--	1	0.6
	I don't know	--	--	44	25.4
Q9	According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?				
	Total daily dose increased by 50mg/day	6	18.8	20	11.6
	*Total daily dose increased by 150mg/day	19	59.4	69	39.9
	Total daily dose increased by 200mg/day	--	--	--	--
	Total daily dose increased by 300mg/day	1	3.1	1	0.6
	None of the above	--	--	1	0.6
	I don't know	6	18.8	82	47.4
Q10	True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.				
	True	9	28.1	15	8.7
	*False	22	68.8	80	46.2
	I don't know	1	3.1	78	45.1
Q11_1	Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	*Yes	28	87.5	105	60.7
	No	2	6.2	7	4.0
	I don't know	2	6.2	61	35.3

		Pharmacists who Have Dispensed POTIGA		Pharmacists who Have Not Dispensed POTIGA	
Total Responding:		32		173	
Q#	Objective	n	%	n	%
Q11_2	Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	6	18.8	14	8.1
	*No	18	56.2	44	25.4
	I don't know	8	25.0	115	66.5
Q11_3	Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	3	9.4	9	5.2
	*No	21	65.6	51	29.5
	I don't know	8	25.0	113	65.3
Q11_4	Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	*Yes	24	75.0	66	38.2
	No	6	18.8	16	9.2
	I don't know	2	6.2	91	52.6
Q11_5	Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?				
	Yes	9	28.1	22	12.7
	*No	12	37.5	40	23.1
	I don't know	11	34.4	111	64.2
Q12	True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.				
	*True	25	78.1	69	39.9
	False	2	6.2	6	3.5
	I don't know	5	15.6	98	56.6
Q13	Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?				
	*Patients with benign prostatic hyperplasia (BPH)	26	81.2	111	64.2
	*Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	21	65.6	78	45.1
	*Patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics)	26	81.2	103	59.5
	Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	5	15.6	28	16.2
	Patients who are obese	3	9.4	9	5.2
	None of the above	--	--	2	1.2
	I don't know	2	6.2	55	31.8

6.4. Adverse Event Reporting

No adverse events were reported during the study.

7. DISCUSSION AND CONCLUSIONS

7.1. Discussion

7.1.1. Healthcare Provider Demographics

Overall, the surveyed population encompassed various levels of experience in practice, with the majority of physicians having 5 to 25 years of medical practice experience and prescribing AEDs of at least 5 to 15 years. The majority of pharmacists had between 5 to 35 years of experience as a practicing pharmacist and have been dispensing or answering question regarding AEDs for the past 5 to 15 years.

Both the majority of physicians and pharmacists state they prescribe or fill prescriptions for AEDs more than 50 times per month within the past year (60% and 41%, respectively). However, within the past 12 months, the healthcare providers mention that POTIGA is prescribed (52%) or dispensed (66%) to only 1-2 patients on average per month.

Physicians report treating patient populations of all ages and most report patient populations of at least 1,000 or more, with an epilepsy patient population size of more than 100 patients.

7.1.2. Healthcare Providers' Understanding of Risks of POTIGA

Generally, the results of this cross-sectional study revealed a good level of understanding of some aspects of the urinary risks associated with the use of POTIGA, although a number of risk questions did not meet the 80% correct response benchmark, especially within the pharmacist population.

Of the 13 primary objectives, 5 were related specifically to urinary retention and symptoms of acute urinary retention risks associated with POTIGA. Of these risk objectives, 3 were correctly answered by more than 80% of physicians based on the point estimate. The urinary retention objectives that met the pre-defined threshold with a point estimate of at least 80% included:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (85.1%, n=143).
- Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (82.7%, n=139).
- Correct Response: Patients with benign prostatic hyperplasia (BPH) (85.7%, n=144), patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients) (79.8%, n=134) and patients who use concomitant

medications that may affect voiding (e.g. anti-cholinergics) (82.1%, n=138) are recommended to have closer monitoring for urinary retention.

The remaining 2 primary risk objectives related to urinary retention and symptoms of urinary risks with POTIGA did not meet the targeted threshold within the physician population:

- True: It is known from controlled clinical studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA (73.8%, n=124).
- Correct Response: Pain when urinating (22.6%, n=38), difficulty starting urination (58.3%, n=98) and inability to urinate (76.8%, n=129) are all urinary symptoms that patients taking POTIGA should be specially advised to watch out for.
 - Only 23 (14%) physicians correctly responded that they should specially be advising patients to watch out for pain when urinating, difficulty starting urination and the inability to urinate.
 - Thirty-four out of 92 Neurologists (37%) reported “urinary retention as a symptom to watch for/an AE/potential side effect” of POTIGA. Seventeen out of 51(33%) Epileptologists provided the same response.

The following three primary objectives, not specifically related to the risk of urinary retention, were correctly answered by more than 80% of physicians based on the point estimate. These objectives that met the pre-defined threshold of 80% were:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (97.6%, n=164).
- False: According to U.S. prescribing information, POTIGA can be used as monotherapy (91.1%, n=153).
- Correct Response (part of question 11): Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=147).

The remaining primary objectives for POTIGA had a point estimate that fell below the 80% targeted threshold:

- Correct Response: According to the U.S. prescribing information, POTIGA can be taken with or without food (69.0%, n=116).
 - Thirty percent (n=52) of total physicians did not know or did not recall the correct response to this objective and almost 25% (n=42) stated they were not sure or uncertain of the appropriate response.

- Correct Response: According to the U.S. prescribing information, 1,200 mg is the maximum recommended daily maintenance dose of POTIGA for the General Population (67.9%, n=114).
 - Almost 15% (n=8) of physicians who provided an incorrect response stated their response were based on “general recall/memory/best recall from PI/from literature/dosing directions”. Thirteen percent (n=7) of physicians either reported they were “not aware of the maximum dose/uncertain or maximum dose” or “do not know/recall” the correct maximum dosing.
- Correct Response: According to the U.S. prescribing information, the youngest age at which POTIGA can be used is 18 (61.9%, n=104).
 - Twelve percent (n=8) of total physicians stated that “persons 12 years of age/adolescents/FDA approved for 12 years” is the youngest age at which the medicine can be used. Five out of the 30 physicians (17%) who stated their specialty was Epileptology provided the same response to the follow-up question.
- Correct Response: According to the U.S. prescribing information, when increasing a dose, 150mg/day is the maximum total daily dose at which POTIGA can be increased once every 7 days (59.5%, n=100).
 - Twenty percent (n=9) Neurologists provided their response was based on the “label/indications/package inserts/prescribing literature” and 21% (n=4) of Epileptologists stated their response was based on “general recall”. Eight (12%) of the total physicians stated the maximum daily dose at which POTIGA could be increased once every 7 days was 150mg.
- False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week (54.8%, n=92).
 - 15 of the 75 total physicians (20%, n=15) stated that 150mg/day as an initial dosage was true and based their response on the “label/indications/package inserts/prescribing literature”, while 12 (16%) physicians stated their rationale to this objective was based on “general recall”.
- Correct Responses (part of question 11):
 - No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe asthma (63.1%, n=106).
 - Yes, the label for POTIGA recommends caution when prescribing for patients over the age of 65 years (55.4%, n=93).

- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe Crohn's disease (51.8%, n=87).
- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe glaucoma (47.0 %, n=79).

None of the primary objectives for the pharmacist cohort achieved the pre-defined 80% threshold; however, when stratified by those pharmacists who had dispensed POTIGA, four objectives met the established threshold:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (90.6%, n=29).
- Correct Response: Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=28).

The following 2 objectives, that met the threshold when stratified, were specifically related to urinary retention risks when using POTIGA:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (81.2%, n=26).

Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (81.2%, n=26)

7.2. Conclusions

This study of physicians and pharmacists assessed their knowledge of the serious urinary retention risks associated with POTIGA. In addition, this study assessed whether or not both physicians and pharmacists recall receiving a Dear Healthcare Provider Letter and where they receive their information about POTIGA.

- Physician comprehension was adequate for the majority of key safety issues addressed in the REMS.
 - Six of the thirteen questions met or exceeded the 80% threshold for the proportion of correct responses and an additional question was near the threshold (74%).
- In the Pharmacist group, there were no scores that achieved the threshold. However, when stratified by whether or not the pharmacists had dispensed POTIGA, those pharmacists (n=32) that had dispensed the medicine scored above the established threshold on 4 of the objectives.
- The majority of physicians (82%, n=137) and pharmacists (91%, n=186) did not learn about the risks associated with POTIGA from a Dear HCP Letter and

relatively few healthcare professionals reported learning information on POTIGA from GSK medical information, promotional materials, websites for both GSK and POTIGA or GSK-sponsored education meetings.

- However, over half of physicians (60%, n=100) who completed the assessment stated they learned about the risks of POTIGA from a GSK sales representative. Seventy-eight percent (n=131) of physicians also learned of the POTIGA risks from the product labeling (including Prescribing Information, Medication Guide), while 46% (n=95) of pharmacists also mentioned learning the risks from the product labeling.
- Due to the short relative time that POTIGA has been available, it was not unexpected that the pharmacists surveyed did not have much experience with dispensing POTIGA to patients yet.

8. REFERENCES

Davis TC, Long SW, Jackson RH, Mayeaux EJ, George RB, Murphy PW, and Crouch MA. (1993) Rapid Estimate of Adult Literacy in Medicine: A Shortened Screening Instrument. *Family Medicine*, 25, 391-396.

9. POST-TEXT TABLES AND FIGURES

Not applicable.

Synopsis

Study Number: WEUKBRE5993

Title: Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA

Investigator(s): None

Study center(s): 1

Publication(s): None at the time of this report

Study Period: 25 Feb 2013 – 10 Apr 2013

Phase of Development: IV

Objective: The objectives of this survey were to assess prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention potentially associated with POTIGA use as evaluated by a survey instrument.

Methodology: A cross-sectional, non-interventional observational survey of physicians who treat patients with epilepsy (including neurologists, neurosurgeons, and epileptologists) and who have prescribed POTIGA, as well as with pharmacists who currently dispense anti-epileptic drugs (AEDs), was conducted to determine prescribing physicians' and pharmacists' understanding of the FDA labeling regarding the risk of urinary retention and the symptoms of acute urinary retention potentially associated with POTIGA use. Physicians' demographic information including clinical specialty, years of practice, and prescribing practices were collected at screening and if qualified and interested, physicians participated in either a telephone or an online physician survey of the prescribing information for POTIGA.

Number of subjects: 373

Prescribing physicians and pharmacists were recruited into the study.

Cohort	Description	Number of Subjects
1	Prescribing Physicians (Neurologists, Neurosurgeons, Epileptologists) who have prescribed POTIGA within the past 12 months	168
2	Pharmacists who have dispensed an AED within the previous three months	205

Main criteria for inclusion: Physicians were required to be currently practicing medicine and have treated patients with epilepsy as well as prescribed POTIGA to their epilepsy patients within the past 12 months.

Pharmacists were required to be currently practicing pharmacy and have filled prescriptions for patients with epilepsy, including at least one AED within the previous three months.

Treatment administration: No treatment was administered.

Criteria for evaluation: The primary outcome of this study is the proportion of subjects that correctly respond to individual survey questions concerning the risk of urinary retention and the symptoms of acute urinary retention associated with POTIGA. The order in which potential responses to survey questions appear were randomized. The proportion responding correctly was tabulated separately for each item in the subject understanding survey instrument. These risks represent those described in the DHCP letter.

Statistical methods: Data analyses were quantitative in nature. Correct responses to the questions about the risks and symptoms of urinary retention associated with POTIGA were tabulated using the proportion of physicians who chose the correct answer. The proportion of health care providers (HCPs) reporting each response was provided for each cohort.

Summary:

Demographics: 168 physicians and 205 pharmacists were enrolled into this study.

Limited demographic information was collected. Physicians stated their primary specialty was in Neurology (64%, n=108) or Epileptology (36%, n=60). Pharmacists stated their primary specialty was in Community/Retail (55%, n=113), and Hospital/Clinic (45%, n=92).

Demographics	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Primary Specialty		
Neurology	108 (64.3)	--
Neurosurgery	--	--
Epileptology	60 (35.7)	--
Pharmacy (Community/Retail)	--	113 (55.1)
Pharmacy (Hospital/Clinical)	-	92 (44.9)

*Columns may not sum to 100% due to rounding.
(--) Indicates a percentage that does not round to 1 or is zero.*

Prescribing Physician Practice History: The largest practice history grouping of physicians surveyed was the category of practicing medicine for 5 to 15 years (41%, n=69) followed by those physicians that have been practicing for more than 16 to 25 years (36%, n=61). Approximately 43% (n=72) had prescribed AEDs for 5 to 15 years (as reflected in the table below), and most (33%, n=55) reported having prescribed POTIGA within the past 1 to 3 months. Fifty-two percent (52%, n=87) of physicians have prescribed POTIGA for only 1-2 patients in the past 12 months; however, over the

past year, 60% (n=101) of physicians reported they have written more than 50 prescriptions for AEDs per month on average. Prescribing physicians treat patient populations across all age ranges, and most reported a patient population size of over 1,000 patients (55%; n=92), and an epilepsy patient population size of more than 100 patients (83%; n=140).

Pharmacist Practice History: The largest practice history grouping of pharmacists surveyed was the category of practicing pharmacy for 5 to 15 years (29%, n=60). Approximately 31% (n=64) had dispensed or answered patient questions regarding prescribed AEDs for 5 to 15 years (as reflected in the table below), and most (83%, n=171) reported not having answered patient questions related to POTIGA in the past 12 months. Seventy-seven percent (77%, n=158) have not dispensed POTIGA in the past 12 months. Of those pharmacists who have dispensed POTIGA within the past 12 months (16%, n=32), most reported having dispensed POTIGA for only 1-3 months and for approximately 1-2 patients within that timeframe. Over 40% of pharmacists (n=13) reported having dispensed an average of 50+ AED prescriptions per month over the past year.

Healthcare Provider Practice History	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Q14(Q22) Practicing Medicine/Pharmacy		
Less than 5 years	8 (4.8)	30 (14.6)
5-15 years	69 (41.1)	60 (29.3)
16-25 years	61 (36.3)	49 (23.9)
26-35 years	25 (14.9)	45 (22.0)
More than 35 years	5 (3.0)	21 (10.2)
Q15(Q23) Prescribing/Dispensing Anti-Epileptic Drugs (AEDs)		
Less than 5 years	6 (3.6)	35 (17.1)
5-15 years	72 (42.9)	64 (31.2)
16-25 years	59 (35.1)	48 (23.4)
26-35 years	26 (15.5)	41 (20.0)
More than 35 years	5 (3.0)	17 (8.3)
Q24 Answered Patient Questions related to POTIGA in past 12 months		
Yes	-- (--)	21 (10.2)
No	-- (--)	171 (83.4)
Don't know/don't remember	-- (--)	13 (6.3)
Q25 Dispensed POTIGA in past 12 months		
Yes	-- (--)	32 (15.6)
No	-- (--)	158 (77.1)
Don't know/don't remember	-- (--)	15 (7.3)
Q16(Q26) Months Prescribing/Dispensing POTIGA		
Less than 1	16 (9.5)	3 (9.4)
1 – 3	55 (32.7)	14 (43.8)
4 – 6	50 (29.8)	5 (15.6)
7 – 9	19 (11.3)	1 (3.1)
10 – 12	12 (7.1)	5 (15.6)
More than 12 months	11 (6.5)	1 (3.1)
Don't know/don't remember	5 (3.0)	3 (9.4)

Healthcare Provider Practice History	Prescribing Physicians	Pharmacists
Total Responding:	168	205
	n (%)	n (%)
Q17(Q27) Patients Prescribed/Dispensed POTIGA in past 12 months		
1 – 2	87 (51.8)	21 (65.6)
3 – 10	66 (39.3)	8 (25.0)
11 – 20	12 (7.1)	1 (3.1)
More than 20	3 (1.8)	1 (3.1)
Don't know/don't remember	-- (--)	1 (3.1)
Q18(Q28) Prescriptions for AEDs written/filled per month on average over past year		
1 – 10	5 (3.0)	4 (12.5)
11 – 30	24 (14.3)	8 (25.0)
31 – 50	38 (22.6)	7 (21.9)
More than 50	101 (60.1)	13 (40.6)
Q19 Range of Patient Population (multiple response)		
Pediatric (Under 18)	53 (31.5)	-- (--)
18-34	155 (92.3)	-- (--)
35-64	157 (93.5)	-- (--)
65 +	143 (85.1)	-- (--)
Q20 Size of Total Patient Population		
Less than 100 patients	1 (0.6)	-- (--)
100 – 500 patients	19 (11.3)	-- (--)
501 – 1000 patients	56 (33.3)	-- (--)
More than 1000 patients	92 (54.8)	-- (--)
Q21 Size of Epilepsy Patient Population		
Less than 10 patients	-- (--)	-- (--)
10 – 50 patients	3 (1.8)	-- (--)
51 – 100 patients	25 (14.9)	-- (--)
101+ patients	140 (83.3)	-- (--)
I do not treat patients with epilepsy	-- (--)	-- (--)

Columns may not sum to 100% due to rounding.

(--) Indicates a percentage that does not round to 1 or is zero

Healthcare Providers Understanding of Risks Associated with POTIGA:

There were 13 primary risk objectives evaluated in this study. However, there was one objective (*Q11- Label for POTIGA recommends caution with prescribing for these patients*) that had 5 parts and therefore 5 questions were asked of the physicians and pharmacists about this objective.

Of the 13 primary objectives, 5 were related specifically to urinary retention and symptoms of acute urinary retention risks associated with POTIGA. Of these risk objectives, 3 were correctly answered by more than 80% of physicians based on the point estimate. The urinary retention objectives that met the pre-defined threshold with a point estimate of at least 80% included:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (85.1%, n=143).

- Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (82.7%, n=139).
- Correct Response: Patients with benign prostatic hyperplasia (BPH) (85.7%, n=144), patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients) (79.8%, n=134) and patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics) (82.1%, n=138) are recommended to have closer monitoring for urinary retention.

The remaining 2 primary risk objectives related to urinary retention and symptoms of urinary risks with POTIGA did not meet the targeted threshold within the physician population:

- True: It is known from controlled clinical studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA (73.8%, n=124).
- Correct Response: Pain when urinating (22.6%, n=38), difficulty starting urination (58.3%, n=98) and inability to urinate (76.8%, n=129) are all urinary symptoms that patients taking POTIGA should be specially advised to watch out for.
 - Only 23 (14%) physicians correctly responded that they should specially be advising patients to watch out for pain when urinating, difficulty starting urination and the inability to urinate.
 - Thirty-four out of 92 Neurologists (37%) reported “urinary retention as a symptom to watch for/an AE/potential side effect” of POTIGA. Seventeen out of 51(33%) Epileptologists provided the same response.

The following three primary objectives, not specifically related to the risk of urinary retention, were correctly answered by more than 80% of physicians based on the point estimate. These objectives that met the pre-defined threshold of 80% were:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (97.6%, n=164).
- False: According to U.S. prescribing information, POTIGA can be used as monotherapy (91.1%, n=153).
- Correct Response (part of question 11): Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=147).

The remaining five primary objectives for POTIGA had a point estimate that fell below the 80% targeted threshold:

- Correct Response: According to the U.S. prescribing information, POTIGA can be taken with or without food (69.0%, n=116).

- Thirty percent (n=52) of total physicians did not know or did not recall the correct response to this objective and almost 25% (n=42) stated they were not sure or uncertain of the appropriate response.
- Correct Response: According to the U.S. prescribing information, 1,200 mg is the maximum recommended daily maintenance dose of POTIGA for the General Population (67.9%, n=114).
 - Almost 15% (n=8) of physicians who provided an incorrect response stated their response were based on “general recall/memory/best recall from PI/from literature/dosing directions”. Thirteen percent (n=7) of physicians either reported they were “not aware of the maximum dose/uncertain or maximum dose” or “do not know/recall” the correct maximum dosing.
- Correct Response: According to the U.S. prescribing information, the youngest age at which POTIGA can be used is 18 (61.9%, n=104).
 - Twelve percent (n=8) of total physicians stated that “persons 12 years of age/adolescents/FDA approved for 12 years” is the youngest age at which the medicine can be used. Five out of the 30 physicians (17%) who stated their specialty was Epileptology provided the same response to the follow-up question.
- Correct Response: According to the U.S. prescribing information, when increasing a dose, 150mg/day is the maximum total daily dose at which POTIGA can be increased once every 7 days (59.5%, n=100).
 - Twenty percent (n=9) Neurologists provided their response was based on the “label/indications/package inserts/prescribing literature” and 21% (n=4) of Epileptologists stated their response was based on “general recall”. Eight (12%) of the total physicians stated the maximum daily dose at which POTIGA could be increased once every 7 days was 150mg.
- False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week (54.8%, n=92).
 - 15 of the 75 total physicians (20%, n=15) stated that 150mg/day as an initial dosage was true and based their response on the “label/indications/package inserts/prescribing literature”, while 12 (16%) physicians stated their rationale to this objective was based on “general recall”.
- Correct Responses (part of question 11):
 - No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe asthma (63.1%, n=106).

- Yes, the label for POTIGA recommends caution when prescribing for patients over the age of 65 years (55.4%, n=93).
- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe Crohn's disease (51.8%, n=87).
- No, the label for POTIGA does not recommend caution when prescribing for patients with moderate to severe glaucoma (47.0 %, n=79).

None of the primary objectives for the pharmacist cohort achieved the pre-defined 80% threshold; however, when the analysis was restricted to those pharmacists who had dispensed POTIGA, four objectives met the established threshold:

- Correct Response: According to the U.S. prescribing information, partial-onset seizures are the FDA-approved indication for POTIGA (90.6%, n=29).
- Correct Response: Yes, the label for POTIGA recommends caution when prescribing for patients with moderate to severe renal or hepatic impairment (87.5%, n=28).

The following two objectives, that met the threshold when stratified, were specifically related to urinary retention risks when using POTIGA:

- Correct Response: According to the U.S. prescribing information, urinary retention is a potential risk associated with POTIGA (81.2%, n=26).
- Correct Response: If a patient on POTIGA experiences inability to pass urine, they should be advised to seek immediate medical attention (81.2%, n=26)

Conclusions:

This study of physicians and pharmacists assessed their knowledge of the serious urinary retention risks associated with POTIGA. In addition, this study assessed whether or not both physicians and pharmacists recall receiving a Dear Healthcare Provider Letter and where they receive their information about POTIGA.

- Physician comprehension was adequate for the majority of key safety issues addressed in the REMS.
 - Six of the thirteen questions met or exceeded the 80% threshold for the proportion of correct responses, including three that were specifically related to urinary retention.
 - An additional question related to urinary retention was near the threshold (74%).
- In the Pharmacist group, there were no scores that achieved the threshold. However, when stratified by whether or not the pharmacists had dispensed

POTIGA, those pharmacists (n=32) that had dispensed the medicine scored above the established threshold on 4 of the objectives.

- The majority of physicians (82%, n=137) and pharmacists (91%, n=186) did not learn about the risks associated with POTIGA from a Dear HCP Letter and relatively few healthcare professionals reported learning information on POTIGA from GSK medical information, promotional materials, websites for both GSK and POTIGA or GSK-sponsored education meetings.
- However, over half of physicians (60%, n=100) who completed the assessment stated they learned about the risks of POTIGA from a GSK sales representative. Seventy-eight percent (n=131) of physicians also learned of the POTIGA risks from the product labeling (including Prescribing Information, Medication Guide), while 46% (n=95) of pharmacists also mentioned learning the risks from the product labeling.

Date of Report: 28-MAY-2013

Division: Worldwide Development
Retention Category: GRS019
Information Type: Worldwide Epidemiology Study Protocol

Title: Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™

Compound Number: GW582892

Development Phase IV

Effective Date: 22-APR-2013

Description: This is a cross-sectional survey of physicians and pharmacists that aims to assess their understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA. This forms part of the Risk Evaluation and Mitigation Strategy (REMS) requirements as detailed in the POTIGA REMS approved by the FDA on 10 June 2011.

Subject: Physician and pharmacist survey of the understanding of the risk of urinary retention with POTIGA, Risk Evaluation and Mitigation Strategy (REMS)

Author(s): [REDACTED] (GlaxoSmithKline); [REDACTED]
(Concentrics Research)

Revision Chronology:

2011N126225_00	2012-SEP-18	Original
2011N126225_01	2013-MAR-15	Amendment No.:01 The survey will now focus on POTIGA prescribers and pharmacists only.
2011N126225_02	2013-APR-22	Amendment No.:02 Honoraria has been increased for POTIGA prescribers and screening question (Q7) has been revised to include only a subset of products based on issues identified during recruitment and lower than expected completion rates.

2011N126225_02


CONFIDENTIAL

WEUKBRE5993


SPONSOR SIGNATORY:

STUDY TITLE: Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA

Study: WEUKBRE5993 Development Phase: IV

Name of Sponsor Signatory: 

Title of Sponsor Signatory: Safety Physician 

Signature:  _____

Date: 22 April 2013

SPONSOR INFORMATION PAGE

Worldwide Epidemiology
Study Identifier:
WEUKBRE5993

GlaxoSmithKline
1-3 Iron Bridge Road
Stockley Park West
Uxbridge, Middlesex UB11 1BT, UK
Telephone: [REDACTED]

TABLE OF CONTENTS

	PAGE
LIST OF ABBREVIATIONS	6
PROTOCOL SUMMARY	7
1. INTRODUCTION.....	8
2. OBJECTIVE(S)	9
3. INVESTIGATION PLAN	9
3.1. Study Design	9
3.2. Study Population.....	10
3.3. Discussion of Design	11
3.3.1. Risk management studies for other GSK medications	11
4. SUBJECT SELECTION AND ELIGIBILITY.....	12
4.1. Number of Subjects	12
4.2. Inclusion and Exclusion criteria.....	12
4.2.1. Inclusion criteria.....	12
4.2.2. Exclusion criteria.....	13
5. STUDY ASSESSMENTS AND PROCEDURES	13
5.1. Screening and baseline assessments.....	13
5.2. Outcomes	14
5.3. Adverse drug experience/event measures	14
6. DATA COLLECTION AND MANAGEMENT	14
7. DATA ANALYSIS	15
7.1. Analysis Populations.....	15
7.2. Analyses.....	15
8. PRECISION BY SAMPLE SIZE.....	16
9. STUDY LIMITATIONS.....	16
10. STUDY MANAGEMENT.....	17
10.1. Ethical approval and subject consent.....	17
10.2. Subject confidentiality	17
10.3. Reporting of adverse drug events	17
10.4. Study reporting and publications	17
11. APPENDICES	18
11.1. Screener.....	18
11.2. Questionnaire	23
11.3. GlaxoSmithKline Adverse Drug Reaction Form – Revised Nov 30, 2009	40

LIST OF ABBREVIATIONS

AE	Adverse Event
AED	Anti-epileptic drug
DHCP	Dear Healthcare Provider (Letter)
GSK	GlaxoSmithKline
HCP	Healthcare Provider
REMS	Risk Evaluation and Mitigation Strategy
US	United States

Trademark Information

Trademarks of the GlaxoSmithKline group of companies
POTIGA
LAMICTAL
LAMICTAL ODT
LAMICTAL XR
TREXIMET

Trademarks not owned by the GlaxoSmithKline group of companies
None

PROTOCOL SUMMARY

Rationale

As part of a post-marketing commitment, GSK will conduct a survey of prescribers' and pharmacists' understanding of the risk of urinary retention with POTIGA™ products. This is to address the effectiveness of the Risk Evaluation and Mitigation Strategy (REMS) as outlined in the REMS approved by the FDA on 10th June 2011.

Objective(s)

The objectives of this survey are to assess prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention potentially associated with POTIGA use as evaluated by a survey instrument.

Study Design

This is a cross-sectional study of approximately:

1. 200 physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed POTIGA at least once in the last 12 months.
2. 200 pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.

Individuals eligible for the survey will be asked to take the survey online or via a telephone interview if the latter is preferred.

Study Endpoints/Assessments

The primary outcome of the survey is the proportion of physicians and pharmacists providing correct responses to a series of questions concerning the risk of urinary retention and the symptoms of acute urinary retention that may be associated with POTIGA. The risks captured will be those described in the POTIGA Dear Healthcare Provider (DHCP) letters, specifically risks of urinary retention.

1. INTRODUCTION

POTIGA was approved with a FDA requirement for a Risk Evaluation and Mitigation Strategy (REMS). The goal of the REMS for POTIGA is to inform healthcare professionals of the risk of urinary retention and the symptoms of acute urinary retention in patients taking POTIGA. The REMS is comprised of a communication plan for healthcare professionals that is designed to disseminate information about the risk of urinary retention with POTIGA and highlight this potential risk and the need to inform patients to seek immediate medical attention for symptoms of urinary retention, inability to urinate, and/or pain with urination. There are two elements of the communication plan: (1) A Dear Healthcare Professional (HCP) Letter designed to disseminate information about the risk of urinary retention with POTIGA; letters are disseminated within 4 weeks of first retail availability (actual – May 7, 2012) and annually for the next two years (2) a REMS Program Website (available at time of launch; actual -April 16, 2012).

The target audience for these communications is: (1) Prescribing physicians i.e., Epileptologists, Neurologists and Neurosurgeons, (2) Pharmacists dispensing POTIGA tablets and the Medication Guide.

As a condition of approval, FDA requires that GlaxoSmithKline (GSK) assess the effectiveness of the communication plan. Accordingly, a survey will be conducted among a sample of prescribing physicians to evaluate whether they can recall the risk of urinary retention with POTIGA. In addition, the survey will evaluate where HCPs prefer to seek information for POTIGA, for example Dear HCP letters, website, or product labeling. The survey will concentrate on the risks described in the DHCP letter for POTIGA, though it is recognised that the DHCP letter is not the only source of information concerning risks associated with medication use. The design for this study is based on previous experience of risk management programs for GSK products.

A survey will also be conducted among a sample of pharmacists to evaluate whether they can recall the risk of urinary retention with POTIGA.

Although the Marketing Application was approved June 10, 2011, initial retail availability could not commence until after the Drug Enforcement Administration (DEA) had completed rule making placing POTIGA into Schedule V under of the Controlled Substances Act. The drug did not become available to patients until early May 2012 (first distribution to wholesalers April 19, 2012). FDA has agreed that with such delayed retail availability of POTIGA, an assessment of HCP understanding submitted on June 10, 2012 would provide little meaningful information. Therefore, the first assessment of the REMS survey will be included with the report due on June 10, 2013.

Originally, ER physicians and urologists were planned to be included in the survey as well. Given the survey will target prescribers only, as of FDA feedback received on January 25, 2013, ER physicians and urologists will no longer be targeted in the survey.

POTIGA was generally available to prescribers and patients for the first time in May 2012 and to date, there has been modest prescribing of the product. The impact of this on

the recruitment goals is uncertain but represents a potential challenge for GSK in this first assessment of HCP knowledge.

2. OBJECTIVE(S)

The objectives of this study are:

1. To assess prescribers' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA as evaluated by a survey instrument.
2. To assess pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA as evaluated by a survey instrument.

3. INVESTIGATION PLAN

3.1. Study Design

This study is sponsored by GlaxoSmithKline (GSK), and will be conducted by Concentrics Research LLC, a contract research organization, on behalf of GSK.

This is a cross-sectional study of individuals prescribing POTIGA or dispensing AEDs.

Physicians and pharmacists will be recruited using a multi-modal approach:

1. Telephone
2. Email
3. Fax

Screening interviews will take place via telephone, email or fax using a standardized screening questionnaire to assess whether the physician or pharmacist is eligible for and interested in participating in the study. Also, demographic information including clinical specialty and geographic location will be collected at screening.

Following recruitment, physicians' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention with POTIGA products will be evaluated using an online survey or the same survey instrument delivered during a telephone interview. If the healthcare provider (HCP) qualifies and is interested in participating, the survey recruiter will schedule an appointment for the interview if the HCP states a preference for the telephone survey, or will send an email including a link to the online survey with their unique passcode. The telephone option will be made available to accommodate individuals who would prefer a telephone call to participate in the survey. It is estimated that approximately 85% will complete the internet survey and the remaining 15% will complete the survey via telephone interview. HCPs will be allowed to respond throughout the entire data collection period, and non-responders will receive up to 5 follow-up messages (sent either via email or phone call) to remind them to participate in the survey.

All physicians and pharmacists will be asked to re-confirm their clinical specialty at the start of the interview (whether online or via telephone). Prescribing physicians (e.g. neurologists, neurosurgeons, epileptologists) will be asked medications prescribed again as well, and pharmacists will similarly be asked to confirm medications dispensed again. Any prescribing physician or pharmacist will be excluded from the survey if he/she gives an answer to these screening questions that would be inconsistent with an answer provided previously during the telephone screening and would also meet an exclusion criteria.

To ensure consistency across interviews, all HCP assessments will be conducted in a structured manner, where all interviews (telephone and on-line) follow a standardized script, and both telephone and on-line surveys will provide the same response options for each question for each participant. Telephone interviewers will be trained on the protocol and questionnaire, as well as following general interviewing practice and quality standards. Telephone interviewers will not be allowed to deviate from the survey procedure or supply additional information or instructions.

Prior to start of the survey, HCPs will be asked to electronically sign a Confidentiality and Consent Agreement, which describes the purpose of the study, data handling, storage and security, expectations of confidentiality of study data and participation, honoraria for study participation, and their rights as a survey subject. All HCPs completing the survey will be required to confirm that he/she is the same HCP who was screened previously to help safeguard against delegation of participation to other colleagues or staff in the HCP's office/pharmacy. Following the HCP's agreement with the Confidentiality and Consent form, the interviewer will administer the telephone survey or the internet survey will begin.

Prior to implementation of the full survey, a pilot study will be conducted involving 30 healthcare providers (HCPs) (10 prescribing physicians, 5 urologists, 5 emergency room physicians and 10 pharmacists), enrolled to complete the survey via telephone. Approximately 5 of the prescribing physicians included in the pilot will have prescribed POTIGA. The objectives of the pilot are to test the physicians' and pharmacists' understanding of the draft questions and follow-up responses, in order to understand the nature of the responses and why specific responses were selected. Feedback from HCPs is intended to improve the clarity of the survey questions and answers. Following the completion of the pilot, all study implementation procedures and assumptions will be reviewed to determine if changes in study procedures and/or training of survey administrators will be required prior to implementation of the full survey.

3.2. Study Population

A listing of physicians eligible to complete the survey will be compiled at one research center utilizing a custom database of approximately 500,000 geographically and therapeutically diverse physicians from all 50 states. Working with a partner, this research center also has access to over 168,000 geographically diverse pharmacists from all 50 states.

Pharmacists and physicians in the targeted specialties will be contacted initially via multiple methods, including, telephone, e-mail, and/or fax, with an invitation to participate in the study. Interested physicians will be asked to contact the market research center staff on the study, who will then complete a telephone screening process to determine if the physician meets all of the study protocol-defined eligibility criteria (see Section 4.2.1 and Section 4.2.2) and, to confirm their interest in participating in the survey if they do meet the eligibility criteria. Eligible physicians who agree to participate will be scheduled for either an appointment with an interviewer to complete the survey via telephone or they will be provided an email containing a link to an on-line survey for completion along with their unique access passcode.

For prescribing physicians, the honorarium for completing the survey will be \$125, and for pharmacists, the honorarium will be \$50. The honorarium for the prescribing physicians was increased from \$100 to \$125 after the start of the study, due to recruitment being significantly lower than expected.

3.3. Discussion of Design

The final study design is based on experience from risk management studies previously completed by GSK.

3.3.1. Risk management studies for other GSK medications

Experience from previous risk management studies was used to determine the threshold for the proportion of correct responses per individual survey question against which to base sample size calculations and precision estimates.

The REMS post marketing commitments for LAMICTAL™ (NDA 022115) included:

- a. A survey of patients' understanding of the serious risks of Lamictal (lamotrigine) Orally Disintegrating Tablets
- b. A report on periodic assessments of the distribution and dispensing of the Medication Guide in accordance with 21 CFR 208.24
- c. A report on failures to adhere to distribution and dispensing requirements, and corrective actions taken to address noncompliance

The REMS post marketing commitments for TREXIMET™ (NDA 21-926) included:

- a. Survey of patients' understanding of the serious risks of TREXIMET;
- b. Report on periodic assessments of the distribution and dispensing of the Medication Guide in accordance with 21 CFR 208.24; and,
- c. Report on failures to adhere to distribution and dispensing requirements, and corrective actions taken to address non-compliance.

Based on these studies, a threshold of 80% was determined to be acceptable for the proportion of subjects answering correctly the questions regarding risks associated with POTIGA. This threshold will be imposed for prescribers and pharmacists, not urologists

nor emergency room doctors. Prescribers and pharmacists are the HCPs who will play an important role in re-enforcing the safety messages for POTIGA.

It should be noted that TREXIMET and POTIGA REMS have since been revised, because the FDA determined that a Medication Guide is not necessary to ensure the benefits of the drug outweigh the risks described above because labeling and a REMS that includes a communication plan will be adequate to describe these serious risks. The Medication Guide will be part of the approved labeling and be subject to the requirements under 21 CFR 208.

4. SUBJECT SELECTION AND ELIGIBILITY

4.1. Number of Subjects

This survey aims to recruit approximately 400 total POTIGA prescribers and pharmacists. These numbers reflect a trade-off between what is practical in terms of recruitment, given the relatively low predicted uptake of POTIGA, and providing sufficient precision around outcome estimates (proportion giving correct responses per question) (Section 8).

Ideally, this study aims to recruit a sample of physicians and pharmacists from a demographically representative population database who prescribe POTIGA (neurologists, neurosurgeons, epileptologists), and dispense POTIGA (pharmacists). In order to achieve 400 completed interviews, it is anticipated that approximately 4,000 potential physicians or pharmacists may be contacted for potential recruitment for this study.

4.2. Inclusion and Exclusion criteria

4.2.1. Inclusion criteria

Physicians and pharmacists will be required to meet all the following inclusion criteria:

1. Able to read, speak, and understand English.
2. Willing to take the online survey or have the survey administered via a telephone interview, including electronically signing a Confidentiality & Consent agreement and completing all study protocol-specified procedures.
3. Prescribing physicians and pharmacists:
 - a. Practicing physician or pharmacist who sees and treats, or fills prescriptions for, patients with epilepsy, currently (within the past 12 months).
 - b. Prescribed POTIGA within the past 12 months (prescribing physicians)
 - c. Filled a prescription for at least one AED within the previous three months (pharmacists).

4.2.2. Exclusion criteria

Physicians or pharmacists meeting any of the following criteria will not be eligible to take the survey:

- a. The physician or pharmacist is currently employed by, or is a representative of any of the following:
 - A A pharmaceutical company or manufacturer of medicines or healthcare products.
 - B Contributor/editor to published guideline committees for epilepsy or UR.
- b. The physician or pharmacist has a visual impairment that would prevent him or her from being able to read independently.
- c. The physician or pharmacist participated in the Pilot REMS study for POTIGA.
- d. The physician or pharmacist is an employee of GSK or Concentrics Research.

5. STUDY ASSESSMENTS AND PROCEDURES

5.1. Screening and baseline assessments

Subjects participating in the pilot study will be removed programmatically from the sample list in order to avoid bias in the screener by specifically mentioning the drug name, even in a masked approach, during screening which may heighten awareness prior to the interview.

After accepting the initial recruitment invitation to participate in the study, individuals will be scheduled for a telephone screening interview. The screener will assess:

- Inclusion/exclusion criteria
 - The screener was amended after the study began to ask physicians a subset of epilepsy drugs at Q7 instead of the full list previously included. This subset still allows for masking of the drug to be studied (POTIGA), but shortens the burden on the physician to respond to the full listing during recruitment. This revision was made based on qualitative feedback during recruitment where physicians were not continuing with screening due to frustration with the length of this question. After reviewing data gathered to date, the most common responses to the drugs prescribed were included in the remaining listing, along with POTIGA.
 - Whether POTIGA has been prescribed within the past 12 months (physicians) or whether AEDs have been dispensed within the past 3 months (pharmacists).
 - Demographics: geographic region and type of healthcare provider. Additional prescribing or dispensing-related questions will be asked in the main survey questionnaire.

5.2. Outcomes

Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with POTIGA will be assessed using the survey instrument.

The primary outcome of this study is the proportion of subjects that correctly respond to individual survey questions concerning the risk of urinary retention and the symptoms of acute urinary retention associated with POTIGA. The order in which potential responses to survey questions appear will be randomized. The proportion responding correctly will be tabulated separately for each item in the subject understanding survey instrument. These risks represent those described in the DHCP letter.

At the conclusion of the online survey, the final screen will display a summary of the relevant information from the POTIGA prescribing information, and a link to <http://www.potiga.com>. The phone respondents will be offered materials by email or the POTIGA website, but will also be given the toll-free number for the POTIGA response center [REDACTED]

5.3. Adverse drug experience/event measures

This study will not investigate adverse events associated with the use of POTIGA. Whilst it is not the intention of the survey to solicit adverse events (AEs), it is possible that a respondent may spontaneously provide information that meets the criteria of an adverse event. Any reported adverse events will be entered into the GSK Safety Database:

- Online respondents will be provided with the number for the GSK Global Clinical Safety and Pharmacovigilance Response Center at the end of the online survey and will be directed to call the Center to report any adverse events potentially associated with POTIGA.
- If, at any time during the telephone interview, the subject describes an adverse event associated with POTIGA or any GSK product, the interviewer will complete an adverse event form and fax it to GSK Global Clinical Safety and Pharmacovigilance at [REDACTED] within 24 hours of receiving the information.

At the end of the project, Concentrics shall provide a summary of all AEs that it has submitted to GSK to enable the reports to be reconciled.

6. DATA COLLECTION AND MANAGEMENT

Subject data from the screening and survey response parts of the questionnaire will be stored confidentially in password protected systems maintained by Concentrics Research.

In all cases, subject identifiers will not be collected or transmitted to GSK according to GSK policy. All subjects will be given a numeric subject identifier.

7. DATA ANALYSIS

7.1. Analysis Populations

The population for analysis will comprise all physicians and pharmacists recruited into the study, meeting eligibility criteria as assessed in the survey screener, and completing the survey.

7.2. Analyses

Demographics including geographic location, HCP specialty and prescribing/dispensing of POTIGA and other AEDs will be summarized using descriptive statistics for continuous data and proportions for categorical data.

The primary outcome is the proportion of HCPs answering each question of understanding of the risks associated with POTIGA correctly. Point estimates for the proportion with correct responses, and associated 95% confidence intervals, will be calculated for each question about the awareness of risks of POTIGA. In the case of multiple choice questions, the number and proportion of subjects reporting each response will also be provided.

GSK considers a proportion (%) of correct responses of at least 80% for each individual question to represent sufficient subject understanding of the risks associated with POTIGA. This is based on previous studies by GSK including the risk management program for LAMICTAL and TREXIMET. This threshold will be imposed for prescribers and pharmacists. Prescribers and pharmacists are the HCPs who will play an important role in re-enforcing the safety messages for POTIGA.

The proportion of correct answers to survey questions will be summarized overall and by demographic subgroups. Consideration of these subgroups may highlight differences in subjects' responses. Although the sample size in some subgroups may be relatively small and have low precision, data will be grouped into 2-3 sub-categories as appropriate to identify potential trends in subject understanding including:

- Demographics (geographic location)
- Type of HCP
- POTIGA prescribing/dispensing (yes or no, months prescribing POTIGA)
- Other practice/prescribing characteristics (years in practice, years prescribing AEDs, size of patient population)

This study is descriptive; hence there will be no formal statistical testing completed.

8. PRECISION BY SAMPLE SIZE

If the estimate of the percentage of subjects indicating a correct response to an individual survey question is 80%, then a sample of 200 subjects will provide a margin of error of ± 5.5 percentage points of this estimate with a 95% confidence interval. The margin of error reduces to ± 4.7 percentage points if the sample size increases to 300. Subgroups of the total sample will have smaller numbers of subjects, resulting in larger margins of error and therefore provide estimates with lower precision. The following table indicates the margin of error at the 95% confidence level provided by varying sample sizes and estimates of percentage of subjects indicating a correct response.

Table 1 Sample size and precision estimates

Sample Size	Proportion of Correct Responses to Each Question						
	50	60	70	75	80	85	90
	Precision/ Margin of Error ($\pm\%$) with 95% Confidence Interval						
50	14	14	12	11	10	9.0	8.0
100	10	10	9.0	8.0	8.0	7.0	6.0
150	8.0	8.0	7.3	7.0	6.7	5.7	4.7
200	7.0	7.0	6.5	6.0	5.5	5.0	4.0
250	6.0	6.0	5.6	5.4	4.8	4.6	3.6
300	5.7	5.7	5.3	5.0	4.7	4.0	3.3
350	5.1	5.1	4.9	4.4	4.3	3.9	3.1
400	5.0	4.8	4.5	4.3	4.0	3.5	3.0
450	4.7	4.4	4.2	3.9	3.8	3.2	2.7
500	4.4	4.2	4.0	3.8	3.6	3.2	2.6

9. STUDY LIMITATIONS

There are some limitations inherent in the study design. The sample may not be fully representative of prescribers and pharmacists typically prescribing/dispensing POTIGA. However, this limitation will be addressed to the extent possible via recruitment across many geographical regions recruiting a demographically diverse sample. This study aims to limit this potential bias by accessing HCPs via one of the largest online databases of healthcare professionals in the US rather than targeting high POTIGA prescribing physicians or those known to GSK through previous collaborations or participation in clinical studies.

Since this is an online survey, we cannot detect whether or not HCPs attempt to utilize any reference materials while taking the survey. They will not be provided with any reference materials.

10. STUDY MANAGEMENT

10.1. Ethical approval and subject consent

Subject participation is voluntary. Subject consent will be implied by the subject completing the survey online or via a telephone interview.

As neither GSK nor Concentrics will have any contact with, nor details of, subjects prior to the subject initiating the survey, IRB approval is not deemed necessary.

10.2. Subject confidentiality

Privacy issues will be addressed and respected at each stage of the study. Concentrics will maintain strict confidentiality in handling all HCP identification information. All data provided to GSK will be de-identified; no individual HCP-level data or protected health information will be communicated to GSK.

10.3. Reporting of adverse drug events

See Section [5.3](#).

10.4. Study reporting and publications

A final report will be written and submitted to FDA.


11. APPENDICES

11.1. Screener

PHYSICIAN/PHARMACIST STUDY

PRE-RECRUIT SCREENER

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.



11.2. Questionnaire

PHYSICIAN/PHARMACIST ASSESSMENT

Quantitative Questionnaire

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.

Confidentiality & Consent Agreement

The purpose of this survey is to assess physician and pharmacist understanding of prescribing information and practice habits related to a medication used to treat epilepsy.

By signing this agreement, you agree not to disclose your participation to anyone unless required by law and to treat what you see confidentially for a period of two (2) years. Any answers, information, and suggestions you may offer are given without obligation of any kind, and your answers to the survey will not affect your ability to [INSERT: prescribe (IF QA = 1/2/3) / dispense (IF QA = 4/5)] the drug.

During your participation in this study, you will be asked a minimal amount of demographic information about yourself. All of this information will be kept confidential and your information will be linked only to your participant number and not directly to you.

Records about you and your part in this survey will be kept private so far as permitted by law. If results of this survey are published, you will not be identified by name. All information recorded during the course of this survey, except your name and contact information, may be provided to the study Sponsor and/or the Food and Drug Administration (FDA).

There are no costs to you for being in this survey. When you have finished all of the survey, you will be paid [INSERT: \$125 (IF QA = 1/2/3) / \$50 (IF QA = 4/5)] for your time.

It is completely up to you if you wish to take part in this survey. You can stop participating in this survey at any time.

After reading the agreement, please select one option below:

- I affirm my understanding of the Confidentiality & Consent agreement and checking this box represents my electronic signature.
- OR
- I would not like to participate in this study.

RECONFIRM IF CLICK 'I WOULD NOT LIKE TO PARTICIPATE IN THIS STUDY'. IF STILL YES – TAKE TO CLOSING SCREEN.

We would also like to confirm that you are the [INSERT: physician/pharmacist] on record for this survey. Please select one of the following options:


- 1. I affirm that I am the same [INSERT: physician/pharmacist] who was screened and sent the survey passcode. [INSERT NAME]
- 2. I am not [INSERT NAME], but I work in this [INSERT: physician's office/pharmacy].

IF PUNCH 1 (SAME PHYSICIAN/PHARMACIST), CONTINUE.


IF PUNCH 2 (NOT PHYSICIAN OR PHARMACIST, BUT WORK IN SAME OFFICE/PHARMACY), SHOW SCREEN WITH MESSAGE: 'THANK YOU FOR YOUR TIME. UNFORTUNATELY, ONLY THE HEALTHCARE PROVIDER ON RECORD MAY PARTICIPATE IN THIS STUDY. IF YOU BELIEVE YOU HAVE RECEIVED THIS MESSAGE IN ERROR, PLEASE CONTACT [INSERT NAME & PHONE #] FOR FURTHER INSTRUCTIONS.' DO NOT ALLOW SUBJECT TO CONTINUE.

Survey

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.



This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.



We would now like for you to take a moment to review some important information about POTIGA. This information can be found in the Prescribing Information, which can be found online at:
http://us.gsk.com/products/assets/us_potiga.pdf

The Dear Healthcare Professional Letters (for prescribing physicians and pharmacists) can be found online at:

Prescribing Physicians:

https://www.gsksource.com/gskprm/en/US/images/gsk_content/POTIGA/PGA056R0_RMS_HCP_Letter_DC.pdf

Pharmacists:

https://www.gsksource.com/gskprm/en/US/images/gsk_content/POTIGA/PGA055R0_RMS_PharmLetter_DC.pdf

11.3. GlaxoSmithKline Adverse Drug Reaction Form – Revised Nov 30, 2009

Global Adverse Event Report Reporting Form for Marketing Research	
<p>To be completed by Market Research Agency – this form applies to both patients and HCPs. This form is to be used for AEs mentioned worldwide in market research commissioned by GSK global. <i>Minimum criteria - A Reporter, at least one patient detail, suspect drug and adverse event</i> Please complete with as much detail as possible and forward within one business day (24 hours) to your Pharmaceutical company contact via fax to:</p>	
<p>For drugs GSK Case Management Group</p> <p>For vaccines GSK Biologicals Case Management Group</p>	<p>Reports from Americas: [REDACTED] Reports outside of Americas: [REDACTED] Reports from US & Canada: [REDACTED] Reports outside US & Canada: [REDACTED]</p>

Market Research Agency:	Date aware of the adverse event/product complaint: <i>Month: Date: Year:</i>
Agency Address (include country):	Project Title and Agency Reference/Project No:
Agency Telephone No:	Researchers Name:
Agency Fax No:	Researchers Signature:

Drug(s)/ Vaccine(s) and Event(s) Details

<p>Drug/ Vaccines Name(s):</p> <p>Indication (condition for which the drug(s)/ vaccine(s) has been prescribed):</p> <p>Unknown <input type="checkbox"/></p> <p>Was the patient pregnant?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <input type="checkbox"/></p> <p>Dose:</p> <p>Unknown <input type="checkbox"/></p>	<p>Adverse Event(s)/Product Complaint details:</p> <p>Reported to the local regulatory agency?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <input type="checkbox"/></p> <p>Lot/Batch number:</p> <p style="text-align: right;">Unknown <input type="checkbox"/></p> <p>Did the HCP/patient consider that the event was possibly related to the drug/ vaccine?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <input type="checkbox"/></p>
--	--


Patient Details (At least one of these patient details MUST be completed)	
Age:	Other (approx. age of patient)
Sex: Male <input type="checkbox"/> Female <input type="checkbox"/>	

Respondent Details	
If consent not given to disclose personal details, just complete the type of reporter (i.e., Dr., nurse, patient, pharm.)	
Respondent name:	Doctor <input type="checkbox"/>
Address:	Nurse <input type="checkbox"/>
Telephone No:	Patient <input type="checkbox"/>
Email:	Pharmacist <input type="checkbox"/>
Is respondent willing for the Pharmaceutical company's safety team to contact them or their doctor to discuss further? Yes <input type="checkbox"/> No <input type="checkbox"/>	Respondent Signature:

PHYSICIAN/PHARMACIST STUDY

PRE-RECRUIT SCREENER

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.



PHYSICIAN/PHARMACIST ASSESSMENT

QUANTITATIVE QUESTIONNAIRE

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.

Confidentiality & Consent Agreement

The purpose of this survey is to assess physician and pharmacist understanding of prescribing information and practice habits related to a medication used to treat epilepsy.

*By signing this agreement, you agree not to disclose your participation to anyone unless required by law and to treat what you see confidentially for a period of two (2) years. Any answers, information, and suggestions you may offer are given without obligation of any kind, and your answers to the survey will not affect your ability to **[INSERT: prescribe (IF QA = 1/2/3) / dispense (IF QA = 4/5)]** the drug.*

During your participation in this study, you will be asked a minimal amount of demographic information about yourself. All of this information will be kept confidential and your information will be linked only to your participant number and not directly to you.

Records about you and your part in this survey will be kept private so far as permitted by law. If results of this survey are published, you will not be identified by name. All information recorded during the course of this survey, except your name and contact information, may be provided to the study Sponsor and/or the Food and Drug Administration (FDA).

*There are no costs to you for being in this survey. When you have finished all of the survey, you will be paid **[INSERT: \$100 (IF QA = 1/2/3) / \$50 (IF QA = 4/5)]** for your time.*

It is completely up to you if you wish to take part in this survey. You can stop participating in this survey at any time.

After reading the agreement, please select one option below:

- I affirm my understanding of the Confidentiality & Consent agreement and checking this box represents my electronic signature.

OR

- I would not like to participate in this study.

RECONFIRM IF CLICK 'I WOULD NOT LIKE TO PARTICIPATE IN THIS STUDY'. IF STILL YES – TAKE TO CLOSING SCREEN.

We would also like to confirm that you are the **[INSERT: physician/pharmacist]** on record for this survey. Please select one of the following options:


1. I affirm that I am the same **[INSERT: physician/pharmacist]** who was screened and sent the survey passcode. **[INSERT NAME]**
2. I am not **[INSERT NAME]**, but I work in this **[INSERT: physician's office/pharmacy]**.

IF PUNCH 1 (SAME PHYSICIAN/PHARMACIST), CONTINUE.

IF PUNCH 2 (NOT PHYSICIAN OR PHARMACIST, BUT WORK IN SAME OFFICE/PHARMACY), SHOW SCREEN WITH MESSAGE: 'THANK YOU FOR YOUR TIME. UNFORTUNATELY, ONLY THE HEALTHCARE PROVIDER ON RECORD MAY PARTICIPATE IN THIS STUDY. IF YOU BELIEVE YOU HAVE RECEIVED THIS MESSAGE IN ERROR, PLEASE CONTACT [INSERT NAME & PHONE #] FOR FURTHER INSTRUCTIONS.' DO NOT ALLOW SUBJECT TO CONTINUE.

Survey

This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.



This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by copyright laws and therefore have been excluded.

We would now like for you to take a moment to review some important information about POTIGA. This information can be found in the Prescribing Information, which can be found online at: http://us.gsk.com/products/assets/us_potiga.pdf

The Dear Healthcare Professional Letters (for prescribing physicians and pharmacists) can be found online at:

Prescribing Physicians:

https://www.gsksource.com/gskprm/en/US/images/gsk_content/POTIGA/PGA056R0_R_EMS_HCP_Letter_DC.pdf

Pharmacists:

https://www.gsksource.com/gskprm/en/US/images/gsk_content/POTIGA/PGA055R0_R_EMS_PharmLetter_DC.pdf

Confidentiality & Consent Agreement

The purpose of this study is to assess physician understanding of prescribing information and practice habits related to a medication used to treat epilepsy.

By signing this agreement, you agree not to disclose your participation to anyone unless required by law and to treat what you see confidentially for a period of two (2) years.

Any answers, information, and suggestions you may offer are given without obligation of any kind, and your answers to the survey will not affect your ability to [INSERT: prescribe/dispense] the drug.

During your participation in this study, you will be asked a minimal amount of demographic information about yourself. All of this information will be kept confidential and your information will be linked only to your participant number and not directly to you.

In all cases, your confidentiality will be maintained. If results of this study are published, you will not be identified by name. All information recorded during the course of this study, except your name and contact information, may be provided to the study Sponsor and/or the Food and Drug Administration (FDA).

You will be paid for your participation in this survey. There are no costs to you for being in this survey. When you have finished all of the survey, you will be paid for your time.

It is completely up to you if you wish to take part in this study. You can stop participating in this study at any time.

After reading the agreement, please select one option below:

- I affirm my understanding of the Confidentiality & Consent agreement and checking this box represents my electronic signature.

OR

- I would not like to participate in this study.

**RECONFIRM IF CLICK 'I WOULD NOT LIKE TO PARTICIPATE IN THIS STUDY'.
IF STILL YES – TAKE TO CLOSING SCREEN.**

We would also like to confirm that you are the [INSERT: physician/pharmacist] on record for this survey. Please select one of the following options:

- 1. I affirm that I am the same [INSERT: physician/pharmacist] who was screened and sent the survey passcode. [INSERT NAME]
- 2. I am not [INSERT NAME], but I work in this [INSERT: physician's office/pharmacy].
- 3. I am a [INSERT: physician/pharmacist] and I was scheduled for a survey, but I am not [INSERT NAME].

SPONSOR SIGNATORY SIGNATURE PAGE

STUDY TITLE: Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™ Study Report

Study: WEUKBRE5993 Development Phase: IV

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Sponsor Signatory: [REDACTED] MD

Title of Sponsor Signatory: Safety Physician

GlaxoSmithKline

Signature: [REDACTED]

Date:

28.5.2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

TABLE OF CONTENTS

Banner 1

Table QSCR3 Page 1.....S3: How would you classify your primary specialty?

Table TYPE Page 2.....Type: Physician/Pharmacist

Table QSCR4 Page 3.....S4: Are you a currently practicing physician? (for physicians only)

Table QSCR5 Page 4.....S5: Do you currently see and treat patients with epilepsy? (physicians only)

Table QSCR6 Page 5.....S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

Table QSCR7 Page 6.....S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Table QSCR8 Page 9.....S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Table QSA Page 12.....SA: How would you classify your primary specialty?

Table QSB Page 13.....SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

Table QSC Page 14.....SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

Table QSD Page 15.....SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

Table Q1 Page 16.....Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

Table Q2 Page 17.....Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3 Page 18.....Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

Table Q4 Page 19.....Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Table Q5 Page 20.....Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q6 Page 21.....Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q7 Page 22.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

Table Q7NET Page 23.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

TABLE OF CONTENTS

Table Q8 Page 24.....Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

Table Q9 Page 25.....Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Table Q10 Page 26.....Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Table Q11R1 Page 27.....Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R2 Page 28.....Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R3 Page 29.....Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R4 Page 30.....Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R5 Page 31.....Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q12 Page 32.....Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Table Q13 Page 33.....Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

Table Q14 Page 34.....Q14: How long have you been practicing medicine?

Table Q15 Page 35.....Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

Table Q16 Page 36.....Q16: How many months have you been prescribing POTIGA?

Table Q17 Page 37.....Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

Table Q18 Page 38.....Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

Table Q19 Page 39.....Q19: What is the age range of your current patient population? Please select all categories that you treat.

Table Q20 Page 40.....Q20: Approximately what is the size of your current total patient population?

Table Q21 Page 41.....Q21: Approximately what is the size of your current epilepsy patient population?

Table Q22 Page 42.....Q22: How long have you been a practicing pharmacist?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

TABLE OF CONTENTS

Table Q23 Page 43.....Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

Table Q24 Page 44.....Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

Table Q25 Page 45.....Q25: Have you dispensed POTIGA in the past 12 months?

Table Q26 Page 46.....Q26: How many months have you been dispensing POTIGA?

Table Q27 Page 47.....Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

Table Q28 Page 48.....Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

Table Q29R1 Page 49.....Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R2 Page 50.....Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R3 Page 51.....Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R4 Page 52.....Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R5 Page 53.....Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R6 Page 54.....Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R7 Page 55.....Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R8 Page 56.....Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q30 Page 57.....Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

Table Q1_1CODE Page 58...Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

Table Q2_1CODE Page 60...Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3_1CODE Page 63...Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Table Q4_1CODE Page 66...Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

TABLE OF CONTENTS

Table Q5_1CODE	Page 69...	Q5. According to U.S. prescribing information, which of the following statements, if any, is true?
Table Q6_1CODE	Page 73...	Q6. According to U.S. prescribing information, which of the following statements, if any, is true?
Table Q7_1CODE	Page 76...	Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?
Table Q8_1CODE	Page 80...	Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?
Table Q9_1CODE	Page 83...	Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?
Table Q10_1CODE	Page 87...	Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.
Table Q11_1ACODE	Page 90...	Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?
Table Q11_1BCODE	Page 92...	Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?
Table Q11_1CCODE	Page 95...	Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?
Table Q11_1DCODE	Page 97...	Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?
Table Q11_1ECODEA	Page 100...	Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?
Table Q12_1CODE	Page 101...	Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.
Table Q13_1CODEA	Page 104...	Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

Table QSCR3 Page 1
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S3: How would you classify your primary specialty?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Neurology	126 33.8	126 75.0 F	-	104 96.3 BFF	-	22 36.7	-	-
Neurosurgery	-	-	-	-	-	-	-	-
Epileptology	42 11.3	42 25.0 D	-	4 3.7	-	38 63.3 BDD	-	-
Pharmacy (Community/ Retail)	108 29.0	-	108 52.7 H	-	-	-	106 93.8 CHH	2 2.2
Pharmacy (Hospital/ Clinical)	97 26.0	-	97 47.3 G	-	-	-	7 6.2	90 97.8 CGG
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Type: Physician/Pharmacist

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Physician	168 45.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Pharmacist	205 55.0	-	205 100.0	-	-	-	113 100.0	92 100.0
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S4: Are you a currently practicing physician? (for physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	373 100.0	168 100.0	205 100.0	108 100.0	-	60 100.0	113 100.0	92 100.0
No	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S5: Do you currently see and treat patients with epilepsy? (physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Yes	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
No	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Yes	205 100.0	-	205 100.0	-	-	-	113 100.0	92 100.0
No	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Ativan (Lorazepam)	167 99.4	167 99.4	-	107 99.1	-	60 100.0	-	-
Carbatrol (Carbamazepine)	83 49.4	83 49.4	-	54 50.0	-	29 48.3	-	-
Celontin (Methsuximide)	28 16.7	28 16.7	-	18 16.7	-	10 16.7	-	-
Cerebyx (Fosphenytoin sodium)	64 38.1	64 38.1	-	42 38.9	-	22 36.7	-	-
Depakote/Depakote ER/ Depakote Sprinkle (Divalproex Sodium)	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Depacon (Valproate sodium)	75 44.6	75 44.6	-	49 45.4	-	26 43.3	-	-
Depakene (Valproic acid)	76 45.2	76 45.2	-	49 45.4	-	27 45.0	-	-
Diastat (Diazepam)	79 47.0	79 47.0	-	51 47.2	-	28 46.7	-	-
Dilantin (Phenytoin)	162 96.4	162 96.4	-	104 96.3	-	58 96.7	-	-
Felbatol (Felbamate)	53 31.5	53 31.5	-	30 27.8	-	23 38.3	-	-
Gabitril (Tiagabine hydrochloride)	52 31.0	52 31.0	-	32 29.6	-	20 33.3	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 7
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Keppra (Levetiracetam)	167 99.4	167 99.4	-	107 99.1	-	60 100.0	-	-
Klonopin (Clonazepam)	83 49.4	83 49.4	-	54 50.0	-	29 48.3	-	-
Lamictal (Lamotrigine)	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Lorazepam Intensol (Lorazepam)	73 43.5	73 43.5	-	47 43.5	-	26 43.3	-	-
Lyrica (Pregabalin)	83 49.4	83 49.4	-	53 49.1	-	30 50.0	-	-
Mebaral (Mephobarbital)	21 12.5	21 12.5	-	11 10.2	-	10 16.7	-	-
Mysoline (Primidone)	75 44.6	75 44.6	-	49 45.4	-	26 43.3	-	-
Neurontin (Gabapentin)	167 99.4	167 99.4	-	108 100.0	-	59 98.3	-	-
Peganone (Ethotoin)	21 12.5	21 12.5	-	14 13.0	-	7 11.7	-	-
Potiga (Ezogabine)	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Tegretol/Tegretol XR (Carbamazepine)	83 49.4	83 49.4	-	54 50.0	-	29 48.3	-	-
Topamax (Topiramate)	157 93.5	157 93.5	-	100 92.6	-	57 95.0	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 8
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Tranxene (Clorazepate dipotassium)	52 31.0	52 31.0	-	31 28.7	-	21 35.0	-	-
Trileptal (Oxcarbazepine)	82 48.8	82 48.8	-	52 48.1	-	30 50.0	-	-
Valium (Diazepam)	81 48.2	81 48.2	-	53 49.1	-	28 46.7	-	-
Zonegran (Zonisamide)	81 48.2	81 48.2	-	52 48.1	-	29 48.3	-	-
NONE OF THESE	-	-	-	-	-	-	-	-
Total	2569	2569	-	1645	-	924	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 9
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Ativan (Lorazepam)	202 98.5	-	202 98.5	-	-	-	112 99.1	90 97.8
Carbatrol (Carbamazepine)	145 70.7	-	145 70.7	-	-	-	84 74.3	61 66.3
Celontin (Methsuximide)	37 18.0	-	37 18.0	-	-	-	22 19.5	15 16.3
Cerebyx (Fosphenytoin sodium)	81 39.5	-	81 39.5 G	-	-	-	18 15.9	63 68.5 CGG
Depakote/Depakote ER/ Depakote Sprinkle (Divalproex Sodium)	198 96.6	-	198 96.6	-	-	-	112 99.1 HH	86 93.5
Depacon (Valproate sodium)	88 42.9	-	88 42.9 G	-	-	-	28 24.8	60 65.2 CGG
Depakene (Valproic acid)	134 65.4	-	134 65.4	-	-	-	64 56.6	70 76.1 cGG
Diastat (Diazepam)	121 59.0	-	121 59.0	-	-	-	71 62.8	50 54.3
Dilantin (Phenytoin)	187 91.2	-	187 91.2	-	-	-	107 94.7 hh	80 87.0

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 10
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Felbatol (Felbamate)	61 29.8	-	61 29.8	-	-	-	32 28.3	29 31.5
Gabitril (Tiagabine hydrochloride)	93 45.4	-	93 45.4	-	-	-	52 46.0	41 44.6
Keppra (Levetiracetam)	201 98.0	-	201 98.0	-	-	-	112 99.1	89 96.7
Klonopin (Clonazepam)	197 96.1	-	197 96.1	-	-	-	112 99.1 cHH	85 92.4
Lamictal (Lamotrigine)	190 92.7	-	190 92.7	-	-	-	110 97.3 CHH	80 87.0
Lorazepam Intensol (Lorazepam)	141 68.8	-	141 68.8 H	-	-	-	92 81.4 CHH	49 53.3
Lyrica (Pregabalin)	193 94.1	-	193 94.1	-	-	-	108 95.6	85 92.4
Mebaral (Mephobarbital)	20 9.8	-	20 9.8	-	-	-	12 10.6	8 8.7
Mysoline (Primidone)	111 54.1	-	111 54.1	-	-	-	57 50.4	54 58.7
Neurontin (Gabapentin)	200 97.6	-	200 97.6	-	-	-	112 99.1	88 95.7
Peganone (Ethotoin)	15 7.3	-	15 7.3	-	-	-	9 8.0	6 6.5

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 11
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Potiga (Ezogabine)	15 7.3	-	15 7.3	-	-	-	8 7.1	7 7.6
Tegretol/Tegretol XR (Carbamazepine)	179 87.3	-	179 87.3	-	-	-	101 89.4	78 84.8
Topamax (Topiramate)	187 91.2	-	187 91.2	-	-	-	108 95.6 HH	79 85.9
Tranxene (Clorazepate dipotassium)	92 44.9	-	92 44.9 h	-	-	-	60 53.1 HH	32 34.8
Trileptal (Oxcarbazepine)	163 79.5	-	163 79.5 H	-	-	-	101 89.4 CHH	62 67.4
Valium (Diazepam)	188 91.7	-	188 91.7	-	-	-	109 96.5 cHH	79 85.9
Zonegran (Zonisamide)	137 66.8	-	137 66.8	-	-	-	83 73.5 HH	54 58.7
NONE OF THESE	-	-	-	-	-	-	-	-
Total	3576	-	3576	-	-	-	1996	1580

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSA Page 12
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

SA: How would you classify your primary specialty?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Neurology	108 29.0	108 64.3	-	108 100.0 B	-	-	-	-
Neurosurgery	-	-	-	-	-	-	-	-
Epileptology	60 16.1	60 35.7	-	-	-	60 100.0 B	-	-
Pharmacy (Community/ Retail)	113 30.3	-	113 55.1	-	-	-	113 100.0 C	-
Pharmacy (Hospital/ Clinical)	92 24.7	-	92 44.9	-	-	-	-	92 100.0 C
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
None	-	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-	-
11-20	1 0.6	1 0.6	-	-	-	1 1.7	-	-
More than 20 patients	167 99.4	167 99.4	-	108 100.0	-	59 98.3	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSC Page 14
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Lamictal (Lamotrigine)	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Lyrica (Pregabalin)	161 95.8	161 95.8	-	105 97.2	-	56 93.3	-	-
Potiga (Ezogabine)	168 100.0	168 100.0	-	108 100.0	-	60 100.0	-	-
Tegretol/Tegretol XR (Carbamazepine)	164 97.6	164 97.6	-	105 97.2	-	59 98.3	-	-
Topamax (Topiramate)	167 99.4	167 99.4	-	107 99.1	-	60 100.0	-	-
None of the above	-	-	-	-	-	-	-	-
Total	828	828	-	533	-	295	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
None	-	-	-	-	-	-	-	-
1-2	2 1.0	-	2 1.0	-	-	-	1 0.9	1 1.1
3-10	17 8.3	-	17 8.3 G	-	-	-	3 2.7	14 15.2 GG
11-20	40 19.5	-	40 19.5	-	-	-	25 22.1	15 16.3
More than 20 prescriptions	146 71.2	-	146 71.2	-	-	-	84 74.3	62 67.4
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1 Page 16
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Migraine	3 0.8	2 1.2	1 0.5	2 1.9	-	-	-	1 1.1
Partial-onset seizures	291 78.0	164 97.6	127 62.0	104 96.3 GH	-	60 100.0 BDDGH	62 54.9	65 70.7 GG
Generalized tonic clonic seizures	15 4.0	9 5.4	6 2.9	8 7.4 ff	-	1 1.7	-	6 6.5
None of the above	-	-	-	-	-	-	-	-
I don't know	76 20.4	2 1.2	74 36.1 HB	2 1.9	-	-	51 45.1 HDH	23 25.0 D
Total	385	177	208	116	-	61	113	95

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
True	37 9.9	8 4.8	29 14.1 B	8 7.4	-	-	13 11.5	16 17.4 D
False	235 63.0	153 91.1 C	82 40.0	95 88.0 GH	-	58 96.7 bDDGH	38 33.6	44 47.8 GG
I don't know	101 27.1	7 4.2	94 45.9 hB	5 4.6	-	2 3.3	62 54.9 HDFH	32 34.8 DF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Urinary retention	260 69.7	143 85.1 C	117 57.1	88 81.5 GH	-	55 91.7 DDGH	60 53.1	57 62.0
Pancreatitis	14 3.8	9 5.4	5 2.4	6 5.6	-	3 5.0	-	5 5.4
Ischemic colitis	4 1.1	3 1.8	1 0.5	2 1.9	-	1 1.7	-	1 1.1
I don't know	104 27.9	19 11.3 f	85 41.5 B	16 14.8 FF	-	3 5.0	53 46.9 hDFh	32 34.8 DF
Total	382	174	208	112	-	62	113	95

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4 Page 19
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
600mg	21 5.6	11 6.5	10 4.9	7 6.5	-	4 6.7	6 5.3	4 4.3
900mg	17 4.6	13 7.7 C	4 2.0	10 9.3	-	3 5.0	-	4 4.3
1200mg	219 58.7	114 67.9 C	105 51.2	74 68.5 G	-	40 66.7 G	51 45.1	54 58.7 gg
2000mg	1 0.3	1 0.6	-	1 0.9	-	-	-	-
None of the above	10 2.7	4 2.4	6 2.9	2 1.9	-	2 3.3	2 1.8	4 4.3
I don't know	111 29.8	27 16.1	84 41.0 hB	16 14.8	-	11 18.3	56 49.6 HDPH	28 30.4 Df
Total	379	170	209	110	-	60	115	94

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
The oldest age at which POTIGA can be used is 65	8 2.1	6 3.6	2 1.0	3 2.8	-	3 5.0	1 0.9	1 1.1
There are no lower age limits for POTIGA	15 4.0	11 6.5 C	4 2.0	8 7.4 Gh	-	3 5.0	2 1.8	2 2.2
The youngest age at which POTIGA can be used is 12	33 8.8	22 13.1 C	11 5.4	11 10.2 G	-	11 18.3 Gh	4 3.5	7 7.6
The youngest age at which POTIGA can be used is 18	189 50.7	104 61.9 C	85 41.5	73 67.6 FFGH	-	31 51.7	44 38.9	41 44.6
None of the above	19 5.1	9 5.4	10 4.9	6 5.6	-	3 5.0	2 1.8	8 8.7 GG
I don't know	119 31.9	25 14.9	94 45.9 B	13 12.0	-	12 20.0	60 53.1 HDFH	34 37.0 DF
Total	383	177	206	114	-	63	113	93

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6 Page 21
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
POTIGA should always be taken with food	11 2.9	6 3.6	5 2.4	4 3.7	-	2 3.3	2 1.8	3 3.3
POTIGA should always be taken on its own, without food	5 1.3	2 1.2	3 1.5	2 1.9	-	-	2 1.8	1 1.1
POTIGA can be taken with or without food	236 63.3	116 69.0	120 58.5	73 67.6	-	43 71.7	61 54.0	59 64.1
			C	G		G		
None of the above	3 0.8	2 1.2	1 0.5	1 0.9	-	1 1.7	-	1 1.1
I don't know	119 31.9	42 25.0	77 37.6	28 25.9	-	14 23.3	49 43.4	28 30.4
			B				hDFh	
Total	374	168	206	108	-	60	114	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7 Page 22
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Pain when urinating	85 22.8	38 22.6	47 22.9	23 21.3	-	15 25.0	25 22.1	22 23.9
Difficulty starting urination	195 52.3	98 58.3 C	97 47.3 g	58 53.7 G	-	40 66.7 ddG	42 37.2	55 59.8 CGG
Renal colic	27 7.2	17 10.1 c	10 4.9	8 7.4	-	9 15.0 G	3 2.7	7 7.6
Inability to urinate	217 58.2	129 76.8 C	88 42.9	80 74.1 GH	-	49 81.7 GH	43 38.1	45 48.9
None of the above	2 0.5	1 0.6	1 0.5	-	-	1 1.7	-	1 1.1
I don't know	85 22.8	12 7.1 F	73 35.6 hB	11 10.2 FF	-	1 1.7	50 44.2 HDFH	23 25.0 DF
Total	611	295	316	180	-	115	163	153

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7NET Page 23
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Correct response (1,2,4)	52 13.9	23 13.7	29 14.1	14 13.0	-	9 15.0	14 12.4	15 16.3
Incorrect response	321 86.1	145 86.3	176 85.9	94 87.0	-	51 85.0	99 87.6	77 83.7
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8 Page 24
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Report the issue at their next doctor's appointment	31 8.3	6 3.6	25 12.2 B	3 2.8	-	3 5.0	15 13.3 DF	10 10.9 D
Drink more water	12 3.2	6 3.6	6 2.9	4 3.7	-	2 3.3	3 2.7	3 3.3
Seek immediate medical attention	277 74.3	139 82.7 C	138 67.3	89 82.4 G	-	50 83.3 G	70 61.9	68 73.9 gg
Stop taking POTIGA	94 25.2	68 40.5 C	26 12.7	43 39.8 GH	-	25 41.7 GH	14 12.4	12 13.0
None of the above	3 0.8	2 1.2	1 0.5	1 0.9	-	1 1.7	-	1 1.1
I don't know	47 12.6	3 1.8	44 21.5 B	3 2.8	-	-	27 23.9 D	17 18.5 D
Total	464	224	240	143	-	81	129	111

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Total daily dose increased by 50mg/day	47 12.6	21 12.5 F	26 12.7	18 16.7 FF	-	3 5.0	15 13.3 f	11 12.0
Total daily dose increased by 150mg/day	188 50.4	100 59.5 C	88 42.9 G	59 54.6 G	-	41 68.3 ddG	36 31.9	52 56.5 CGG
Total daily dose increased by 200mg/day	8 2.1	8 4.8	-	5 4.6	-	3 5.0	-	-
Total daily dose increased by 300mg/day	15 4.0	13 7.7 C	2 1.0	9 8.3 GH	-	4 6.7 g	1 0.9	1 1.1
None of the above	5 1.3	4 2.4	1 0.5	4 3.7	-	-	1 0.9	-
I don't know	110 29.5	22 13.1	88 42.9 HB	13 12.0	-	9 15.0	60 53.1 cHDFH	28 30.4 DF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10 Page 26
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
True	78 20.9	54 32.1 C	24 11.7	33 30.6 GH	-	21 35.0 GH	12 10.6	12 13.0
False	194 52.0	92 54.8	102 49.8	61 56.5 G	-	31 51.7	48 42.5	54 58.7 GG
I don't know	101 27.1	22 13.1	79 38.5 hB	14 13.0	-	8 13.3	53 46.9 HDPH	26 28.3 DF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R1 Page 27
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	280 75.1	147 87.5 C	133 64.9	93 86.1 GH	-	54 90.0 GH	65 57.5	68 73.9 GG
No	17 4.6	8 4.8	9 4.4	6 5.6	-	2 3.3	4 3.5	5 5.4
Don't know	76 20.4	13 7.7	63 30.7 hB	9 8.3	-	4 6.7	44 38.9 HDFH	19 20.7 DF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R2 Page 28
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	38 10.2	18 10.7	20 9.8	15 13.9 FF	-	3 5.0	10 8.8	10 10.9
No	149 39.9	87 51.8 C	62 30.2 g	53 49.1 G	-	34 56.7 Gh	24 21.2	38 41.3 cGG
Don't know	186 49.9	63 37.5	123 60.0 hB	40 37.0	-	23 38.3	79 69.9 cHDPH	44 47.8
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R3 Page 29
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	18 4.8	6 3.6	12 5.9	3 2.8	-	3 5.0	5 4.4	7 7.6
No	178 47.7	106 63.1	72 35.1	65 60.2	-	41 68.3	32 28.3	40 43.5
			C	GH		GH		GG
Don't know	177 47.5	56 33.3	121 59.0	40 37.0	-	16 26.7	76 67.3	45 48.9
			B				HDFH	dF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R4 Page 30
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	183 49.1	93 55.4 C	90 43.9 g	60 55.6 G	-	33 55.0 G	39 34.5	51 55.4 cGG
No	61 16.4	39 23.2 C	22 10.7	24 22.2 GH	-	15 25.0 GH	12 10.6	10 10.9
Don't know	129 34.6	36 21.4	93 45.4 hB	24 22.2	-	12 20.0	62 54.9 HDPH	31 33.7 df
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R5 Page 31
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	51 13.7	20 11.9	31 15.1	13 12.0	-	7 11.7	12 10.6	19 20.7 9g
No	131 35.1	79 47.0 C	52 25.4	50 46.3 GH	-	29 48.3 GH	25 22.1	27 29.3
Don't know	191 51.2	69 41.1	122 59.5 B	45 41.7	-	24 40.0	76 67.3 HDPH	46 50.0
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12 Page 32
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
True	218 58.4	124 73.8 C	94 45.9 g	79 73.1 GH	-	45 75.0 GH	41 36.3	53 57.6 cGG
False	16 4.3	8 4.8	8 3.9	7 6.5 ffH	-	1 1.7	7 6.2 HH	1 1.1
I don't know	139 37.3	36 21.4	103 50.2 B	22 20.4	-	14 23.3	65 57.5 HDPH	38 41.3 DF
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13 Page 33
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Patients with benign prostatic hyperplasia (BPH)	281 75.3	144 85.7 C	137 66.8	94 87.0 GH	-	50 83.3 Gh	71 62.8	66 71.7
Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	233 62.5	134 79.8 C	99 48.3	82 75.9 GH	-	52 86.7 ddGH	51 45.1	48 52.2
Patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics)	267 71.6	138 82.1 C	129 62.9	90 83.3 GH	-	48 80.0 Gh	67 59.3	62 67.4
Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	46 12.3	13 7.7	33 16.1 B	9 8.3	-	4 6.7	18 15.9 dF	15 16.3 df
Patients who are obese	16 4.3	4 2.4	12 5.9 b	3 2.8	-	1 1.7	7 6.2	5 5.4
None of the above	3 0.8	1 0.6	2 1.0	1 0.9	-	-	1 0.9	1 1.1
I don't know	68 18.2	11 6.5	57 27.8 B	7 6.5	-	4 6.7	38 33.6 HDFH	19 20.7 DF
Total	914	445	469	286	-	159	253	216

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q14 Page 34
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q14: How long have you been practicing medicine?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Less than 5 years	8 4.8	8 4.8	-	4 3.7	-	4 6.7	-	-
5-15 years	69 41.1	69 41.1	-	40 37.0	-	29 48.3	-	-
16-25 years	61 36.3	61 36.3	-	42 38.9	-	19 31.7	-	-
26-35 years	25 14.9	25 14.9	-	19 17.6	-	6 10.0	-	-
More than 35 years	5 3.0	5 3.0	-	3 2.8	-	2 3.3	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q15 Page 35
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Less than 5 years	6 3.6	6 3.6	-	3 2.8	-	3 5.0	-	-
5-15 years	72 42.9	72 42.9	-	39 36.1	-	33 55.0 DD	-	-
16-25 years	59 35.1	59 35.1	-	42 38.9	-	17 28.3	-	-
26-35 years	26 15.5	26 15.5	-	20 18.5	-	6 10.0	-	-
More than 35 years	5 3.0	5 3.0	-	4 3.7	-	1 1.7	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q16 Page 36
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q16: How many months have you been prescribing POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Less than 1	16 9.5	16 9.5	-	11 10.2	-	5 8.3	-	-
1-3	55 32.7	55 32.7	-	35 32.4	-	20 33.3	-	-
4-6	50 29.8	50 29.8	-	35 32.4	-	15 25.0	-	-
7-9	19 11.3	19 11.3	-	9 8.3	-	10 16.7	-	-
10-12	12 7.1	12 7.1	-	6 5.6	-	6 10.0	-	-
More than 12 months	11 6.5	11 6.5	-	8 7.4	-	3 5.0	-	-
I don't know/don't remember	5 3.0	5 3.0	-	4 3.7	-	1 1.7	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q17 Page 37
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
1-2	87 51.8	87 51.8	-	63 58.3 FF	-	24 40.0	-	-
3-10	66 39.3	66 39.3	-	36 33.3	-	30 50.0 DD	-	-
11-20	12 7.1	12 7.1	-	8 7.4	-	4 6.7	-	-
More than 20 patients	3 1.8	3 1.8	-	1 0.9	-	2 3.3	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q18 Page 38
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
1-10	5 3.0	5 3.0	-	5 4.6	-	-	-	-
11-30	24 14.3	24 14.3	-	22 20.4 FF	-	2 3.3	-	-
31-50	38 22.6	38 22.6	-	29 26.9 ff	-	9 15.0	-	-
More than 50	101 60.1	101 60.1 d	-	52 48.1	-	49 81.7 BDD	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q19 Page 39
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q19: What is the age range of your current patient population? Please select all categories that you treat.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Pediatric (Under 18)	53 31.5	53 31.5	-	29 26.9	-	24 40.0 dd	-	-
18-34	155 92.3	155 92.3	-	100 92.6	-	55 91.7	-	-
35-64	157 93.5	157 93.5	-	102 94.4	-	55 91.7	-	-
65 +	143 85.1	143 85.1	-	91 84.3	-	52 86.7	-	-
Total	508	508	-	322	-	186	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q20 Page 40
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q20: Approximately what is the size of your current total patient population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Less than 100 patients	1 0.6	1 0.6	-	-	-	1 1.7	-	-
100 - 500 patients	19 11.3	19 11.3	-	10 9.3	-	9 15.0	-	-
501 - 1000 patients	56 33.3	56 33.3	-	35 32.4	-	21 35.0	-	-
More than 1000 patients	92 54.8	92 54.8	-	63 58.3	-	29 48.3	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q21 Page 41
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q21: Approximately what is the size of your current epilepsy patient population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	168	168	-	108	-	60	-	-
Less than 10 patients	-	-	-	-	-	-	-	-
10 - 50 patients	3 1.8	3 1.8	-	3 2.8	-	-	-	-
51 - 100 patients	25 14.9	25 14.9 F	-	24 22.2 FF	-	1 1.7	-	-
101+ patients	140 83.3	140 83.3 d	-	81 75.0	-	59 98.3 BDD	-	-
I do not treat patients with epilepsy	-	-	-	-	-	-	-	-
Total	168	168	-	108	-	60	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q22 Page 42
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q22: How long have you been a practicing pharmacist?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Less than 5 years	30 14.6	-	30 14.6 H	-	-	-	28 24.8 CHH	2 2.2
5-15 years	60 29.3	-	60 29.3 H	-	-	-	43 38.1 HH	17 18.5
16-25 years	49 23.9	-	49 23.9	-	-	-	22 19.5	27 29.3
26-35 years	45 22.0	-	45 22.0 G	-	-	-	12 10.6	33 35.9 CGG
More than 35 years	21 10.2	-	21 10.2	-	-	-	8 7.1	13 14.1
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Less than 5 years	35 17.1	-	35 17.1 H	-	-	-	30 26.5 cHH	5 5.4
5-15 years	64 31.2	-	64 31.2 H	-	-	-	47 41.6 cHH	17 18.5
16-25 years	48 23.4	-	48 23.4	-	-	-	21 18.6	27 29.3 gg
26-35 years	41 20.0	-	41 20.0 G	-	-	-	10 8.8	31 33.7 CGG
More than 35 years	17 8.3	-	17 8.3	-	-	-	5 4.4	12 13.0 GG
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q24 Page 44
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Yes	21 10.2	-	21 10.2	-	-	-	9 8.0	12 13.0
No	171 83.4	-	171 83.4	-	-	-	98 86.7	73 79.3
I don't know/don't remember	13 6.3	-	13 6.3	-	-	-	6 5.3	7 7.6
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q25 Page 45
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q25: Have you dispensed POTIGA in the past 12 months?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	205	-	205	-	-	-	113	92
Yes	32 15.6	-	32 15.6	-	-	-	12 10.6	20 21.7 GG
No	158 77.1	-	158 77.1	-	-	-	92 81.4	66 71.7
I don't know/don't remember	15 7.3	-	15 7.3	-	-	-	9 8.0	6 6.5
Total	205	-	205	-	-	-	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q26 Page 46
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q26: How many months have you been dispensing POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	32	-	32	-	-	-	12	20
Less than 1	3 9.4	-	3 9.4	-	-	-	-	3 15.0
1-3	14 43.8	-	14 43.8	-	-	-	7 58.3	7 35.0
4-6	5 15.6	-	5 15.6	-	-	-	2 16.7	3 15.0
7-9	1 3.1	-	1 3.1	-	-	-	-	1 5.0
10-12	5 15.6	-	5 15.6	-	-	-	1 8.3	4 20.0
More than 12 months	1 3.1	-	1 3.1	-	-	-	1 8.3	-
I don't know/don't remember	3 9.4	-	3 9.4	-	-	-	1 8.3	2 10.0
Total	32	-	32	-	-	-	12	20

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q27 Page 47
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	32	-	32	-	-	-	12	20
1-2	21 65.6	-	21 65.6	-	-	-	9 75.0	12 60.0
3-10	8 25.0	-	8 25.0	-	-	-	3 25.0	5 25.0
11-20	1 3.1	-	1 3.1	-	-	-	-	1 5.0
More than 20 patients	1 3.1	-	1 3.1	-	-	-	-	1 5.0
I don't know/don't remember	1 3.1	-	1 3.1	-	-	-	-	1 5.0
Total	32	-	32	-	-	-	12	20

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q28 Page 48
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	32	-	32	-	-	-	12	20
1 - 10	4 12.5	-	4 12.5	-	-	-	-	4 20.0
11 - 30	8 25.0	-	8 25.0	-	-	-	5 41.7	3 15.0
31 - 50	7 21.9	-	7 21.9	-	-	-	3 25.0	4 20.0
More than 50 prescriptions	13 40.6	-	13 40.6	-	-	-	4 33.3	9 45.0
Total	32	-	32	-	-	-	12	20

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R1 Page 49
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	24 6.4	14 8.3	10 4.9	5 4.6	-	9 15.0 DDG	4 3.5	6 6.5
No	323 86.6	137 81.5	186 90.7 B	89 82.4	-	48 80.0	103 91.2 df	83 90.2 f
Don't know	26 7.0	17 10.1 C	9 4.4	14 13.0 ffGH	-	3 5.0	6 5.3	3 3.3
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R2 Page 50
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	79 21.2	58 34.5 C	21 10.2	31 28.7 GH	-	27 45.0 DDGH	7 6.2	14 15.2 GG
No	275 73.7	98 58.3	177 86.3 B	68 63.0	-	30 50.0	101 89.4 DF	76 82.6 DF
Don't know	19 5.1	12 7.1	7 3.4	9 8.3 H	-	3 5.0	5 4.4	2 2.2
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R3 Page 51
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	95 25.5	67 39.9 C	28 13.7	44 40.7 GH	-	23 38.3 GH	13 11.5	15 16.3
No	261 70.0	90 53.6	171 83.4 B	56 51.9	-	34 56.7	96 85.0 DF	75 81.5 DF
Don't know	17 4.6	11 6.5	6 2.9	8 7.4 h	-	3 5.0	4 3.5	2 2.2
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R4 Page 52
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	80 21.4	39 23.2	41 20.0	23 21.3	-	16 26.7	23 20.4	18 19.6
No	277 74.3	118 70.2	159 77.6	76 70.4	-	42 70.0	88 77.9	71 77.2
Don't know	16 4.3	11 6.5 c	5 2.4	9 8.3 G	-	2 3.3	2 1.8	3 3.3
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R5 Page 53
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	109 29.2	100 59.5 C	9 4.4	68 63.0 GH	-	32 53.3 GH	5 4.4	4 4.3
No	254 68.1	64 38.1	190 92.7 B	37 34.3	-	27 45.0	105 92.9 DF	85 92.4 DF
Don't know	10 2.7	4 2.4	6 2.9	3 2.8	-	1 1.7	3 2.7	3 3.3
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R6 Page 54
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	34 9.1	30 17.9 C	4 2.0	14 13.0 GH	-	16 26.7 DDGH	2 1.8	2 2.2
No	325 87.1	130 77.4	195 95.1 B	87 80.6	-	43 71.7	108 95.6 DF	87 94.6 DF
Don't know	14 3.8	8 4.8	6 2.9	7 6.5 ff	-	1 1.7	3 2.7	3 3.3
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	226 60.6	131 78.0 C	95 46.3	79 73.1 GH	-	52 86.7 DDGH	47 41.6	48 52.2
No	134 35.9	30 17.9	104 50.7 B	23 21.3 ff	-	7 11.7	63 55.8 DF	41 44.6 DF
Don't know	13 3.5	7 4.2	6 2.9	6 5.6	-	1 1.7	3 2.7	3 3.3
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
Yes	119 31.9	74 44.0 C	45 22.0	38 35.2 Gh	-	36 60.0 BDDGH	23 20.4	22 23.9
No	239 64.1	85 50.6 F	154 75.1 B	64 59.3 FF	-	21 35.0	86 76.1 DF	68 73.9 DF
Don't know	15 4.0	9 5.4	6 2.9	6 5.6	-	3 5.0	4 3.5	2 2.2
Total	373	168	205	108	-	60	113	92

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q30 Page 57
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	373	168	205	108	-	60	113	92
POTIGA Dear HCP Letter	85 22.8	21 12.5	64 31.2 B	13 12.0	-	8 13.3	29 25.7 DF	35 38.0 gDFg
GlaxoSmithKline Medical Information	89 23.9	41 24.4	48 23.4	21 19.4	-	20 33.3 ddg	24 21.2	24 26.1
Other Healthcare Professionals	96 25.7	60 35.7 C	36 17.6	36 33.3 GH	-	24 40.0 GH	17 15.0	19 20.7
GlaxoSmithKline Promotional Materials	88 23.6	28 16.7	60 29.3 B	22 20.4 ff	-	6 10.0	34 30.1 dF	26 28.3 F
GSK Website: POTIGA.com	98 26.3	37 22.0	61 29.8 b	23 21.3	-	14 23.3	33 29.2	28 30.4
GlaxoSmithKline Sales Representatives	148 39.7	77 45.8 FC	71 34.6 h	58 53.7 FFgH	-	19 31.7	48 42.5 HH	23 25.0
GlaxoSmithKline-sponsored Educational Meeting	166 44.5	92 54.8 C	74 36.1	57 52.8 gH	-	35 58.3 GH	45 39.8	29 31.5
POTIGA Product Labeling (including Prescribing Information, Medication Guide)	161 43.2	60 35.7	101 49.3 B	37 34.3	-	23 38.3	62 54.9 hDFh	39 42.4
Total	931	416	515	267	-	149	292	223

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	91	11	80	10	-	1	51	29
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	62 68.1	1 9.1	61 76.2 B	1 10.0	-	-	41 80.4 D	20 69.0 D
FDA approved only for partial on-set seizures/ used for partial seizures	6 6.6	4 36.4 C	2 2.5	4 40.0 GH	-	-	1 2.0	1 3.4
Used for all indications listed/aware of different uses for the med/med used for expanded indications in other countries	3 3.3	1 9.1	2 2.5	1 10.0	-	-	-	2 6.9
General recall/memory	4 4.4	1 9.1	3 3.8	1 10.0	-	-	-	3 10.3
Seizures/severe seizure disorder	2 2.2	1 9.1	1 1.2	1 10.0	-	-	-	1 3.4
Adjunctive therapy for CP seizures	1 1.1	1 9.1	-	1 10.0	-	-	-	-
Information provided from Pharmaceutical Representative	1 1.1	1 9.1	-	1 10.0	-	-	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1_1CODE Page 59
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
GTC could be partial with secondary or primary generalization (indicated)/this drug works well with partial seizure & also may work with generalized tonic clonic seizure	2 2.2	1 9.1	1 1.2	-	-	1 100.0 BH	-	1 3.4
Epilepsy	1 1.1	-	1 1.2	-	-	-	1 2.0	-
Not seen the approved uses for POTIGA	2 2.2	-	2 2.5	-	-	-	1 2.0	1 3.4
Not sure for what type of seizures	3 3.3	-	3 3.8	-	-	-	3 5.9	-
Forgot	1 1.1	-	1 1.2	-	-	-	1 2.0	-
Misunderstood question/ Question is vague	3 3.3	2 18.2	1 1.2	1 10.0	-	1 100.0 BDDG	1 2.0	-
Don't know/Do not recall	4 4.4	-	4 5.0	-	-	-	3 5.9	1 3.4
Total	95	13	82	11	-	2	52	30

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 60
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	135	13	122	11	-	2	74	48
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	72 53.3	-	72 59.0	-	-	-	50 67.6 HH	22 45.8
I believe so/I think it can be used for monotherapy	2 1.5	1 7.7	1 0.8	1 9.1	-	-	-	1 2.1
Using clinically/on- going trials for monotherapy use	2 1.5	2 15.4	-	2 18.2	-	-	-	-
Do not believe it is approved, but can be used as monotherapy	1 0.7	1 7.7	-	-	-	1 50.0	-	-
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions	12 8.9	1 7.7	11 9.0	1 9.1	-	-	6 8.1	5 10.4
To be used as add-on therapy/approved as add- on to be treat seizures associated with epilepsy	2 1.5	1 7.7	1 0.8	1 9.1	-	-	-	1 2.1

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 61
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Can be used as mono-therapy/believe it can be used for monotherapy/have patients just using POTIGA/have seen it prescribed as a monotherapy/general mechanism lends itself to monotherapy	6 4.4	1 7.7	5 4.1	1 9.1	-	-	3 4.1	2 4.2
Information provided from Pharmaceutical Representative	1 0.7	1 7.7	-	1 9.1	-	-	-	-
Newer medications are usually monotherapy treatment	1 0.7	-	1 0.8	-	-	-	1 1.4	-
Have not seen the PI	1 0.7	-	1 0.8	-	-	-	1 1.4	-
Could be more effective as a monotherapy	1 0.7	-	1 0.8	-	-	-	1 1.4	-
Can use used in patients with previous failed therapies	1 0.7	-	1 0.8	-	-	-	-	1 2.1
The drug information does not state it is used in conjunction	1 0.7	-	1 0.8	-	-	-	-	1 2.1
Have not seen it promoted as adjunct therapy	1 0.7	-	1 0.8	-	-	-	-	1 2.1

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 62
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Literature states can be used with other agents but dose may need to be increased	1 0.7	-	1 0.8	-	-	-	-	1 2.1
Cannot be used a monotherapy	1 0.7	-	1 0.8	-	-	-	-	1 2.1
Not sure/not sure if it can be used as monotherapy	6 4.4	4 30.8	2 1.6	3 27.3	-	1 50.0	-	2 4.2
Miscellaneous	5 3.7	-	5 4.1	-	-	-	3 4.1	2 4.2
Don't know/Do not recall	11 8.1	1 7.7	10 8.2	1 9.1	-	-	5 6.8	5 10.4
Used as adjunctive therapy/only prescribed as adjunctive therapy/FDA approved as adjunctive therapy/can be used with other seizure meds	7 5.2	-	7 5.7	-	-	-	4 5.4	3 6.2
Total	135	13	122	11	-	2	74	48

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 63
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	117	28	89	22	-	6	52	37
Lack of familiarity/ never heard of POTIGA, POTIGA risks or side effects/never dispensed POTIGA/no experience with POTIGA	59 50.4	1 3.6	58 65.2 B	1 4.5	-	-	38 73.1 hDh	20 54.1 D
Pancreatitis is common with AEDs	1 0.9	1 3.6	-	1 4.5	-	-	-	-
Ischemic colitis possible/may be reported	1 0.9	1 3.6	-	1 4.5	-	-	-	-
Risks reported in literature	1 0.9	1 3.6	-	1 4.5	-	-	-	-
General recall/memory/ best recall from PI/ clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data	4 3.4	3 10.7	1 1.1	2 9.1	-	1 16.7	-	1 2.7
Conditions can occur when stopping use of POTIGA	1 0.9	1 3.6	-	1 4.5	-	-	-	-
Aware of some risks associated with medicine, but not aware of all risks/aware of the major risks	4 3.4	2 7.1	2 2.2	2 9.1	-	-	-	2 5.4

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 64
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Aware of urinary issues/ problem with urinary function	6 5.1	2 7.1	4 4.5	2 9.1	-	-	3 5.8	1 2.7
Incorporated POTIGA into regimen, but not able to learn about the drug yet	1 0.9	1 3.6	-	1 4.5	-	-	-	-
Side effect/recall some of the side effects	2 1.7	2 7.1	-	-	-	2 33.3	-	-
Kidney, liver problems/ potentially toxic to kidneys	2 1.7	1 3.6	1 1.1	1 4.5	-	-	1 1.9	-
Never read the PI and not explained by pharmaceutical representative/never had a POTIGA representative visit/never fully read prescribing information	9 7.7	3 10.7	6 6.7	2 9.1	-	1 16.7	4 7.7	2 5.4
Known caution when using POTIGA	1 0.9	1 3.6	-	1 4.5	-	-	-	-
Have not done research yet	2 1.7	-	2 2.2	-	-	-	2 3.8	-
Not a lot of information available on POTIGA	1 0.9	-	1 1.1	-	-	-	1 1.9	-
Could cause hepatic issues/requires dose adjustments in hepatic diseases	2 1.7	-	2 2.2	-	-	-	-	2 5.4

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 65
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Mistaken POTIGA for another medicine/ mistaken in initial response	2 1.7	2 7.1	-	1 4.5	-	1 16.7	-	-
Risks listed on the article on the list server	1 0.9	-	1 1.1	-	-	-	-	1 2.7
Adverse event reported by patient, not ruled out as the cause	1 0.9	-	1 1.1	-	-	-	-	1 2.7
Limited knowledge of drug	1 0.9	-	1 1.1	-	-	-	-	1 2.7
Not sure/not sure about the side effects, risks	8 6.8	3 10.7	5 5.6	2 9.1	-	1 16.7	3 5.8	2 5.4
Miscellaneous	6 5.1	2 7.1	4 4.5	2 9.1	-	-	1 1.9	3 8.1
Misunderstood question/ Question is vague	1 0.9	1 3.6	-	-	-	1 16.7	-	-
Don't know/Do not recall	8 6.8	3 10.7	5 5.6	3 13.6	-	-	2 3.8	3 8.1
Total	125	31	94	24	-	7	55	39

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 66
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	156	54	102	34	-	20	63	39
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	58 37.2	1 1.9	57 55.9 B	1 2.9	-	-	39 61.9 D	18 46.2 D
Not aware of the maximum dosage/uncertain of maximum dosage/not seen information on maximum dosing/not heard of maximum dosing	19 12.2	7 13.0	12 11.8	3 8.8	-	4 20.0	10 15.9 hh	2 5.1
Recall maximum dose from pharmaceutical representative/ information from pharmaceutical representative	4 2.6	4 7.4	-	4 11.8	-	-	-	-
400mg three times a day/ 1200mg maximum dose	11 7.1	6 11.1	5 4.9	4 11.8 g	-	2 10.0	1 1.6	4 10.3 gg
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	9 5.8	8 14.8 C	1 1.0	6 17.6 H	-	2 10.0	-	1 2.6

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 67
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Thought it was a different value	1 0.6	1 1.9	-	-	-	1 5.0	-	-
Representative said 1200mg, but being conservative	1 0.6	1 1.9	-	1 2.9	-	-	-	-
Clinical trials tested at 900mg-1200mg maximum dose	1 0.6	1 1.9	-	1 2.9	-	-	-	-
Personal experience/how currently prescribing	2 1.3	2 3.7	-	2 5.9	-	-	-	-
Previous studies indication a dose greater than 900mg offered no significant increased benefit, but greater side effects/ 1200mg not shown to be efficacious than 900mg/ seizure frequency reduced at a lesser percent with higher dose	5 3.2	3 5.6	2 2.0	1 2.9	-	2 10.0	1 1.6	1 2.6
Never read the PI/never fully read the prescribing information	4 2.6	1 1.9	3 2.9	-	-	1 5.0	2 3.2	1 2.6
Never met with a pharmaceutical representative	2 1.3	1 1.9	1 1.0	1 2.9	-	-	1 1.6	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 68
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
150mg per day/per week that can be titrated	1 0.6	1 1.9	-	1 2.9	-	-	-	-
Incorrect suggested maximum dose stated	10 6.4	3 5.6	7 6.9	2 5.9	-	1 5.0	3 4.8	4 10.3
Refer/consult PI/would look up before dispensing	5 3.2	2 3.7	3 2.9	-	-	2 10.0	2 3.2	1 2.6
Rarely use POTIGA/only used POTIGA a few times	3 1.9	3 5.6	-	-	-	3 15.0	-	-
Depends on the patient	1 0.6	-	1 1.0	-	-	-	1 1.6	-
Not had a chance to look up dosing recommendations/research of the drug/need further info	4 2.6	-	4 3.9	-	-	-	2 3.2	2 5.1
Maximum dose is between 600mg-1200mg	3 1.9	-	3 2.9	-	-	-	2 3.2	1 2.6
Not sure	2 1.3	1 1.9	1 1.0	1 2.9	-	-	-	1 2.6
Miscellaneous	4 2.6	2 3.7	2 2.0	-	-	2 10.0	-	2 5.1
Don't know/Do not recall	10 6.4	7 13.0 C	3 2.9	6 17.6 Gh	-	1 5.0	1 1.6	2 5.1
Total	160	55	105	34	-	21	65	40

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 69
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	184	67	117	37	-	30	66	51
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	58 31.5	1 1.5	57 48.7 B	1 2.7	-	-	36 54.5 D	21 41.2 D
Not aware of the minimum age/do not know lower age limit/have not heard about what the lower age limit is	25 13.6	7 10.4	18 15.4	4 10.8	-	3 10.0	10 15.2	8 15.7
Pharmaceutical representative unsure of the age limits	1 0.5	1 1.5	-	1 2.7	-	-	-	-
No known upper age limits	2 1.1	1 1.5	1 0.9	1 2.7	-	-	-	1 2.0
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	8 4.3	6 9.0 C	2 1.7	4 10.8	-	2 6.7	-	2 3.9
Persons 12 years of age/ believe 12 years of age/ adolescents/most recently approved AEDs for age 12	9 4.9	8 11.9 C	1 0.9	3 8.1	-	5 16.7 G	1 1.5	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 70
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Adults/only approved for adults/approved for 18+	9 4.9	4 6.0	5 4.3	3 8.1	-	1 3.3	2 3.0	3 5.9
Clinical trials/studies did not include children/not established data in children	6 3.3	2 3.0	4 3.4	-	-	2 6.7	2 3.0	2 3.9
Incorrect label reference/indications	1 0.5	1 1.5	-	1 2.7	-	-	-	-
Data does not provide/indicate/cannot recall from clinical trials/information not available	3 1.6	2 3.0	1 0.9	1 2.7	-	1 3.3	-	1 2.0
Used for medically refractory seizures	1 0.5	1 1.5	-	1 2.7	-	-	-	-
Not approved for children/do not use in the pediatric population/new anticonvulsants do not have pediatric dosing	5 2.7	4 6.0 c	1 0.9	3 8.1	-	1 3.3	-	1 2.0
Information form pharmaceutical representative	1 0.5	1 1.5	-	-	-	1 3.3	-	-
Do not use POTIGA enough to have this experience	1 0.5	1 1.5	-	1 2.7	-	-	-	-
No lower age limit/safe for infants and children/AEDs do not have a lower age limit	3 1.6	2 3.0	1 0.9	2 5.4	-	-	1 1.5	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 71
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Uncertain whether lower age limit is 12 or 18/ uncertain if age limit is 18 years	6 3.3	5 7.5 C	1 0.9	2 5.4	-	3 10.0	1 1.5	-
Used with caution for those 65+/over 65 could have urination problems, immune system problems, weakness/65 is age limit/ not sure if contraindicated for patients over 65	16 8.7	5 7.5	11 9.4	3 8.1	-	2 6.7	7 10.6	4 7.8
No indication in the prescribing information	3 1.6	3 4.5	-	2 5.4	-	1 3.3	-	-
Would refer to the package insert/have to research the drug/not studied drug yet	4 2.2	1 1.5	3 2.6	-	-	1 3.3	2 3.0	1 2.0
Based on FDA labeling	1 0.5	1 1.5	-	-	-	1 3.3	-	-
Do not treat pediatrics/ patients are over age 18	2 1.1	2 3.0	-	-	-	2 6.7	-	-
Age 17 and above	1 0.5	1 1.5	-	-	-	1 3.3	-	-
Have used it in patients over 65 and under 12 years	1 0.5	1 1.5	-	-	-	1 3.3	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 72
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Dosage limits based on age, hepatic, renal functions	1 0.5	-	1 0.9	-	-	-	1 1.5	-
Label is unclear	1 0.5	-	1 0.9	-	-	-	-	1 2.0
Not sure of age limit / best guess from PI	7 3.8	2 3.0	5 4.3	-	-	2 6.7	4 6.1	1 2.0
Miscellaneous	9 4.9	5 7.5	4 3.4	4 10.8	-	1 3.3	-	4 7.8
Don't know/Do not recall	13 7.1	6 9.0	7 6.0	4 10.8	-	2 6.7	3 4.5	4 7.8
Total	198	74	124	41	-	33	70	54

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 73
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	136	51	85	34	-	17	52	33
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	56 41.2	4 7.8	52 61.2 hB	3 8.8	-	1 5.9	38 73.1 HDPH	14 42.4 DF
POTIGA can be taken with or without food/pretty sure can be taken with or without food	6 4.4	3 5.9	3 3.5	2 5.9	-	1 5.9	2 3.8	1 3.0
POTIGA should be taken with food/think it should be taken with food	2 1.5	2 3.9	-	1 2.9	-	1 5.9	-	-
POTIGA should be taken without food/believe absorption is better with an empty stomach	1 0.7	1 2.0	-	1 2.9	-	-	-	-
Not sure about the absorption of this medication/unaware how food effects absorption of product	4 2.9	1 2.0	3 3.5	1 2.9	-	-	-	3 9.1
Not aware of any need to specify that it should be taken with or without food	2 1.5	1 2.0	1 1.2	1 2.9	-	-	-	1 3.0
General recall/believe to be true	3 2.2	1 2.0	2 2.4	1 2.9	-	-	1 1.9	1 3.0

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 74
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Taken with food due to stomach side effects	1 0.7	1 2.0	-	-	-	1 5.9	-	-
Food slows the absorption but not area under the curve	1 0.7	1 2.0	-	1 2.9	-	-	-	-
Minimize nonspecific neurocognitive side effects on multiple AEDs	1 0.7	1 2.0	-	-	-	1 5.9	-	-
Incorrect selection	2 1.5	-	2 2.4	-	-	-	2 3.8	-
From the prescribing literature/from pharmaceutical representative/from the information	3 2.2	2 3.9	1 1.2	2 5.9	-	-	-	1 3.0
Never met with a pharmaceutical representative	1 0.7	1 2.0	-	1 2.9	-	-	-	-
Normally advise to take without food unless seen that it should be taken with food	1 0.7	-	1 1.2	-	-	-	1 1.9	-
Nothing in literature about recommendation with or without food/nothing in literature about specific guidelines/information not readily available	3 2.2	-	3 3.5	-	-	-	1 1.9	2 6.1

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 75
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Refer/consult PI/would look up before dispensing	2 1.5	1 2.0	1 1.2	-	-	1 5.9	1 1.9	-
Never had a patient on POTIGA	2 1.5	-	2 2.4	-	-	-	-	2 6.1
GI side effects	1 0.7	-	1 1.2	-	-	-	-	1 3.0
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	7 5.1	4 7.8	3 3.5	3 8.8	-	1 5.9	3 5.8	-
Not sure/uncertain/unaware	11 8.1	7 13.7 c	4 4.7	6 17.6 H	-	1 5.9	3 5.8	1 3.0
Miscellaneous	2 1.5	1 2.0	1 1.2	-	-	1 5.9	-	1 3.0
Don't know/Do not recall	27 19.9	20 39.2 C	7 8.2	12 35.3 Gh	-	8 47.1 GH	2 3.8	5 15.2 gg
Total	139	52	87	35	-	17	54	33

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 76
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	318	143	175	92	-	51	98	77
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	55 17.3	2 1.4	53 30.3 B	1 1.1	-	1 2.0	37 37.8 HDPH	16 20.8 DF
Unique side effect/side effects reported by patients/side effects/ symptom/potential complication	43 13.5	22 15.4	21 12.0	14 15.2	-	8 15.7	14 14.3	7 9.1
Unaware of the urinary symptoms/unaware of side effects, symptoms when taking POTIGA	6 1.9	1 0.7	5 2.9	1 1.1	-	-	4 4.1	1 1.3
Urinary retention is a symptom or AE/watch for urinary retention/ urinary retention/ urinary retention potential side effect/ urinary retention has been reported	80 25.2	51 35.7 C	29 16.6	34 37.0 GH	-	17 33.3 G	13 13.3	16 20.8
POTIGA may make symptoms worse	1 0.3	1 0.7	-	-	-	1 2.0	-	-
Affect urinary flow/ difficulty starting urination/voiding dysfunction/difficulty urinating/urinary problems/pain with urination	22 6.9	6 4.2	16 9.1 b	4 4.3	-	2 3.9	9 9.2	7 9.1

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 77
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
General recall/memory/ knowledge	15 4.7	10 7.0 c	5 2.9	6 6.5	-	4 7.8	2 2.0	3 3.9
Forgot, but did know about urinary symptoms/ forgot about these risks	2 0.6	1 0.7	1 0.6	1 1.1	-	-	1 1.0	-
Warning from package insert/from package insert and patient info materials/warning for the drug/drug info/main warning	18 5.7	12 8.4 c	6 3.4	7 7.6 g	-	5 9.8 g	2 2.0	4 5.2
Read/heard about it (non- specific)	5 1.6	3 2.1	2 1.1	1 1.1	-	2 3.9	1 1.0	1 1.3
Clinical trials/results of clinical trials	11 3.5	8 5.6 c	3 1.7	5 5.4 g	-	3 5.9	1 1.0	2 2.6
From the prescribing literature/from pharmaceutical representative/from the information, medication inserts/drug company/ online pamphlet, REMS literature	29 9.1	18 12.6 c	11 6.3	13 14.1 G	-	5 9.8	5 5.1	6 7.8
Indications and label/ label	3 0.9	1 0.7	2 1.1	1 1.1	-	-	-	2 2.6

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 78
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
From internet/Google	1 0.3	1 0.7	-	1 1.1	-	-	-	-
From past experience with patients/personal experience	6 1.9	6 4.2	-	1 1.1	-	5 9.8 DD	-	-
Never discussed/seen POTIGA representative	1 0.3	1 0.7	-	1 1.1	-	-	-	-
Easiest to tell patients to look out for/discuss with patients/advise patients	6 1.9	3 2.1	3 1.7	2 2.2	-	1 2.0	2 2.0	1 1.3
Bladder hypotonia can occur	1 0.3	1 0.7	-	1 1.1	-	-	-	-
Never read prescribing information	1 0.3	-	1 0.6	-	-	-	1 1.0	-
Not enough information on drug/not enough time to research it/not specific recommendations to patients	4 1.3	-	4 2.3	-	-	-	1 1.0	3 3.9
Side effects of an urinary tract infection	1 0.3	-	1 0.6	-	-	-	1 1.0	-
Black box warning	1 0.3	-	1 0.6	-	-	-	1 1.0	-
Ask a doctor right away if pain when urinating/seek medical attention right away	3 0.9	-	3 1.7	-	-	-	2 2.0	1 1.3

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 79
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Associated with renal function/renal adverse effects	1 0.3	-	1 0.6	-	-	-	1 1.0	-
Urinary obstruction, which is serious	1 0.3	-	1 0.6	-	-	-	-	1 1.3
Subject error/mouse error	1 0.3	-	1 0.6	-	-	-	-	1 1.3
Anticholinergic	4 1.3	-	4 2.3	-	-	-	1 1.0	3 3.9
Not sure/uncertain/unaware	4 1.3	-	4 2.3	-	-	-	2 2.0	2 2.6
Miscellaneous	7 2.2	4 2.8	3 1.7	2 2.2	-	2 3.9	2 2.0	1 1.3
Nothing	1 0.3	-	1 0.6	-	-	-	-	1 1.3
Don't know/Do not recall	3 0.9	2 1.4	1 0.6	2 2.2	-	-	-	1 1.3
Total	337	154	183	98	-	56	103	80

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 80
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	173	80	93	52	-	28	53	40
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	35 20.2	1 1.2	34 36.6 B	1 1.9	-	-	21 39.6 D	13 32.5 D
Stop use and seek immediate medical attention	13 7.5	9 11.2 c	4 4.3	8 15.4 ffGh	-	1 3.6	2 3.8	2 5.0
Medical emergency/seek medical care/seek medical attention right away	20 11.6	12 15.0	8 8.6	7 13.5	-	5 17.9	3 5.7	5 12.5
Stop use/stop use, cause of the problem	11 6.4	7 8.8	4 4.3	6 11.5	-	1 3.6	2 3.8	2 5.0
Prudent action to take with urinary retention/ prudent response	2 1.2	1 1.2	1 1.1	1 1.9	-	-	-	1 2.5
Advise given to my patients/recommendation	6 3.5	5 6.2 c	1 1.1	1 1.9	-	4 14.3 ddg	1 1.9	-
Correct course of action/ best possible action, advice/most logical action/best next steps/ right thing to do	8 4.6	7 8.8 C	1 1.1	4 7.7	-	3 10.7	-	1 2.5
Information found in studies	1 0.6	1 1.2	-	1 1.9	-	-	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 81
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
POTIGA causes urinary retention	5 2.9	4 5.0	1 1.1	2 3.8	-	2 7.1	1 1.9	-
Urinary retention may be reversible	4 2.3	4 5.0	-	3 5.8	-	1 3.6	-	-
Information from the PI	3 1.7	2 2.5	1 1.1	2 3.8	-	-	1 1.9	-
Label/label indications	2 1.2	1 1.2	1 1.1	1 1.9	-	-	-	1 2.5
Side effects/serious side effect/dangerous issue	11 6.4	7 8.8	4 4.3	6 11.5 h	-	1 3.6	3 5.7	1 2.5
General recall/general knowledge	8 4.6	6 7.5	2 2.2	3 5.8	-	3 10.7	1 1.9	1 2.5
Information from pharmaceutical representative/drug company	3 1.7	3 3.8	-	2 3.8	-	1 3.6	-	-
Titrate down the dose	1 0.6	1 1.2	-	1 1.9	-	-	-	-
Helps with urination	1 0.6	1 1.2	-	-	-	1 3.6	-	-
Common sense	5 2.9	5 6.2	-	1 1.9	-	4 14.3 dd	-	-
Not familiar with urinary dysfunction	1 0.6	1 1.2	-	1 1.9	-	-	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 82
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Further research necessary	4 2.3	1 1.2	3 3.2	1 1.9	-	-	2 3.8	1 2.5
Would not give advice about a product not familiar with	1 0.6	-	1 1.1	-	-	-	-	1 2.5
Ask a doctor	11 6.4	-	11 11.8	-	-	-	7 13.2	4 10.0
Patient needs follow-up	1 0.6	-	1 1.1	-	-	-	-	1 2.5
Prevent patient harm/could lead to further complications	2 1.2	-	2 2.2	-	-	-	1 1.9	1 2.5
Urinary retention is acute issue that needs to be treated	4 2.3	2 2.5	2 2.2	1 1.9	-	1 3.6	1 1.9	1 2.5
Based on other drugs in this category	1 0.6	-	1 1.1	-	-	-	1 1.9	-
Doctor needs to update the dose	1 0.6	-	1 1.1	-	-	-	1 1.9	-
Not sure/uncertain/unaware	2 1.2	-	2 2.2	-	-	-	1 1.9	1 2.5
Miscellaneous	9 5.2	2 2.5	7 7.5	1 1.9	-	1 3.6	4 7.5	3 7.5
Don't know/Do not recall	4 2.3	2 2.5	2 2.2	2 3.8	-	-	2 3.8	-
Total	180	85	95	56	-	29	55	40

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 83
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	180	65	115	46	-	19	75	40
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	60 33.3	1 1.5	59 51.3 B	1 2.2	-	-	40 53.3 D	19 47.5 D
Uncertain of maximum weekly dosage	11 6.1	5 7.7	6 5.2	2 4.3	-	3 15.8	5 6.7	1 2.5
Start at a lower dosage/ conservative when adjusting dosage	2 1.1	2 3.1	-	2 4.3	-	-	-	-
Thought answer provided was correct response	3 1.7	2 3.1	1 0.9	2 4.3	-	-	1 1.3	-
From internet/Google	1 0.6	1 1.5	-	1 2.2	-	-	-	-
50mg per day is minimal increased dosage/ recalled 50mg	6 3.3	1 1.5	5 4.3	1 2.2	-	-	5 6.7	-
General recall/recall from reading	8 4.4	5 7.7	3 2.6	1 2.2	-	4 21.1 DDG	1 1.3	2 5.0
150mg per day/do not exceed 150 mg per day150mg per day/do not exceed 150 mg per day	11 6.1	8 12.3 C	3 2.6	6 13.0 gh	-	2 10.5	2 2.7	1 2.5

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 84
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
1200mg/maximum dose is 1200mg	2 1.1	1 1.5	1 0.9	1 2.2	-	-	-	1 2.5
Have not titrated patient to maximum dosage	1 0.6	1 1.5	-	1 2.2	-	-	-	-
Titrate slowly/titrate patient 50mg weekly/ titration scale/dosing charts	8 4.4	5 7.7	3 2.6	5 10.9 G	-	-	1 1.3	2 5.0
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information	22 12.2	11 16.9	11 9.6	9 19.6 g	-	2 10.5	6 8.0	5 12.5
From manufacturer's recommendation/ pharmaceutical representative	4 2.2	4 6.2	-	4 8.7	-	-	-	-
No adverse effects/ adverse effects limitations	1 0.6	1 1.5	-	-	-	1 5.3	-	-
Depends on patient/based on patient's tolerability and frequency of seizures	4 2.2	2 3.1	2 1.7	1 2.2	-	1 5.3	2 2.7	-
Past experience	3 1.7	2 3.1	1 0.9	2 4.3	-	-	-	1 2.5

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Titration should not be more than 300mg per week/ 300mg would be the reasonable maximum	2 1.1	2 3.1	-	1 2.2	-	1 5.3	-	-
Can increase by one pill per week	2 1.1	2 3.1	-	1 2.2	-	1 5.3	-	-
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	4 2.2	1 1.5	3 2.6	-	-	1 5.3	2 2.7	1 2.5
No pediatric dosing recommendations	1 0.6	1 1.5	-	-	-	1 5.3	-	-
Not familiar with titration being necessary	1 0.6	-	1 0.9	-	-	-	1 1.3	-
Looked up information in reference book	1 0.6	-	1 0.9	-	-	-	1 1.3	-
Based on the drug's side effects	1 0.6	-	1 0.9	-	-	-	1 1.3	-
Not sure	4 2.2	2 3.1	2 1.7	2 4.3	-	-	1 1.3	1 2.5

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 86
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Miscellaneous	5 2.8	1 1.5	4 3.5	1 2.2	-	-	4 5.3	-
Misunderstood question/ Question is vague	2 1.1	1 1.5	1 0.9	1 2.2	-	-	-	1 2.5
Nothing	2 1.1	2 3.1	-	2 4.3	-	-	-	-
Don't know/Do not recall	15 8.3	6 9.2	9 7.8	4 8.7	-	2 10.5	3 4.0	6 15.0
Total	187	70	117	51	-	19	76	41

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 87
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	176	75	101	46	-	29	64	37
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	50 28.4	1 1.3	49 48.5 B	1 2.2	-	-	32 50.0 D	17 45.9 D
300mg per day is initial dose/100mg TID	11 6.2	7 9.3	4 4.0	3 6.5	-	4 13.8	3 4.7	1 2.7
Do not know initial dose/ unsure of initial dose/ unsure of initial dose for general population	14 8.0	7 9.3	7 6.9	4 8.7	-	3 10.3	4 6.2	3 8.1
200mg per day is initial dose	1 0.6	1 1.3	-	1 2.2	-	-	-	-
150mg per day is minimal dose for efficacy	2 1.1	2 2.7	-	1 2.2	-	1 3.4	-	-
150mg is for geriatric population/renal population	1 0.6	1 1.3	-	1 2.2	-	-	-	-
General recall/recall from reading	17 9.7	12 16.0 C	5 5.0	9 19.6 G	-	3 10.3	2 3.1	3 8.1
Titrate slowly/start low/ start low and go slow	6 3.4	6 8.0	-	4 8.7	-	2 6.9	-	-
150mg is initial dosage increase/not to exceed 150mg dosage increase per week	3 1.7	2 2.7	1 1.0	2 4.3	-	-	-	1 2.7

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 88
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
150mg is dose for general population/start patients with 150mg initially	6 3.4	3 4.0	3 3.0	3 6.5	-	-	1 1.6	2 5.4
Conservative response/ initially conservative when prescribing	1 0.6	1 1.3	-	1 2.2	-	-	-	-
From label/indications/ samples to patients/pkg insert/prescribing literature/ from the info/representative starter kits	22 12.5	15 20.0 C	7 6.9	7 15.2 g	-	8 27.6 Gh	3 4.7	4 10.8
300mg three times a day	1 0.6	1 1.3	-	-	-	1 3.4	-	-
Clinical trials/studies	1 0.6	1 1.3	-	1 2.2	-	-	-	-
Depends on patient/ titrate based on patient's tolerability	2 1.1	1 1.3	1 1.0	1 2.2	-	-	1 1.6	-
Recommended dosing of POTIGA	5 2.8	3 4.0	2 2.0	-	-	3 10.3	1 1.6	1 2.7
Past prescribing experience	3 1.7	3 4.0	-	-	-	3 10.3	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 89
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	7 4.0	-	7 6.9	-	-	-	6 9.4	1 2.7
Wrong response provided/selected	2 1.1	2 2.7	-	1 2.2	-	1 3.4	-	-
Not sure/uncertain/unaware	4 2.3	4 5.3	-	3 6.5	-	1 3.4	-	-
Miscellaneous	12 6.8	3 4.0	9 8.9	1 2.2	-	2 6.9	6 9.4 d	3 8.1
Don't know/Do not recall	10 5.7	3 4.0	7 6.9	3 6.5	-	-	6 9.4	1 2.7
Total	181	79	102	47	-	32	65	37

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 90
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	89	20	69	14	-	6	46	23
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	50 56.2	1 5.0	49 71.0 B	1 7.1	-	-	34 73.9 D	15 65.2 D
General recall/recall from reading/general understanding	3 3.4	2 10.0	1 1.4	2 14.3	-	-	-	1 4.3
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	3 3.4	2 10.0	1 1.4	1 7.1	-	1 16.7	1 2.2	-
No information available/ could not find the information	3 3.4	-	3 4.3	-	-	-	1 2.2	2 8.7
Urinary contraindications/ contraindicated	1 1.1	-	1 1.4	-	-	-	-	1 4.3
A safe dose can be found for patients	1 1.1	1 5.0	-	-	-	1 16.7	-	-
Unaware of precautions/ problems/issues/ contraindications	5 5.6	2 10.0	3 4.3	1 7.1	-	1 16.7	3 6.5	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 91
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Unaware of renal/hepatic issues/not aware of specific renal/hepatic issues	4 4.5	2 10.0	2 2.9	1 7.1	-	1 16.7	2 4.3	-
Answer should be "yes"	1 1.1	-	1 1.4	-	-	-	-	1 4.3
Not sure/uncertain/unaware	3 3.4	2 10.0	1 1.4	1 7.1	-	1 16.7	-	1 4.3
Miscellaneous	5 5.6	1 5.0	4 5.8	-	-	1 16.7	3 6.5	1 4.3
Don't know/Do not recall	10 11.2	7 35.0	3 4.3	7 50.0	-	-	2 4.3	1 4.3
		C		GH				
Total	89	20	69	14	-	6	46	23

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 92
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	218	78	140	52	-	26	86	54
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	54 24.8	1 1.3	53 37.9 B	1 1.9	-	-	35 40.7 D	18 33.3 D
General recall/recall from reading/general understanding	4 1.8	3 3.8	1 0.7	2 3.8	-	1 3.8	1 1.2	-
Use with caution/a precaution	4 1.8	-	4 2.9	-	-	-	2 2.3	2 3.7
Worsen the condition/ because of side effects/ might cause problems with condition	10 4.6	1 1.3	9 6.4 B	1 1.9	-	-	5 5.8	4 7.4
Conservative response/ initially conservative when prescribing/lower starting dose	1 0.5	1 1.3	-	1 1.9	-	-	-	-
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	10 4.6	5 6.4	5 3.6	4 7.7	-	1 3.8	2 2.3	3 5.6

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 93
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
No information available/ could not find the information	3 1.4	2 2.6	1 0.7	2 3.8	-	-	-	1 1.9
Never heard about this/ never heard one way or the other	8 3.7	7 9.0 C	1 0.7	3 5.8	-	4 15.4 G	1 1.2	-
Urinary contraindications/ contraindicated	3 1.4	3 3.8	-	3 5.8	-	-	-	-
Unaware of precautions/ problems/issues/ contraindications	31 14.2	15 19.2	16 11.4	11 21.2 g	-	4 15.4	8 9.3	8 14.8
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	3 1.4	-	3 2.1	-	-	-	1 1.2	2 3.7
Wrong response provided/ selected	1 0.5	-	1 0.7	-	-	-	1 1.2	-
Not sure/uncertain/ unaware	29 13.3	12 15.4	17 12.1	8 15.4	-	4 15.4	11 12.8	6 11.1
Miscellaneous	12 5.5	7 9.0	5 3.6	3 5.8	-	4 15.4 h	4 4.7	1 1.9

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 94
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Misunderstood question/ Question is vague	2 0.9	1 1.3	1 0.7	1 1.9	-	-	1 1.2	-
Don't know/Do not recall	43 19.7	20 25.6	23 16.4	12 23.1	-	8 30.8	14 16.3	9 16.7
Total	218	78	140	52	-	26	86	54

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 95
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	190	60	130	41	-	19	78	52
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	51 26.8	1 1.7	50 38.5 B	1 2.4	-	-	30 38.5 D	20 38.5 D
Data from past research/ studies/clinical trials	1 0.5	-	1 0.8	-	-	-	1 1.3	-
Patients need to be monitored	1 0.5	1 1.7	-	1 2.4	-	-	-	-
Use with caution/a precaution	4 2.1	1 1.7	3 2.3	1 2.4	-	-	2 2.6	1 1.9
Worsen the condition/ because of side effects/ might cause problems with condition	3 1.6	1 1.7	2 1.5	1 2.4	-	-	1 1.3	1 1.9
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	7 3.7	3 5.0	4 3.1	2 4.9	-	1 5.3	1 1.3	3 5.8
No information available/ could not find the information	4 2.1	1 1.7	3 2.3	1 2.4	-	-	1 1.3	2 3.8

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 96
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Never heard about this/ never heard one way or the other	4 2.1	2 3.3	2 1.5	2 4.9	-	-	1 1.3	1 1.9
Unaware of precautions/ problems/issues/ contraindications	29 15.3	8 13.3	21 16.2	5 12.2	-	3 15.8	10 12.8	11 21.2
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	5 2.6	-	5 3.8	-	-	-	4 5.1	1 1.9
Wrong response provided/ selected	4 2.1	2 3.3	2 1.5	1 2.4	-	1 5.3	2 2.6	-
Answer should be "yes"	1 0.5	1 1.7	-	1 2.4	-	-	-	-
Not sure/uncertain/ unaware	20 10.5	7 11.7	13 10.0	5 12.2	-	2 10.5	8 10.3	5 9.6
Miscellaneous	17 8.9	11 18.3	6 4.6	5 12.2	-	6 31.6 GH	4 5.1	2 3.8
Don't know/Do not recall	41 21.6	23 38.3 C	18 13.8	17 41.5 GH	-	6 31.6 h	13 16.7	5 9.6
Total	192	62	130	43	-	19	78	52

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 97
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	186	74	112	47	-	27	71	41
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	48 25.8	1 1.4	47 42.0 B	1 2.1	-	-	31 43.7 D	16 39.0 D
Depends on the patient	1 0.5	1 1.4	-	1 2.1	-	-	-	-
Odds of BPH/urinary retention increase after age 65/higher rate of renal problems	8 4.3	3 4.1	5 4.5	3 6.4	-	-	2 2.8	3 7.3
Personal prescribing history	1 0.5	1 1.4	-	1 2.1	-	-	-	-
No upper age limit/ unaware of upper age limit/no age limit	22 11.8	9 12.2	13 11.6	7 14.9	-	2 7.4	9 12.7	4 9.8
Data from past research/ studies/clinical trials	1 0.5	1 1.4	-	-	-	1 3.7	-	-
Patients need to be monitored	1 0.5	1 1.4	-	1 2.1	-	-	-	-
Use with caution/a precaution	5 2.7	4 5.4	1 0.9	3 6.4	-	1 3.7	-	1 2.4
Worsen the condition/ because of side effects/ might cause problems with condition	2 1.1	2 2.7	-	1 2.1	-	1 3.7	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 98
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Conservative response/ initially conservative when prescribing/lower starting dose	3 1.6	-	3 2.7	-	-	-	1 1.4	2 4.9
No information available/ could not find the information	2 1.1	-	2 1.8	-	-	-	1 1.4	1 2.4
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	13 7.0	8 10.8	5 4.5	5 10.6	-	3 11.1	2 2.8	3 7.3
Never heard about this/ never heard one way or the other	1 0.5	-	1 0.9	-	-	-	1 1.4	-
Urinary contraindications/ contraindicated	1 0.5	-	1 0.9	-	-	-	-	1 2.4
A safe dose can be found for patients	1 0.5	1 1.4	-	-	-	1 3.7	-	-
Unaware of precautions/ problems/issues/ contraindications	13 7.0	8 10.8	5 4.5	4 8.5 g	-	4 14.8 g	1 1.4	4 9.8 gg

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 99
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	6 3.2	-	6 5.4	-	-	-	5 7.0	1 2.4
Caution when using in patients 65+/not recommended for 65+ patients	3 1.6	2 2.7	1 0.9	2 4.3	-	-	-	1 2.4
Treat pediatric patients only/do not treat adult populations	2 1.1	2 2.7	-	-	-	2 7.4	-	-
There are dosing limits for 65+	2 1.1	-	2 1.8	-	-	-	1 1.4	1 2.4
Not sure/uncertain/unaware	13 7.0	8 10.8	5 4.5	4 8.5	-	4 14.8 h	4 5.6	1 2.4
Miscellaneous	19 10.2	13 17.6 C	6 5.4	8 17.0 H	-	5 18.5 H	5 7.0	1 2.4
Don't know/Do not recall	20 10.8	9 12.2	11 9.8	6 12.8	-	3 11.1	8 11.3	3 7.3
Total	188	74	114	47	-	27	71	43

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ECODEA Page 100
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	2	-	2	-	-	-	1	1
Use with caution/a precaution	1 50.0	-	1 50.0	-	-	-	-	1 100.0
Worsen the condition/ because of side effects/ might cause problems with condition	1 50.0	-	1 50.0	-	-	-	1 100.0	-
Total	2	-	2	-	-	-	1	1

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 101
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	153	44	109	29	-	15	70	39
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	52 34.0	4 9.1	48 44.0 B	3 10.3	-	1 6.7	33 47.1 DF	15 38.5 DF
Unaware of AE time frame/ never heard of the timeframe/unsure of the timeframe/did not recall specific timeframe	23 15.0	8 18.2	15 13.8	6 20.7	-	2 13.3	6 8.6	9 23.1 99
Not familiar with studies referenced in statement	8 5.2	3 6.8	5 4.6	-	-	3 20.0	2 2.9	3 7.7
Do not recall any data on this/do not recall this fact	4 2.6	3 6.8	1 0.9	2 6.9	-	1 6.7	-	1 2.6
Timing is usual for most side effects	1 0.7	1 2.3	-	-	-	1 6.7	-	-
AE's can occur at any time/soon after starting medicine	2 1.3	1 2.3	1 0.9	1 3.4	-	-	-	1 2.6
General recall	1 0.7	1 2.3	-	1 3.4	-	-	-	-
AE's may not be reported within 6 mos/can occur after 6 mos	3 2.0	2 4.5	1 0.9	1 3.4	-	1 6.7	1 1.4	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 102
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Clinical trials still pending/will require post-market data/research	3 2.0	2 4.5	1 0.9	1 3.4	-	1 6.7	1 1.4	-
AE's should be reported immediately/earlier than 6 mos	3 2.0	1 2.3	2 1.8	1 3.4	-	-	2 2.9	-
Label/PI/resources do not mention	4 2.6	2 4.5	2 1.8	2 6.9	-	-	-	2 5.1
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	1 0.7	-	1 0.9	-	-	-	1 1.4	-
From label/indications/samples to patients/package insert/the prescribing literature/from the information/representative starter kits/pharmaceutical rep/internet research	2 1.3	2 4.5	-	2 6.9	-	-	-	-
Should have answered "yes"/true statement	5 3.3	2 4.5	3 2.8	1 3.4	-	1 6.7	2 2.9	1 2.6

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 103
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Not sure/uncertain/ unaware	5 3.3	1 2.3	4 3.7	-	-	1 6.7	2 2.9	2 5.1
Miscellaneous	14 9.2	3 6.8	11 10.1	3 10.3	-	-	9 12.9	2 5.1
Misunderstood question/ Question is vague	1 0.7	-	1 0.9	-	-	-	1 1.4	-
Don't know/Do not recall	24 15.7	11 25.0	13 11.9	5 17.2	-	6 40.0	10 14.3	3 7.7
		c				gH		
Total	156	47	109	29	-	18	70	39

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 104
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Total Answering	192	60	132	40	-	20	74	58
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	37 19.3	1 1.7	36 27.3 B	1 2.5	-	-	23 31.1 D	13 22.4 D
All are high risk groups/ need to be monitored	11 5.7	2 3.3	9 6.8	2 5.0	-	-	5 6.8	4 6.9
Patients cannot report symptoms/problems	12 6.2	8 13.3 C	4 3.0	5 12.5	-	3 15.0	4 5.4	-
Patients are at higher risk for BPH/voiding difficulty/urinary retention/underlying urinary retention concerns	66 34.4	23 38.3	43 32.6	16 40.0	-	7 35.0	27 36.5	16 27.6
Side effects/known side effect(s) of urinary retention	19 9.9	3 5.0	16 12.1 b	3 7.5	-	-	7 9.5	9 15.5
Approach on a patient by patient basis	1 0.5	1 1.7	-	1 2.5	-	-	-	-
General recall	3 1.6	2 3.3	1 0.8	2 5.0	-	-	-	1 1.7
Previous knowledge/past experience	3 1.6	2 3.3	1 0.8	1 2.5	-	1 5.0	-	1 1.7

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 105
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Understanding of product labeling	1 0.5	1 1.7	-	-	-	1 5.0	-	-
Patients with kidney/stomach issues monitored closely/NSAIDS patients/effect kidney	7 3.6	1 1.7	6 4.5	1 2.5	-	-	5 6.8	1 1.7
Obvious precautions	2 1.0	-	2 1.5	-	-	-	-	2 3.4
From label/indications/samples to patients/package insert/the prescribing literature/from the information/representative starter kits/pharmaceutical rep/internet research, past clinical research	9 4.7	4 6.7	5 3.8	4 10.0 g	-	-	1 1.4	4 6.9
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	2 1.0	-	2 1.5	-	-	-	2 2.7	-
Make situation worse	1 0.5	1 1.7	-	1 2.5	-	-	-	-

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 106
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Banner 1

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Total	Physician	Pharmacist	Neurology	Neurosurg	Epileptol	Pharmacy (Com/Ret)	Pharmacy (Hosp/Cli)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)
Not sure/uncertain/ unaware	6 3.1	2 3.3	4 3.0	1 2.5	-	1 5.0	2 2.7	2 3.4
Miscellaneous	22 11.5	11 18.3	11 8.3	5 12.5	-	6 30.0 Gh	5 6.8	6 10.3
Misunderstood question/ Question is vague	1 0.5	-	1 0.8	-	-	-	-	1 1.7
Don't know/Do not recall	10 5.2	3 5.0	7 5.3	1 2.5	-	2 10.0	4 5.4	3 5.2
Total	213	65	148	44	-	21	85	63

Comparison Groups: BC/DEFGH/BDEF/CGH
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

TABLE OF CONTENTS

Pharmacist

Table QSCR3 Page 1.....S3: How would you classify your primary specialty?

Table TYPE Page 2.....Type: Physician/Pharmacist

Table QSCR4 Page 3.....S4: Are you a currently practicing physician? (for physicians only)

Table QSCR5 Page 4.....S5: Do you currently see and treat patients with epilepsy? (physicians only)

Table QSCR6 Page 5.....S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

Table QSCR7 Page 6.....S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Table QSCR8 Page 9.....S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Table QSA Page 13.....SA: How would you classify your primary specialty?

Table QSB Page 14.....SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

Table QSC Page 15.....SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

Table QSD Page 16.....SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

Table Q1 Page 17.....Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

Table Q2 Page 18.....Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3 Page 19.....Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

Table Q4 Page 20.....Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Table Q5 Page 21.....Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q6 Page 22.....Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q7 Page 23.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

Table Q7NET Page 24.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

TABLE OF CONTENTS

Table Q8 Page 25.....Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

Table Q9 Page 26.....Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Table Q10 Page 27.....Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Table Q11R1 Page 28.....Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R2 Page 29.....Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R3 Page 30.....Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R4 Page 31.....Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R5 Page 32.....Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q12 Page 33.....Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Table Q13 Page 34.....Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

Table Q14 Page 35.....Q14: How long have you been practicing medicine?

Table Q15 Page 36.....Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

Table Q16 Page 37.....Q16: How many months have you been prescribing POTIGA?

Table Q17 Page 38.....Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

Table Q18 Page 39.....Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

Table Q19 Page 40.....Q19: What is the age range of your current patient population? Please select all categories that you treat.

Table Q20 Page 41.....Q20: Approximately what is the size of your current total patient population?

Table Q21 Page 42.....Q21: Approximately what is the size of your current epilepsy patient population?

Table Q22 Page 43.....Q22: How long have you been a practicing pharmacist?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

TABLE OF CONTENTS

Table Q23 Page 44.....Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

Table Q24 Page 45.....Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

Table Q25 Page 46.....Q25: Have you dispensed POTIGA in the past 12 months?

Table Q26 Page 47.....Q26: How many months have you been dispensing POTIGA?

Table Q27 Page 48.....Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

Table Q28 Page 49.....Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

Table Q29R1 Page 50.....Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R2 Page 51.....Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R3 Page 52.....Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R4 Page 53.....Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R5 Page 54.....Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R6 Page 55.....Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R7 Page 56.....Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R8 Page 57.....Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q30 Page 58.....Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

Table Q1_1CODE Page 59...Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

Table Q2_1CODE Page 61...Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3_1CODE Page 64...Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Table Q4_1CODE Page 66...Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

TABLE OF CONTENTS

Table Q5_1CODE Page 69...Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Table Q6_1CODE Page 72...Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

Table Q7_1CODE Page 75...Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Table Q8_1CODE Page 79...Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

Table Q9_1CODE Page 82...Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Table Q10_1CODE Page 85...Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Table Q11_1ACODE Page 87...Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1BCODE Page 89...Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1CCODE Page 91...Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1DCODE Page 93...Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1ECODEA Page 96...Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q12_1CODE Page 97...Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Table Q13_1CODEA Page 99...Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

Table QSCR3 Page 1
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S3: How would you classify your primary specialty?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Neurology	-	-	-	-	-	-	-
Neurosurgery	-	-	-	-	-	-	-
Epileptology	-	-	-	-	-	-	-
Pharmacy (Community/ Retail)	108 52.7	29 82.9 DE	45 70.3 DE	18 37.5	16 27.6	12 37.5	96 55.5 f
Pharmacy (Hospital/ Clinical)	97 47.3	6 17.1	19 29.7	30 62.5 BC	42 72.4 BC	20 62.5 g	77 44.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table TYPE Page 2
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Type: Physician/Pharmacist

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Physician	-	-	-	-	-	-	-
Pharmacist	205	35	64	48	58	32	173
	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR4 Page 3
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S4: Are you a currently practicing physician? (for physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	205	35	64	48	58	32	173
	100.0	100.0	100.0	100.0	100.0	100.0	100.0
No	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR5 Page 4
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S5: Do you currently see and treat patients with epilepsy? (physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Yes	-	-	-	-	-	-	-
No	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	205 100.0	35 100.0	64 100.0	48 100.0	58 100.0	32 100.0	173 100.0
No	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Ativan (Lorazepam)	-	-	-	-	-	-	-
Carbatrol (Carbamazepine)	-	-	-	-	-	-	-
Celontin (Methsuximide)	-	-	-	-	-	-	-
Cerebyx (Fosphenytoin sodium)	-	-	-	-	-	-	-
Depakote/Depakote ER/ Depakote Sprinkle (Divalproex Sodium)	-	-	-	-	-	-	-
Depacon (Valproate sodium)	-	-	-	-	-	-	-
Depakene (Valproic acid)	-	-	-	-	-	-	-
Diastat (Diazepam)	-	-	-	-	-	-	-
Dilantin (Phenytoin)	-	-	-	-	-	-	-
Felbatol (Felbamate)	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 7
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Gabitril (Tiagabine hydrochloride)	-	-	-	-	-	-	-
Keppra (Levetiracetam)	-	-	-	-	-	-	-
Klonopin (Clonazepam)	-	-	-	-	-	-	-
Lamictal (Lamotrigine)	-	-	-	-	-	-	-
Lorazepam Intensol (Lorazepam)	-	-	-	-	-	-	-
Lyrica (Pregabalin)	-	-	-	-	-	-	-
Mebaral (Mephobarbital)	-	-	-	-	-	-	-
Mysoline (Primidone)	-	-	-	-	-	-	-
Neurontin (Gabapentin)	-	-	-	-	-	-	-
Peganone (Ethotoin)	-	-	-	-	-	-	-
Potiga (Ezogabine)	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 8
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Tegretol/Tegretol XR (Carbamazepine)	-	-	-	-	-	-	-
Topamax (Topiramate)	-	-	-	-	-	-	-
Tranxene (Clorazepate dipotassium)	-	-	-	-	-	-	-
Trileptal (Oxcarbazepine)	-	-	-	-	-	-	-
Valium (Diazepam)	-	-	-	-	-	-	-
Zonegran (Zonisamide)	-	-	-	-	-	-	-
NONE OF THESE	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 9
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Years Dispensing QED's					Dispensed POTIGA	
	Pharmacist	< 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Ativan (Lorazepam)	202 98.5	35 100.0	62 96.9	47 97.9	58 100.0	32 100.0	170 98.3
Carbatrol (Carbamazepine)	145 70.7	26 74.3	45 70.3	35 72.9	39 67.2	26 81.2	119 68.8
Celontin (Methsuximide)	37 18.0	7 20.0	12 18.8 e	13 27.1 E	5 8.6	10 31.2 g	27 15.6
Cerebyx (Fosphenytoin sodium)	81 39.5	9 25.7	18 28.1	24 50.0 BC	30 51.7 BC	23 71.9 G	58 33.5
Depakote/Depakote ER/ Depakote Sprinkle (Divalproex Sodium)	198 96.6	35 100.0 e	62 96.9	46 95.8	55 94.8	32 100.0 G	166 96.0
Depacon (Valproate sodium)	88 42.9	12 34.3	21 32.8	24 50.0 c	31 53.4 bC	25 78.1 G	63 36.4
Depakene (Valproic acid)	134 65.4	15 42.9	40 62.5 b	34 70.8 B	45 77.6 Bc	27 84.4 G	107 61.8
Diastat (Diazepam)	121 59.0	19 54.3	44 68.8	26 54.2	32 55.2	22 68.8	99 57.2
Dilantin (Phenytoin)	187 91.2	33 94.3	58 90.6	43 89.6	53 91.4	31 96.9 g	156 90.2

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 10
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist	< 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Felbatol (Felbamate)	61 29.8	9 25.7	19 29.7	18 37.5	15 25.9	17 53.1 G	44 25.4
Gabitril (Tiagabine hydrochloride)	93 45.4	13 37.1	32 50.0	26 54.2 e	22 37.9	22 68.8 G	71 41.0
Keppra (Levetiracetam)	201 98.0	35 100.0 e	63 98.4	48 100.0 e	55 94.8	32 100.0 G	169 97.7
Klonopin (Clonazepam)	197 96.1	35 100.0 cd	61 95.3	45 93.8	56 96.6	32 100.0 G	165 95.4
Lamictal (Lamotrigine)	190 92.7	35 100.0 CDE	57 89.1	44 91.7	54 93.1	30 93.8	160 92.5
Lorazepam IntenSol (Lorazepam)	141 68.8	30 85.7 DE	54 84.4 DE	30 62.5 e	27 46.6	24 75.0	117 67.6
Lyrica (Pregabalin)	193 94.1	34 97.1	61 95.3	45 93.8	53 91.4	31 96.9	162 93.6
Mebaral (Mephobarbital)	20 9.8	2 5.7	9 14.1 e	6 12.5	3 5.2	9 28.1 G	11 6.4
Mysoline (Primidone)	111 54.1	14 40.0	31 48.4	31 64.6 Bc	35 60.3 b	22 68.8 g	89 51.4

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 11
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Neurontin (Gabapentin)	200 97.6	34 97.1	62 96.9	47 97.9	57 98.3	32 100.0 G	168 97.1
Peganone (Ethotoin)	15 7.3	2 5.7	4 6.2	6 12.5	3 5.2	7 21.9 G	8 4.6
Potiga (Ezogabine)	15 7.3	2 5.7	7 10.9	4 8.3	2 3.4	13 40.6 G	2 1.2
Tegretol/Tegretol XR (Carbamazepine)	179 87.3	33 94.3 C	50 78.1	43 89.6 c	53 91.4 C	30 93.8	149 86.1
Topamax (Topiramate)	187 91.2	33 94.3	55 85.9	47 97.9 Ce	52 89.7	30 93.8	157 90.8
Tranxene (Clorazepate dipotassium)	92 44.9	13 37.1	29 45.3	27 56.2 be	23 39.7	19 59.4 g	73 42.2
Trileptal (Oxcarbazepine)	163 79.5	33 94.3 CDE	50 78.1	38 79.2	42 72.4	29 90.6 G	134 77.5
Valium (Diazepam)	188 91.7	35 100.0 CDE	59 92.2	44 91.7	50 86.2	30 93.8	158 91.3
Zonegran (Zonisamide)	137 66.8	23 65.7	47 73.4 e	33 68.8	34 58.6	27 84.4 G	110 63.6

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 12
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
NONE OF THESE	-	-	-	-	-	-	-
Total	3576	606	1112	874	984	664	2912

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSA Page 13
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

SA: How would you classify your primary specialty?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Neurology	-	-	-	-	-	-	-
Neurosurgery	-	-	-	-	-	-	-
Epileptology	-	-	-	-	-	-	-
Pharmacy (Community/ Retail)	113 55.1	30 85.7 DE	47 73.4 DE	21 43.8 e	15 25.9	12 37.5	101 58.4 F
Pharmacy (Hospital/ Clinical)	92 44.9	5 14.3	17 26.6	27 56.2 BC	43 74.1 BCd	20 62.5 G	72 41.6
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSB Page 14
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
None	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-
11-20	-	-	-	-	-	-	-
More than 20 patients	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Lamictal (Lamotrigine)	-	-	-	-	-	-	-
Lyrica (Pregabalin)	-	-	-	-	-	-	-
Potiga (Ezogabine)	-	-	-	-	-	-	-
Tegretol/Tegretol XR (Carbamazepine)	-	-	-	-	-	-	-
Topamax (Topiramate)	-	-	-	-	-	-	-
None of the above	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSD Page 16
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
None	-	-	-	-	-	-	-
1-2	2 1.0	-	1 1.6	1 2.1	-	1 3.1	1 0.6
3-10	17 8.3	3 8.6	4 6.2	5 10.4	5 8.6	3 9.4	14 8.1
11-20	40 19.5	10 28.6	14 21.9	6 12.5	10 17.2	5 15.6	35 20.2
More than 20 prescriptions	146 71.2	22 62.9	45 70.3	36 75.0	43 74.1	23 71.9	123 71.1
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

	Years Dispensing QED's					Dispensed POTIGA	
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Migraine	1 0.5	-	1 1.6	-	-	1 3.1	-
Partial-onset seizures	127 62.0	17 48.6	40 62.5	29 60.4	41 70.7	29 90.6	98 56.6
Generalized tonic clonic seizures	6 2.9	-	1 1.6	2 4.2	3 5.2	3 9.4	3 1.7
None of the above	-	-	-	-	-	-	-
I don't know	74 36.1	18 51.4	24 37.5	17 35.4	15 25.9	2 6.2	72 41.6
Total	208	35	66	48	59	35	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
True	29 14.1	2 5.7	8 12.5	7 14.6	12 20.7 B	9 28.1 G	20 11.6
False	82 40.0	13 37.1	26 40.6	19 39.6	24 41.4	20 62.5 G	62 35.8
I don't know	94 45.9	20 57.1 e	30 46.9	22 45.8	22 37.9	3 9.4	91 52.6 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Urinary retention	117 57.1	19 54.3	38 59.4 d	21 43.8	39 67.2 D	26 81.2 G	91 52.6
Pancreatitis	5 2.4	-	1 1.6	1 2.1	3 5.2	3 9.4	2 1.2
Ischemic colitis	1 0.5	-	1 1.6	-	-	1 3.1	-
I don't know	85 41.5	16 45.7	26 40.6	26 54.2 E	17 29.3	4 12.5	81 46.8 F
Total	208	35	66	48	59	34	174

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
600mg	10 4.9	2 5.7	4 6.2	1 2.1	3 5.2	4 12.5	6 3.5
900mg	4 2.0	-	1 1.6	3 6.2	-	2 6.2	2 1.2
1200mg	105 51.2	14 40.0	32 50.0	23 47.9	36 62.1 B	24 75.0 G	81 46.8
2000mg	-	-	-	-	-	-	-
None of the above	6 2.9	1 2.9	2 3.1	-	3 5.2	-	6 3.5
I don't know	84 41.0	18 51.4 E	28 43.8 e	21 43.8	17 29.3	4 12.5	80 46.2 F
Total	209	35	67	48	59	34	175

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
The oldest age at which POTIGA can be used is 65	2 1.0	-	1 1.6	1 2.1	-	1 3.1	1 0.6
There are no lower age limits for POTIGA	4 2.0	1 2.9	1 1.6	-	2 3.4	1 3.1	3 1.7
The youngest age at which POTIGA can be used is 12	11 5.4	3 8.6	3 4.7	2 4.2	3 5.2	5 15.6	6 3.5
The youngest age at which POTIGA can be used is 18	85 41.5	12 34.3	26 40.6	20 41.7	27 46.6	18 56.2	67 38.7
None of the above	10 4.9	-	1 1.6	3 6.2	6 10.3	1 3.1	9 5.2
I don't know	94 45.9	19 54.3	33 51.6	22 45.8	20 34.5	7 21.9	87 50.3
Total	206	35	65	48	58	33	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
POTIGA should always be taken with food	5 2.4	-	2 3.1	-	3 5.2	2 6.2	3 1.7
POTIGA should always be taken on its own, without food	3 1.5	-	1 1.6	2 4.2	-	3 9.4	-
POTIGA can be taken with or without food	120 58.5	17 48.6	39 60.9	27 56.2	37 63.8	24 75.0 G	96 55.5
None of the above	1 0.5	-	-	-	1 1.7	-	1 0.6
I don't know	77 37.6	18 51.4 cE	22 34.4	20 41.7	17 29.3	4 12.5	73 42.2 F
Total	206	35	64	49	58	33	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7 Page 23
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Pain when urinating	47 22.9	9 25.7	14 21.9	6 12.5	18 31.0 D	14 43.8 G	33 19.1
Difficulty starting urination	97 47.3	16 45.7	25 39.1	19 39.6	37 63.8 bCD	24 75.0 G	73 42.2
Renal colic	10 4.9	-	2 3.1	2 4.2	6 10.3	3 9.4	7 4.0
Inability to urinate	88 42.9	12 34.3	27 42.2	16 33.3	33 56.9 BD	22 68.8 G	66 38.2
None of the above	1 0.5	-	-	-	1 1.7	-	1 0.6
I don't know	73 35.6	16 45.7 E	24 37.5	19 39.6 e	14 24.1	2 6.2	71 41.0 F
Total	316	53	92	62	109	65	251

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7NET Page 24
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Correct response (1,2,4)	29 14.1	7 20.0	6 9.4	3 6.2	13 22.4	10 31.2	19 11.0
		d			CD	G	
Incorrect response	176 85.9	28 80.0	58 90.6	45 93.8	45 77.6	22 68.8	154 89.0
			E	bE			F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Report the issue at their next doctor's appointment	25 12.2	5 14.3	8 12.5	7 14.6	5 8.6	6 18.8	19 11.0
Drink more water	6 2.9	2 5.7	3 4.7	-	1 1.7	2 6.2	4 2.3
Seek immediate medical attention	138 67.3	18 51.4	45 70.3 b	32 66.7	43 74.1 B	26 81.2 G	112 64.7
Stop taking POTIGA	26 12.7	4 11.4	8 12.5	7 14.6	7 12.1	6 18.8	20 11.6
None of the above	1 0.5	-	-	1 2.1	-	-	1 0.6
I don't know	44 21.5	12 34.3 E	13 20.3	10 20.8	9 15.5	-	44 25.4
Total	240	41	77	57	65	40	200

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Total daily dose increased by 50mg/day	26 12.7	3 8.6	10 15.6	7 14.6	6 10.3	6 18.8	20 11.6
Total daily dose increased by 150mg/day	88 42.9	11 31.4	27 42.2	18 37.5	32 55.2 Bd	19 59.4 G	69 39.9
Total daily dose increased by 200mg/day	-	-	-	-	-	-	-
Total daily dose increased by 300mg/day	2 1.0	-	1 1.6	-	1 1.7	1 3.1	1 0.6
None of the above	1 0.5	1 2.9	-	-	-	-	1 0.6
I don't know	88 42.9	20 57.1 E	26 40.6	23 47.9	19 32.8	6 18.8	82 47.4 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10 Page 27
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
True	24 11.7	3 8.6	5 7.8	5 10.4	11 19.0 c	9 28.1 G	15 8.7
False	102 49.8	15 42.9	35 54.7	22 45.8	30 51.7	22 68.8 G	80 46.2
I don't know	79 38.5	17 48.6 e	24 37.5	21 43.8	17 29.3	1 3.1	78 45.1 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R1 Page 28
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	133 64.9	20 57.1	41 64.1	31 64.6	41 70.7	28 87.5 G	105 60.7
No	9 4.4	-	2 3.1	3 6.2	4 6.9	2 6.2	7 4.0
Don't know	63 30.7	15 42.9 E	21 32.8	14 29.2	13 22.4	2 6.2	61 35.3 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R2 Page 29
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	20 9.8	3 8.6	7 10.9	4 8.3	6 10.3	6 18.8	14 8.1
No	62 30.2	9 25.7	12 18.8	18 37.5	23 39.7	18 56.2	44 25.4
Don't know	123 60.0	23 65.7	45 70.3	26 54.2	29 50.0	8 25.0	115 66.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R3 Page 30
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	12 5.9	1 2.9	5 7.8	3 6.2	3 5.2	3 9.4	9 5.2
No	72 35.1	14 40.0	15 23.4	19 39.6	24 41.4	21 65.6	51 29.5
Don't know	121 59.0	20 57.1	44 68.8 e	26 54.2	31 53.4	8 25.0	113 65.3 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R4 Page 31
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	90 43.9	11 31.4	28 43.8	24 50.0 b	27 46.6	24 75.0 G	66 38.2
No	22 10.7	2 5.7	7 10.9	5 10.4	8 13.8	6 18.8	16 9.2
Don't know	93 45.4	22 62.9 cDE	29 45.3	19 39.6	23 39.7	2 6.2	91 52.6 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R5 Page 32
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	31 15.1	3 8.6	6 9.4	10 20.8	12 20.7	9 28.1	22 12.7
No	52 25.4	12 34.3	11 17.2	10 20.8	19 32.8	12 37.5	40 23.1
Don't know	122 59.5	20 57.1	47 73.4	28 58.3	27 46.6	11 34.4	111 64.2
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12 Page 33
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
True	94 45.9	10 28.6	28 43.8	26 54.2 B	30 51.7 B	25 78.1 G	69 39.9
False	8 3.9	3 8.6	4 6.2	-	1 1.7	2 6.2	6 3.5
I don't know	103 50.2	22 62.9	32 50.0	22 45.8	27 46.6	5 15.6	98 56.6 F
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13 Page 34
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Patients with benign prostatic hyperplasia (BPH)	137 66.8	18 51.4	44 68.8 b	34 70.8 b	41 70.7 b	26 81.2 G	111 64.2
Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	99 48.3	15 42.9	34 53.1	21 43.8	29 50.0	21 65.6 G	78 45.1
Patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics)	129 62.9	18 51.4	45 70.3 b	27 56.2	39 67.2	26 81.2 G	103 59.5
Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	33 16.1	3 8.6	16 25.0 BE	9 18.8	5 8.6	5 15.6	28 16.2
Patients who are obese	12 5.9	2 5.7	5 7.8	3 6.2	2 3.4	3 9.4	9 5.2
None of the above	2 1.0	1 2.9	1 1.6	-	-	-	2 1.2
I don't know	57 27.8	15 42.9 Cde	15 23.4	12 25.0	15 25.9	2 6.2	55 31.8 F
Total	469	72	160	106	131	83	386

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q14 Page 35
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q14: How long have you been practicing medicine?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Less than 5 years	-	-	-	-	-	-	-
5-15 years	-	-	-	-	-	-	-
16-25 years	-	-	-	-	-	-	-
26-35 years	-	-	-	-	-	-	-
More than 35 years	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q15 Page 36
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Less than 5 years	-	-	-	-	-	-	-
5-15 years	-	-	-	-	-	-	-
16-25 years	-	-	-	-	-	-	-
26-35 years	-	-	-	-	-	-	-
More than 35 years	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q16 Page 37
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q16: How many months have you been prescribing POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Less than 1	-	-	-	-	-	-	-
1-3	-	-	-	-	-	-	-
4-6	-	-	-	-	-	-	-
7-9	-	-	-	-	-	-	-
10-12	-	-	-	-	-	-	-
More than 12 months	-	-	-	-	-	-	-
I don't know/don't remember	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q17 Page 38
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-
11-20	-	-	-	-	-	-	-
More than 20 patients	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q18 Page 39
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
1-10	-	-	-	-	-	-	-
11-30	-	-	-	-	-	-	-
31-50	-	-	-	-	-	-	-
More than 50	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q19 Page 40
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q19: What is the age range of your current patient population? Please select all categories that you treat.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Pediatric (Under 18)	-	-	-	-	-	-	-
18-34	-	-	-	-	-	-	-
35-64	-	-	-	-	-	-	-
65 +	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q20 Page 41
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q20: Approximately what is the size of your current total patient population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Less than 100 patients	-	-	-	-	-	-	-
100 - 500 patients	-	-	-	-	-	-	-
501 - 1000 patients	-	-	-	-	-	-	-
More than 1000 patients	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q21 Page 42
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q21: Approximately what is the size of your current epilepsy patient population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	-	-	-	-	-	-	-
Less than 10 patients	-	-	-	-	-	-	-
10 - 50 patients	-	-	-	-	-	-	-
51 - 100 patients	-	-	-	-	-	-	-
101+ patients	-	-	-	-	-	-	-
I do not treat patients with epilepsy	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q22 Page 43
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q22: How long have you been a practicing pharmacist?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Less than 5 years	30 14.6	29 82.9 C	1 1.6	-	-	3 9.4	27 15.6
5-15 years	60 29.3	2 5.7	57 89.1 BD	1 2.1	-	8 25.0	52 30.1
16-25 years	49 23.9	2 5.7	3 4.7	44 91.7 BC	-	9 28.1	40 23.1
26-35 years	45 22.0	1 2.9	3 4.7	1 2.1	40 69.0 BCD	9 28.1	36 20.8
More than 35 years	21 10.2	1 2.9	-	2 4.2	18 31.0 BD	3 9.4	18 10.4
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q23 Page 44
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Less than 5 years	35 17.1	35 100.0	-	-	-	5 15.6	30 17.3
5-15 years	64 31.2	-	64 100.0	-	-	9 28.1	55 31.8
16-25 years	48 23.4	-	-	48 100.0	-	9 28.1	39 22.5
26-35 years	41 20.0	-	-	-	41 70.7	7 21.9	34 19.7
More than 35 years	17 8.3	-	-	-	17 29.3	2 6.2	15 8.7
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q24 Page 45
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	21 10.2	4 11.4	7 10.9	5 10.4	5 8.6	15 46.9 G	6 3.5
No	171 83.4	31 88.6	52 81.2	40 83.3	48 82.8	14 43.8	157 90.8 F
I don't know/don't remember	13 6.3	-	5 7.8	3 6.2	5 8.6	3 9.4	10 5.8
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q25 Page 46
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q25: Have you dispensed POTIGA in the past 12 months?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	32 15.6	5 14.3	9 14.1	9 18.8	9 15.5	32 100.0	-
No	158 77.1	29 82.9	48 75.0	37 77.1	44 75.9	-	158 91.3
I don't know/don't remember	15 7.3	1 2.9	7 10.9	2 4.2	5 8.6	-	15 8.7
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q26 Page 47
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q26: How many months have you been dispensing POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	
Total Answering	32	5	9	9	9	32	-
Less than 1	3 9.4	-	-	1 11.1	2 22.2	3 9.4	-
1-3	14 43.8	3 60.0	4 44.4	4 44.4	3 33.3	14 43.8	-
4-6	5 15.6	1 20.0	3 33.3	1 11.1	-	5 15.6	-
7-9	1 3.1	-	-	-	1 11.1	1 3.1	-
10-12	5 15.6	1 20.0	-	3 33.3	1 11.1	5 15.6	-
More than 12 months	1 3.1	-	1 11.1	-	-	1 3.1	-
I don't know/don't remember	3 9.4	-	1 11.1	-	2 22.2	3 9.4	-
Total	32	5	9	9	9	32	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q27 Page 48
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	
Total Answering	32	5	9	9	9	32	-
1-2	21 65.6	3 60.0	6 66.7	6 66.7	6 66.7	21 65.6	-
3-10	8 25.0	2 40.0	2 22.2	2 22.2	2 22.2	8 25.0	-
11-20	1 3.1	-	1 11.1	-	-	1 3.1	-
More than 20 patients	1 3.1	-	-	1 11.1	-	1 3.1	-
I don't know/don't remember	1 3.1	-	-	-	1 11.1	1 3.1	-
Total	32	5	9	9	9	32	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q28 Page 49
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	32	5	9	9	9	32	-
1 - 10	4 12.5	1 20.0	-	1 11.1	2 22.2	4 12.5	-
11 - 30	8 25.0	-	4 44.4 d	1 11.1	3 33.3	8 25.0	-
31 - 50	7 21.9	1 20.0	3 33.3	1 11.1	2 22.2	7 21.9	-
More than 50 prescriptions	13 40.6	3 60.0	2 22.2	6 66.7 CE	2 22.2	13 40.6	-
Total	32	5	9	9	9	32	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R1 Page 50
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	10 4.9	-	4 6.2	4 8.3	2 3.4	5 15.6	5 2.9
No	186 90.7	35 100.0 CDE	57 89.1	41 85.4	53 91.4	27 84.4	159 91.9
Don't know	9 4.4	-	3 4.7	3 6.2	3 5.2	-	9 5.2
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R2 Page 51
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	21 10.2	2 5.7	2 3.1	8 16.7 C	9 15.5 C	8 25.0 G	13 7.5
No	177 86.3	33 94.3 DE	60 93.8 DE	38 79.2	46 79.3	24 75.0	153 88.4 f
Don't know	7 3.4	-	2 3.1	2 4.2	3 5.2	-	7 4.0
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R3 Page 52
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	28 13.7	2 5.7	10 15.6 b	7 14.6	9 15.5	7 21.9	21 12.1
No	171 83.4	33 94.3 cDE	53 82.8	38 79.2	47 81.0	25 78.1	146 84.4
Don't know	6 2.9	-	1 1.6	3 6.2	2 3.4	-	6 3.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R4 Page 53
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	41 20.0	7 20.0	16 25.0	8 16.7	10 17.2	10 31.2	31 17.9
No	159 77.6	28 80.0	48 75.0	37 77.1	46 79.3	22 68.8	137 79.2
Don't know	5 2.4	-	-	3 6.2	2 3.4	-	5 2.9
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R5 Page 54
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	9 4.4	2 5.7	2 3.1	3 6.2	2 3.4	5 15.6	4 2.3
No	190 92.7	33 94.3	62 96.9 d	42 87.5	53 91.4	27 84.4	163 94.2
Don't know	6 2.9	-	-	3 6.2	3 5.2	-	6 3.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R6 Page 55
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	4 2.0	-	2 3.1	1 2.1	1 1.7	2 6.2	2 1.2
No	195 95.1	35 100.0 DE	62 96.9	44 91.7	54 93.1	30 93.8	165 95.4
Don't know	6 2.9	-	-	3 6.2	3 5.2	-	6 3.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R7 Page 56
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	95 46.3	10 28.6	31 48.4 B	24 50.0 B	30 51.7 B	26 81.2 G	69 39.9
No	104 50.7	25 71.4 CDE	32 50.0	21 43.8	26 44.8	6 18.8	98 56.6 F
Don't know	6 2.9	-	1 1.6	3 6.2	2 3.4	-	6 3.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R8 Page 57
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
Yes	45 22.0	10 28.6	13 20.3	8 16.7	14 24.1	14 43.8	31 17.9
No	154 75.1	25 71.4	50 78.1	38 79.2	41 70.7	18 56.2	136 78.6
Don't know	6 2.9	-	1 1.6	2 4.2	3 5.2	-	6 3.5
Total	205	35	64	48	58	32	173

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q30 Page 58
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	205	35	64	48	58	32	173
POTIGA Dear HCP Letter	64 31.2	11 31.4	17 26.6	17 35.4	19 32.8	11 34.4	53 30.6
GlaxoSmithKline Medical Information	48 23.4	6 17.1	19 29.7	10 20.8	13 22.4	9 28.1	39 22.5
Other Healthcare Professionals	36 17.6	7 20.0	12 18.8	5 10.4	12 20.7	6 18.8	30 17.3
GlaxoSmithKline Promotional Materials	60 29.3	8 22.9	16 25.0	18 37.5	18 31.0	5 15.6	55 31.8 F
GSK Website: POTIGA.com	61 29.8	17 48.6 CDE	15 23.4	13 27.1	16 27.6	7 21.9	54 31.2
GlaxoSmithKline Sales Representatives	71 34.6	11 31.4	30 46.9 dE	15 31.2	15 25.9	12 37.5	59 34.1
GlaxoSmithKline-sponsored Educational Meeting	74 36.1	12 34.3	24 37.5	15 31.2	23 39.7	13 40.6	61 35.3
POTIGA Product Labeling (including Prescribing Information, Medication Guide)	101 49.3	22 62.9 Cd	27 42.2	21 43.8	31 53.4	15 46.9	86 49.7
Total	515	94	160	114	147	78	437

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	80	18	25	19	18	5	75
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	61 76.2	15 83.3	18 72.0	15 78.9	13 72.2	-	61 81.3
FDA approved only for partial on-set seizures/ used for partial seizures	2 2.5	1 5.6	1 4.0	-	-	-	2 2.7
Used for all indications listed/aware of different uses for the med/med used for expanded indications in other countries	2 2.5	-	-	-	2 11.1	2 40.0	-
General recall/memory	3 3.8	-	1 4.0	1 5.3	1 5.6	2 40.0 g	1 1.3
Seizures/severe seizure disorder	1 1.2	-	-	-	1 5.6	-	1 1.3
GTC could be partial with secondary or primary generalization (indicated)/this drug works well with partial seizure & also may work with generalized tonic clonic seizure	1 1.2	-	-	1 5.3	-	-	1 1.3

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1_1CODE Page 60
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Epilepsy	1 1.2	-	-	-	1 5.6	-	1 1.3
Not seen the approved uses for POTIGA	2 2.5	-	1 4.0	-	1 5.6	1 20.0	1 1.3
Not sure for what type of seizures	3 3.8	1 5.6	1 4.0	1 5.3	-	-	3 4.0
Forgot	1 1.2	-	1 4.0	-	-	-	1 1.3
Misunderstood question/ Question is vague	1 1.2	-	-	-	1 5.6	-	1 1.3
Don't know/Do not recall	4 5.0	1 5.6	2 8.0	1 5.3	-	1 20.0	3 4.0
Total	82	18	25	19	20	6	76

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 61
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	122	22	37	29	34	12	110
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	72 59.0	18 81.8 cdE	22 59.5	17 58.6	15 44.1	2 16.7	70 63.6 F
I believe so/I think it can be used for monotherapy	1 0.8	-	-	1 3.4	-	-	1 0.9
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions	11 9.0	-	2 5.4	4 13.8	5 14.7	4 33.3 g	7 6.4
To be used as add-on therapy/approved as add- on to be treat seizures associated with epilepsy	1 0.8	-	-	-	1 2.9	-	1 0.9
Can be used as mono- therapy/believe it can be used for monotherapy/ have patients just using POTIGA/have seen it prescribed as a monotherapy/general mechanism lends itself to monotherapy	5 4.1	-	2 5.4	-	3 8.8	3 25.0 g	2 1.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 62
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Years Dispensing QED's				Dispensed POTIGA	
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK
	(A)	(B)	(C)	(D)	(E)	(F)
Newer medications are usually monotherapy treatment	1 0.8	-	1 2.7	-	-	- 1 0.9
Have not seen the PI	1 0.8	-	1 2.7	-	-	- 1 0.9
Could be more effective as a monotherapy	1 0.8	1 4.5	-	-	-	- 1 0.9
Can use used in patients with previous failed therapies	1 0.8	-	-	-	1 2.9	- 1 0.9
The drug information does not state it is used in conjunction	1 0.8	-	1 2.7	-	-	- 1 0.9
Have not seen it promoted as adjunct therapy	1 0.8	-	1 2.7	-	-	- 1 0.9
Literature states can be used with other agents but dose may need to be increased	1 0.8	-	-	-	1 2.9	- 1 0.9
Cannot be used a monotherapy	1 0.8	-	1 2.7	-	-	- 1 0.9
Not sure/not sure if it can be used as monotherapy	2 1.6	-	-	-	2 5.9	- 2 1.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 63
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Miscellaneous	5 4.1	1 4.5	-	3 10.3	1 2.9	1 8.3	4 3.6
Don't know/Do not recall	10 8.2	1 4.5	3 8.1	3 10.3	3 8.8	1 8.3	9 8.2
Used as adjunctive therapy/only prescribed as adjunctive therapy/FDA approved as adjunctive therapy/can be used with other seizure meds	7 5.7	1 4.5	3 8.1	1 3.4	2 5.9	1 8.3	6 5.5
Total	122	22	37	29	34	12	110

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	89	16	26	27	20	7	82
Lack of familiarity/ never heard of POTIGA, POTIGA risks or side effects/never dispensed POTIGA/no experience with POTIGA	58 65.2	15 93.8 CDE	16 61.5	15 55.6	12 60.0	-	58 70.7
General recall/memory/ best recall from PI/ clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data	1 1.1	-	1 3.8	-	-	1 14.3	-
Aware of some risks associated with medicine, but not aware of all risks/aware of the major risks	2 2.2	-	1 3.8	1 3.7	-	-	2 2.4
Aware of urinary issues/ problem with urinary function	4 4.5	-	1 3.8	3 11.1	-	1 14.3	3 3.7
Kidney, liver problems/ potentially toxic to kidneys	1 1.1	-	1 3.8	-	-	-	1 1.2
Never read the PI and not explained by pharmaceutical representative/never had a POTIGA representative visit/never fully read prescribing information	6 6.7	-	3 11.5	1 3.7	2 10.0	1 14.3	5 6.1

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 65
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Have not done research yet	2 2.2	-	1 3.8	1 3.7	-	-	2 2.4
Not a lot of information available on POTIGA	1 1.1	-	-	1 3.7	-	-	1 1.2
Could cause hepatic issues/requires dose adjustments in hepatic diseases	2 2.2	-	-	1 3.7	1 5.0	1 14.3	1 1.2
Risks listed on the article on the list server	1 1.1	-	-	-	1 5.0	-	1 1.2
Adverse event reported by patient, not ruled out as the cause	1 1.1	-	-	-	1 5.0	1 14.3	-
Limited knowledge of drug	1 1.1	-	1 3.8	-	-	-	1 1.2
Not sure/not sure about the side effects, risks	5 5.6	1 6.2	2 7.7	1 3.7	1 5.0	-	5 6.1
Miscellaneous	4 4.5	-	-	1 3.7	3 15.0	-	4 4.9
Don't know/Do not recall	5 5.6	-	1 3.8	4 14.8	-	2 28.6	3 3.7
Total	94	16	28	29	21	7	87

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	102	21	34	25	22	9	93
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	57 55.9	15 71.4 C	15 44.1	14 56.0	13 59.1	1 11.1	56 60.2 F
Not aware of the maximum dosage/uncertain of maximum dosage/not seen information on maximum dosing/not heard of maximum dosing	12 11.8	1 4.8	7 20.6 be	3 12.0	1 4.5	-	12 12.9
400mg three times a day/ 1200mg maximum dose	5 4.9	-	1 2.9	1 4.0	3 13.6	1 11.1	4 4.3
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	1 1.0	-	-	-	1 4.5	1 11.1	-
Previous studies indication a dose greater than 900mg offered no significant increased benefit, but greater side effects/ 1200mg not shown to be efficacious than 900mg/ seizure frequency reduced at a lesser percent with higher dose	2 2.0	1 4.8	-	1 4.0	-	1 11.1	1 1.1

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.

Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 67
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Never read the PI/never fully read the prescribing information	3 2.9	-	3 8.8	-	-	1 11.1	2 2.2
Never met with a pharmaceutical representative	1 1.0	-	-	1 4.0	-	-	1 1.1
Incorrect suggested maximum dose stated	7 6.9	1 4.8	2 5.9	3 12.0	1 4.5	-	7 7.5
Refer/consult PI/would look up before dispensing	3 2.9	-	1 2.9	1 4.0	1 4.5	-	3 3.2
Depends on the patient	1 1.0	1 4.8	-	-	-	-	1 1.1
Not had a chance to look up dosing recommendations/research of the drug/need further info	4 3.9	2 9.5	1 2.9	1 4.0	-	-	4 4.3
Maximum dose is between 600mg-1200mg	3 2.9	-	3 8.8	-	-	2 22.2	1 1.1
Not sure	1 1.0	-	-	-	1 4.5	-	1 1.1
Miscellaneous	2 2.0	-	1 2.9	-	1 4.5	2 22.2	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 68
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Don't know/Do not recall	3 2.9	-	1 2.9	2 8.0	-	1 11.1	2 2.2
Total	105	21	35	27	22	10	95

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 69
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	117	23	35	28	31	14	103
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	57 48.7	15 65.2 cE	15 42.9	15 53.6	12 38.7	1 7.1	56 54.4 F
Not aware of the minimum age/do not know lower age limit/have not heard about what the lower age limit is	18 15.4	4 17.4	8 22.9 D	1 3.6	5 16.1 d	5 35.7 g	13 12.6
No known upper age limits	1 0.9	-	-	-	1 3.2	-	1 1.0
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	2 1.7	-	-	1 3.6	1 3.2	1 7.1	1 1.0
Persons 12 years of age/ believe 12 years of age/ adolescents/most recently approved AEDs for age 12	1 0.9	-	1 2.9	-	-	-	1 1.0
Adults/only approved for adults/approved for 18+	5 4.3	2 8.7	-	-	3 9.7	1 7.1	4 3.9

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 70
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Clinical trials/studies did not include children/ not established data in children	4 3.4	-	2 5.7	-	2 6.5	1 7.1	3 2.9
Data does not provide/ indicate/cannot recall from clinical trials/ information not available	1 0.9	-	1 2.9	-	-	-	1 1.0
Not approved for children/do not use in the pediatric population/ new anticonvulsants do not have pediatric dosing	1 0.9	-	-	-	1 3.2	-	1 1.0
No lower age limit/safe for infants and children/ AEDs do not have a lower age limit	1 0.9	-	1 2.9	-	-	1 7.1	-
Uncertain whether lower age limit is 12 or 18/ uncertain if age limit is 18 years	1 0.9	-	1 2.9	-	-	-	1 1.0
Used with caution for those 65+/over 65 could have urination problems, immune system problems, weakness/65 is age limit/ not sure if contraindicated for patients over 65	11 9.4	3 13.0	1 2.9	2 7.1	5 16.1 c	2 14.3	9 8.7

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 71
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Would refer to the package insert/have to research the drug/not studied drug yet	3 2.6	-	1 2.9	-	2 6.5	-	3 2.9
Dosage limits based on age, hepatic, renal functions	1 0.9	-	-	1 3.6	-	-	1 1.0
Label is unclear	1 0.9	-	-	1 3.6	-	-	1 1.0
Not sure of age limit / best guess from PI	5 4.3	1 4.3	2 5.7	1 3.6	1 3.2	-	5 4.9
Miscellaneous	4 3.4	-	2 5.7	1 3.6	1 3.2	3 21.4 g	1 1.0
Don't know/Do not recall	7 6.0	-	2 5.7	5 17.9	-	1 7.1	6 5.8
Total	124	25	37	28	34	16	108

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 72
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	85	18	24	22	21	9	76
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	52 61.2	17 94.4 CDE	15 62.5	10 45.5	10 47.6	-	52 68.4
POTIGA can be taken with or without food/pretty sure can be taken with or without food	3 3.5	-	1 4.2	2 9.1	-	3 33.3	-
Not sure about the absorption of this medication/unaware how food effects absorption of product	3 3.5	-	1 4.2	1 4.5	1 4.8	1 11.1	2 2.6
Not aware of any need to specify that it should be taken with or without food	1 1.2	-	-	1 4.5	-	1 11.1	-
General recall/believe to be true	2 2.4	-	1 4.2	-	1 4.8	1 11.1	1 1.3
Incorrect selection	2 2.4	-	-	1 4.5	1 4.8	1 11.1	1 1.3
From the prescribing literature/from pharmaceutical representative/from the information	1 1.2	-	-	-	1 4.8	-	1 1.3

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 73
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Normally advise to take without food unless seen that it should be taken with food	1 1.2	-	1 4.2	-	-	1 11.1	-
Nothing in literature about recommendation with or without food/nothing in literature about specific guidelines/information not readily available	3 3.5	-	1 4.2	2 9.1	-	-	3 3.9
Refer/consult PI/would look up before dispensing	1 1.2	1 5.6	-	-	-	1 11.1	-
Never had a patient on POTIGA	2 2.4	-	-	2 9.1	-	-	2 2.6
GI side effects	1 1.2	-	-	-	1 4.8	-	1 1.3
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	3 3.5	-	2 8.3	1 4.5	-	1 11.1	2 2.6

Comparison Groups: ECDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 74
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Not sure/uncertain/ unaware	4 4.7	1 5.6	2 8.3	-	1 4.8	-	4 5.3
Miscellaneous	1 1.2	-	-	-	1 4.8	-	1 1.3
Don't know/Do not recall	7 8.2	-	-	3 13.6	4 19.0	-	7 9.2
Total	87	19	24	23	21	10	77

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 75
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	175	28	57	45	45	22	153
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	53 30.3	14 50.0 CDE	16 28.1	12 26.7	11 24.4	-	53 34.6
Unique side effect/side effects reported by patients/side effects/ symptom/potential complication	21 12.0	3 10.7	9 15.8	5 11.1	4 8.9	4 18.2	17 11.1
Unaware of the urinary symptoms/unaware of side effects, symptoms when taking POTIGA	5 2.9	1 3.6	3 5.3	1 2.2	-	-	5 3.3
Urinary retention is a symptom or AE/watch for urinary retention/ urinary retention/ urinary retention potential side effect/ urinary retention has been reported	29 16.6	3 10.7	10 17.5	6 13.3	10 22.2	3 13.6	26 17.0
Affect urinary flow/ difficulty starting urination/voiding dysfunction/difficulty urinating/urinary problems/pain with urination	16 9.1	2 7.1	7 12.3	3 6.7	4 8.9	4 18.2	12 7.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 76
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
General recall/memory/knowledge	5 2.9	-	1 1.8	2 4.4	2 4.4	3 13.6	2 1.3
Forgot, but did know about urinary symptoms/forgot about these risks	1 0.6	-	-	1 2.2	-	-	1 0.7
Warning from package insert/from package insert and patient info materials/warning for the drug/drug info/main warning	6 3.4	1 3.6	-	1 2.2	4 8.9	1 4.5	5 3.3
Read/heard about it (non-specific)	2 1.1	-	2 3.5	-	-	1 4.5	1 0.7
Clinical trials/results of clinical trials	3 1.7	-	2 3.5	1 2.2	-	2 9.1	1 0.7
From the prescribing literature/from pharmaceutical representative/from the information, medication inserts/drug company/online pamphlet, REMS literature	11 6.3	-	4 7.0	3 6.7	4 8.9	3 13.6	8 5.2
Indications and label/label	2 1.1	-	-	1 2.2	1 2.2	-	2 1.3

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 77
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Easiest to tell patients to look out for/discuss with patients/advise patients	3 1.7	-	2 3.5	1 2.2	-	1 4.5	2 1.3
Never read prescribing information	1 0.6	-	1 1.8	-	-	1 4.5	-
Not enough information on drug/not enough time to research it/not specific recommendations to patients	4 2.3	-	1 1.8	1 2.2	2 4.4	-	4 2.6
Side effects of an urinary tract infection	1 0.6	1 3.6	-	-	-	-	1 0.7
Black box warning	1 0.6	-	-	-	1 2.2	-	1 0.7
Ask a doctor right away if pain when urinating/seek medical attention right away	3 1.7	1 3.6	1 1.8	1 2.2	-	-	3 2.0
Associated with renal function/renal adverse effects	1 0.6	-	1 1.8	-	-	-	1 0.7
Urinary obstruction, which is serious	1 0.6	-	-	-	1 2.2	-	1 0.7
Subject error/mouse error	1 0.6	-	1 1.8	-	-	-	1 0.7

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 78
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Anticholinergic	4 2.3	2 7.1	-	1 2.2	1 2.2	2 9.1	2 1.3
Not sure/uncertain/ unaware	4 2.3	-	1 1.8	2 4.4	1 2.2	-	4 2.6
Miscellaneous	3 1.7	1 3.6	-	2 4.4	-	-	3 2.0
Nothing	1 0.6	-	-	-	1 2.2	-	1 0.7
Don't know/Do not recall	1 0.6	-	-	1 2.2	-	-	1 0.7
Total	183	29	62	45	47	25	158

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 79
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	93	20	28	23	22	12	81
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	34 36.6	11 55.0 c	8 28.6	8 34.8	7 31.8	-	34 42.0
Stop use and seek immediate medical attention	4 4.3	1 5.0	1 3.6	-	2 9.1	1 8.3	3 3.7
Medical emergency/seek medical care/seek medical attention right away	8 8.6	3 15.0	4 14.3	1 4.3	-	1 8.3	7 8.6
Stop use/stop use, cause of the problem	4 4.3	3 15.0	-	1 4.3	-	3 25.0 g	1 1.2
Prudent action to take with urinary retention/ prudent response	1 1.1	-	-	-	1 4.5	-	1 1.2
Advise given to my patients/recommendation	1 1.1	-	1 3.6	-	-	-	1 1.2
Correct course of action/ best possible action, advice/most logical action/best next steps/ right thing to do	1 1.1	-	-	-	1 4.5	1 8.3	-

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 80
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
POTIGA causes urinary retention	1 1.1	-	-	1 4.3	-	-	1 1.2
Information from the PI	1 1.1	-	1 3.6	-	-	1 8.3	-
Label/label indications	1 1.1	-	-	1 4.3	-	-	1 1.2
Side effects/serious side effect/dangerous issue	4 4.3	-	2 7.1	1 4.3	1 4.5	1 8.3	3 3.7
General recall/general knowledge	2 2.2	-	1 3.6	-	1 4.5	1 8.3	1 1.2
Further research necessary	3 3.2	-	2 7.1	-	1 4.5	-	3 3.7
Would not give advice about a product not familiar with	1 1.1	-	-	1 4.3	-	-	1 1.2
Ask a doctor	11 11.8	1 5.0	2 7.1	4 17.4	4 18.2	1 8.3	10 12.3
Patient needs follow-up	1 1.1	-	-	1 4.3	-	-	1 1.2
Prevent patient harm/could lead to further complications	2 2.2	-	1 3.6	1 4.3	-	1 8.3	1 1.2
Urinary retention is acute issue that needs to be treated	2 2.2	-	-	1 4.3	1 4.5	-	2 2.5

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 81
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Based on other drugs in this category	1 1.1	-	1 3.6	-	-	-	1 1.2
Doctor needs to update the dose	1 1.1	-	-	-	1 4.5	-	1 1.2
Not sure/uncertain/unaware	2 2.2	-	1 3.6	1 4.3	-	-	2 2.5
Miscellaneous	7 7.5	1 5.0	2 7.1	2 8.7	2 9.1	1 8.3	6 7.4
Don't know/Do not recall	2 2.2	1 5.0	1 3.6	-	-	-	2 2.5
Total	95	21	28	24	22	12	83

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 82
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	115	24	36	30	25	13	102
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	59 51.3	15 62.5	15 41.7	15 50.0	14 56.0	1 7.7	58 56.9 F
Uncertain of maximum weekly dosage	6 5.2	1 4.2	3 8.3	1 3.3	1 4.0	2 15.4	4 3.9
Thought answer provided was correct response	1 0.9	-	1 2.8	-	-	-	1 1.0
50mg per day is minimal increased dosage/ recalled 50mg	5 4.3	1 4.2	2 5.6	1 3.3	1 4.0	-	5 4.9
General recall/recall from reading	3 2.6	-	-	2 6.7	1 4.0	1 7.7	2 2.0
150mg per day/do not exceed 150 mg per day150mg per day/do not exceed 150 mg per day	3 2.6	2 8.3	-	-	1 4.0	-	3 2.9
1200mg/maximum dose is 1200mg	1 0.9	-	-	1 3.3	-	-	1 1.0
Titrate slowly/titrate patient 50mg weekly/ titration scale/dosing charts	3 2.6	-	2 5.6	1 3.3	-	2 15.4	1 1.0

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 83
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information	11 9.6	1 4.2	5 13.9	-	5 20.0 b	3 23.1	8 7.8
Depends on patient/based on patient's tolerability and frequency of seizures	2 1.7	2 8.3	-	-	-	-	2 2.0
Past experience	1 0.9	-	-	-	1 4.0	1 7.7	-
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	3 2.6	-	2 5.6	1 3.3	-	1 7.7	2 2.0
Not familiar with titration being necessary	1 0.9	-	1 2.8	-	-	-	1 1.0
Looked up information in reference book	1 0.9	-	1 2.8	-	-	-	1 1.0
Based on the drug's side effects	1 0.9	-	-	1 3.3	-	-	1 1.0

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 84
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Not sure	2 1.7	-	-	2 6.7	-	1 7.7	1 1.0
Miscellaneous	4 3.5	2 8.3	2 5.6	-	-	-	4 3.9
Misunderstood question/ Question is vague	1 0.9	-	-	-	1 4.0	1 7.7	-
Don't know/Do not recall	9 7.8	1 4.2	2 5.6	5 16.7	1 4.0	1 7.7	8 7.8
Total	117	25	36	30	26	14	103

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	101	20	28	26	27	10	91
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	49 48.5	13 65.0 e	12 42.9	13 50.0	11 40.7	-	49 53.8
300mg per day is initial dose/100mg TID	4 4.0	1 5.0	2 7.1	-	1 3.7	1 10.0	3 3.3
Do not know initial dose/ unsure of initial dose/ unsure of initial dose for general population	7 6.9	-	3 10.7	3 11.5	1 3.7	-	7 7.7
General recall/recall from reading	5 5.0	-	-	1 3.8	4 14.8	2 20.0	3 3.3
150mg is initial dosage increase/not to exceed 150mg dosage increase per week	1 1.0	-	1 3.6	-	-	-	1 1.1
150mg is dose for general population/start patients with 150mg initially	3 3.0	-	3 10.7	-	-	1 10.0	2 2.2
From label/indications/ samples to patients/pkg insert/prescribing literature/ from the info/representative starter kits	7 6.9	-	1 3.6	1 3.8	5 18.5 cd	3 30.0 g	4 4.4

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 86
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Depends on patient/ titrate based on patient's tolerability	1 1.0	-	1 3.6	-	-	-	1 1.1
Recommended dosing of POTIGA	2 2.0	1 5.0	-	-	1 3.7	1 10.0	1 1.1
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	7 6.9	1 5.0	3 10.7	2 7.7	1 3.7	1 10.0	6 6.6
Miscellaneous	9 8.9	2 10.0	3 10.7	3 11.5	1 3.7	1 10.0	8 8.8
Don't know/Do not recall	7 6.9	2 10.0	-	3 11.5	2 7.4	-	7 7.7
Total	102	20	29	26	27	10	92

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 87
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	69	15	21	17	16	3	66
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	49 71.0	14 93.3 CdE	13 61.9	12 70.6	10 62.5	1 33.3	48 72.7
General recall/recall from reading/general understanding	1 1.4	-	-	-	1 6.2	-	1 1.5
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	1 1.4	-	-	1 5.9	-	-	1 1.5
No information available/ could not find the information	3 4.3	-	-	1 5.9	2 12.5	-	3 4.5
Urinary contraindications/ contraindicated	1 1.4	-	-	1 5.9	-	1 33.3	-
Unaware of precautions/ problems/issues/ contraindications	3 4.3	-	3 14.3	-	-	-	3 4.5

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 88
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Unaware of renal/hepatic issues/not aware of specific renal/hepatic issues	2 2.9	-	2 9.5	-	-	-	2 3.0
Answer should be "yes"	1 1.4	-	-	-	1 6.2	-	1 1.5
Not sure/uncertain/unaware	1 1.4	-	-	-	1 6.2	-	1 1.5
Miscellaneous	4 5.8	-	2 9.5	1 5.9	1 6.2	-	4 6.1
Don't know/Do not recall	3 4.3	1 6.7	1 4.8	1 5.9	-	1 33.3	2 3.0
Total	69	15	21	17	16	3	66

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 89
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	140	26	49	30	35	14	126
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	53 37.9	13 50.0	15 30.6	12 40.0	13 37.1	2 14.3	51 40.5 F
General recall/recall from reading/general understanding	1 0.7	-	1 2.0	-	-	1 7.1	-
Use with caution/a precaution	4 2.9	-	3 6.1	1 3.3	-	2 14.3	2 1.6
Worsen the condition/ because of side effects/ might cause problems with condition	9 6.4	2 7.7	1 2.0	2 6.7	4 11.4	2 14.3	7 5.6
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	5 3.6	-	-	2 6.7	3 8.6	1 7.1	4 3.2
No information available/ could not find the information	1 0.7	-	-	1 3.3	-	-	1 0.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 90
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Never heard about this/ never heard one way or the other	1 0.7	-	1 2.0	-	-	-	1 0.8
Unaware of precautions/ problems/issues/ contraindications	16 11.4	1 3.8	9 18.4 B	2 6.7	4 11.4	1 7.1	15 11.9
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	3 2.1	-	1 2.0	1 3.3	1 2.9	-	3 2.4
Wrong response provided/ selected	1 0.7	-	1 2.0	-	-	-	1 0.8
Not sure/uncertain/ unaware	17 12.1	2 7.7	5 10.2	5 16.7	5 14.3	2 14.3	15 11.9
Miscellaneous	5 3.6	2 7.7	3 6.1	-	-	-	5 4.0
Misunderstood question/ Question is vague	1 0.7	-	1 2.0	-	-	-	1 0.8
Don't know/Do not recall	23 16.4	6 23.1	8 16.3	4 13.3	5 14.3	3 21.4	20 15.9
Total	140	26	49	30	35	14	126

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 91
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	130	20	47	29	34	11	119
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	50 38.5	12 60.0 Ce	13 27.7	13 44.8	12 35.3	-	50 42.0
Data from past research/ studies/clinical trials	1 0.8	-	1 2.1	-	-	1 9.1	-
Use with caution/a precaution	3 2.3	-	3 6.4	-	-	-	3 2.5
Worsen the condition/ because of side effects/ might cause problems with condition	2 1.5	-	1 2.1	-	1 2.9	-	2 1.7
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	4 3.1	-	-	1 3.4	3 8.8	1 9.1	3 2.5
No information available/ could not find the information	3 2.3	-	2 4.3	1 3.4	-	-	3 2.5
Never heard about this/ never heard one way or the other	2 1.5	-	1 2.1	-	1 2.9	-	2 1.7

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 92
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Unaware of precautions/ problems/issues/ contraindications	21 16.2	1 5.0	9 19.1 bd	2 6.9	9 26.5 BD	2 18.2	19 16.0
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	5 3.8	-	2 4.3	2 6.9	1 2.9	1 9.1	4 3.4
Wrong response provided/ selected	2 1.5	1 5.0	1 2.1	-	-	-	2 1.7
Not sure/uncertain/ unaware	13 10.0	1 5.0	4 8.5	5 17.2	3 8.8	2 18.2	11 9.2
Miscellaneous	6 4.6	1 5.0	3 6.4	2 6.9	-	1 9.1	5 4.2
Don't know/Do not recall	18 13.8	4 20.0	7 14.9	3 10.3	4 11.8	3 27.3	15 12.6
Total	130	20	47	29	34	11	119

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 93
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	112	24	33	24	31	8	104
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	47 42.0	13 54.2	12 36.4	10 41.7	12 38.7	-	47 45.2
Odds of BPH/urinary retention increase after age 65/higher rate of renal problems	5 4.5	1 4.2	2 6.1	-	2 6.5	1 12.5	4 3.8
No upper age limit/ unaware of upper age limit/no age limit	13 11.6	4 16.7	5 15.2	-	4 12.9	2 25.0	11 10.6
Use with caution/a precaution	1 0.9	-	-	-	1 3.2	-	1 1.0
Conservative response/ initially conservative when prescribing/lower starting dose	3 2.7	-	1 3.0	-	2 6.5	-	3 2.9
No information available/ could not find the information	2 1.8	-	-	1 4.2	1 3.2	-	2 1.9
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	5 4.5	-	1 3.0	1 4.2	3 9.7	1 12.5	4 3.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 94
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Never heard about this/ never heard one way or the other	1 0.9	-	1 3.0	-	-	-	1 1.0
Urinary contraindications/ contraindicated	1 0.9	-	-	1 4.2	-	1 12.5	-
Unaware of precautions/ problems/issues/ contraindications	5 4.5	-	-	-	5 16.1	-	5 4.8
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	6 5.4	1 4.2	2 6.1	3 12.5	-	1 12.5	5 4.8
Caution when using in patients 65+/not recommended for 65+ patients	1 0.9	-	-	1 4.2	-	-	1 1.0
There are dosing limits for 65+	2 1.8	-	1 3.0	1 4.2	-	1 12.5	1 1.0
Not sure/uncertain/ unaware	5 4.5	-	1 3.0	3 12.5	1 3.2	-	5 4.8

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 95
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Miscellaneous	6 5.4	1 4.2	3 9.1	1 4.2	1 3.2	1 12.5	5 4.8
Don't know/Do not recall	11 9.8	4 16.7	4 12.1	2 8.3	1 3.2	-	11 10.6
Total	114	24	33	24	33	8	106

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ECODEA Page 96
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	2	-	-	-	2	-	2
Use with caution/a precaution	1 50.0	-	-	-	1 50.0	-	1 50.0
Worsen the condition/ because of side effects/ might cause problems with condition	1 50.0	-	-	-	1 50.0	-	1 50.0
Total	2	-	-	-	2	-	2

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	109	25	34	22	28	7	102
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	48 44.0	15 60.0 ce	12 35.3	11 50.0	10 35.7	-	48 47.1
Unaware of AE time frame/ never heard of the timeframe/unsure of the timeframe/did not recall specific timeframe	15 13.8	3 12.0	3 8.8	4 18.2	5 17.9	-	15 14.7
Not familiar with studies referenced in statement	5 4.6	-	1 2.9	-	4 14.3	1 14.3	4 3.9
Do not recall any data on this/do not recall this fact	1 0.9	-	-	-	1 3.6	1 14.3	-
AE's can occur at any time/soon after starting medicine	1 0.9	-	-	-	1 3.6	-	1 1.0
AE's may not be reported within 6 mos/can occur after 6 mos	1 0.9	1 4.0	-	-	-	1 14.3	-
Clinical trials still pending/will require post-market data/ research	1 0.9	1 4.0	-	-	-	-	1 1.0

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 98
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
AE's should be reported immediately/earlier than 6 mos	2 1.8	1 4.0	1 2.9	-	-	-	2 2.0
Label/PI/resources do not mention	2 1.8	-	1 2.9	-	1 3.6	-	2 2.0
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	1 0.9	-	1 2.9	-	-	1 14.3	-
Should have answered "yes"/true statement	3 2.8	1 4.0	-	1 4.5	1 3.6	-	3 2.9
Not sure/uncertain/unaware	4 3.7	-	2 5.9	1 4.5	1 3.6	-	4 3.9
Miscellaneous	11 10.1	2 8.0	5 14.7	2 9.1	2 7.1	1 14.3	10 9.8
Misunderstood question/Question is vague	1 0.9	-	-	-	1 3.6	-	1 1.0
Don't know/Do not recall	13 11.9	1 4.0	8 23.5 BE	3 13.6	1 3.6	2 28.6	11 10.8
Total	109	25	34	22	28	7	102

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 99
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Total Answering	132	25	41	32	34	18	114
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	36 27.3	11 44.0 C	7 17.1	9 28.1	9 26.5	-	36 31.6
All are high risk groups/ need to be monitored	9 6.8	2 8.0	4 9.8	2 6.2	1 2.9	2 11.1	7 6.1
Patients cannot report symptoms/problems	4 3.0	1 4.0	3 7.3	-	-	1 5.6	3 2.6
Patients are at higher risk for BPH/voiding difficulty/urinary retention/underlying urinary retention concerns	43 32.6	8 32.0	18 43.9 e	9 28.1	8 23.5	7 38.9	36 31.6
Side effects/known side effect(s) of urinary retention	16 12.1	1 4.0	7 17.1 b	2 6.2	6 17.6 b	2 11.1	14 12.3
General recall	1 0.8	-	1 2.4	-	-	1 5.6	-
Previous knowledge/past experience	1 0.8	-	-	1 3.1	-	-	1 0.9
Patients with kidney/ stomach issues monitored closely/NSAIDS patients/ effect kidney	6 4.5	1 4.0	4 9.8	1 3.1	-	1 5.6	5 4.4

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 100
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Obvious precautions	2 1.5	-	-	-	2 5.9	2 11.1	-
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep/ internet research, past clinical research	5 3.8	1 4.0	-	3 9.4	1 2.9	2 11.1	3 2.6
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/ would need to look up drug/not aware of this detail/never read prescribing information	2 1.5	1 4.0	1 2.4	-	-	1 5.6	1 0.9
Not sure/uncertain/ unaware	4 3.0	-	-	3 9.4	1 2.9	-	4 3.5
Miscellaneous	11 8.3	2 8.0	1 2.4	3 9.4	5 14.7 c	1 5.6	10 8.8
Misunderstood question/ Question is vague	1 0.8	-	1 2.4	-	-	-	1 0.9

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 101
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Pharmacist Banner

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

	Years Dispensing QED's				Dispensed POTIGA		
	Pharmacist < 5 years	5-15 yrs	16-25 yrs	26+ yrs	Yes	No/DK	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)
Don't know/Do not recall	7 5.3	1 4.0	2 4.9	1 3.1	3 8.8	1 5.6	6 5.3
Total	148	29	49	34	36	21	127

Comparison Groups: BCDE/FG
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

TABLE OF CONTENTS

Physician

Table QSCR3 Page 1.....S3: How would you classify your primary specialty?

Table TYPE Page 2.....Type: Physician/Pharmacist

Table QSCR4 Page 3.....S4: Are you a currently practicing physician? (for physicians only)

Table QSCR5 Page 4.....S5: Do you currently see and treat patients with epilepsy? (physicians only)

Table QSCR6 Page 5.....S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

Table QSCR7 Page 6.....S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Table QSCR8 Page 9.....S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Table QSA Page 12.....SA: How would you classify your primary specialty?

Table QSB Page 13.....SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

Table QSC Page 14.....SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

Table QSD Page 15.....SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

Table Q1 Page 16.....Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

Table Q2 Page 17.....Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3 Page 18.....Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

Table Q4 Page 19.....Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Table Q5 Page 20.....Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q6 Page 21.....Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Table Q7 Page 22.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

Table Q7NET Page 23.....Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

TABLE OF CONTENTS

Table Q8 Page 24.....Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

Table Q9 Page 25.....Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Table Q10 Page 26.....Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Table Q11R1 Page 27.....Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R2 Page 28.....Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R3 Page 29.....Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R4 Page 30.....Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11R5 Page 31.....Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q12 Page 32.....Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Table Q13 Page 33.....Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

Table Q14 Page 34.....Q14: How long have you been practicing medicine?

Table Q15 Page 35.....Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

Table Q16 Page 36.....Q16: How many months have you been prescribing POTIGA?

Table Q17 Page 37.....Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

Table Q18 Page 38.....Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

Table Q19 Page 39.....Q19: What is the age range of your current patient population? Please select all categories that you treat.

Table Q20 Page 40.....Q20: Approximately what is the size of your current total patient population?

Table Q21 Page 41.....Q21: Approximately what is the size of your current epilepsy patient population?

Table Q22 Page 42.....Q22: How long have you been a practicing pharmacist?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

TABLE OF CONTENTS

Table Q23 Page 43.....Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

Table Q24 Page 44.....Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

Table Q25 Page 45.....Q25: Have you dispensed POTIGA in the past 12 months?

Table Q26 Page 46.....Q26: How many months have you been dispensing POTIGA?

Table Q27 Page 47.....Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

Table Q28 Page 48.....Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

Table Q29R1 Page 49.....Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R2 Page 50.....Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R3 Page 51.....Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R4 Page 52.....Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R5 Page 53.....Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R6 Page 54.....Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R7 Page 55.....Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q29R8 Page 56.....Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Table Q30 Page 57.....Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

Table Q1_1CODE Page 58...Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

Table Q2_1CODE Page 60...Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Table Q3_1CODE Page 62...Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Table Q4_1CODE Page 65...Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

TABLE OF CONTENTS

Table Q5_1CODE Page 68...Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Table Q6_1CODE Page 72...Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

Table Q7_1CODE Page 75...Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Table Q8_1CODE Page 78...Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

Table Q9_1CODE Page 81...Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Table Q10_1CODE Page 85...Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Table Q11_1ACODE Page 88...Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1BCODE Page 90...Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1CCODE Page 92...Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1DCODE Page 94...Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q11_1ECODEA Page 97...Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Table Q12_1CODE Page 98...Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Table Q13_1CODEA Page 100...Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

Table QSCR3 Page 1
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S3: How would you classify your primary specialty?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Neurology	126	3	50	49	24	13	40	42	28	70	56	59	67	51	75
	75.0	50.0	69.4	83.1 c	77.4	81.2	72.7	84.0 i	66.7	80.5 k	69.1	88.1 M	66.3	67.1	81.5 N
Neurosurgery	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Epileptology	42	3	22	10	7	3	15	8	14	17	25	8	34	25	17
	25.0	50.0	30.6 d	16.9	22.6	18.8	27.3	16.0	33.3 h	19.5	30.9 j	11.9	33.7 L	32.9 O	18.5
Pharmacy (Community/ Retail)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pharmacy (Hospital/ Clinical)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table TYPE Page 2
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Type: Physician/Pharmacist

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Physician	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Pharmacist	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR4 Page 3
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S4: Are you a currently practicing physician? (for physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
No	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR5 Page 4
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S5: Do you currently see and treat patients with epilepsy? (physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
No	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR6 Page 5
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S6: Do you currently fill prescriptions for patients with epilepsy? (pharmacist only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Yes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
No	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Don't know	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 6
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Ativan (Lorazepam)	167	6	72	59	30	16	55	50	41	86	81	66	101	75	92
	99.4	100.0	100.0	100.0	96.8	100.0	100.0	100.0	97.6	98.9	100.0	98.5	100.0	98.7	100.0
Carbatrol (Carbamazepine)	83	-	36	29	18	6	31	24	21	41	42	30	53	37	46
	49.4		50.0	49.2	58.1	37.5	56.4	48.0	50.0	47.1	51.9	44.8	52.5	48.7	50.0
Celontin (Methsuximide)	28	-	14	9	5	3	8	8	9	12	16	8	20	10	18
	16.7		19.4	15.3	16.1	18.8	14.5	16.0	21.4	13.8	19.8	11.9	19.8	13.2	19.6
Cerebyx (Fosphenytoin sodium)	64	-	28	22	14	5	20	21	17	29	35	23	41	27	37
	38.1		38.9	37.3	45.2	31.2	36.4	42.0	40.5	33.3	43.2	34.3	40.6	35.5	40.2
Depakote/Depakote ER/Depakote Sprinkle (Divalproex Sodium)	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Depacon (Valproate sodium)	75	-	33	27	15	5	27	23	19	35	40	26	49	32	43
	44.6		45.8	45.8	48.4	31.2	49.1	46.0	45.2	40.2	49.4	38.8	48.5	42.1	46.7
Depakene (Valproic acid)	76	-	35	26	15	5	27	24	19	36	40	27	49	32	44
	45.2		48.6	44.1	48.4	31.2	49.1	48.0	45.2	41.4	49.4	40.3	48.5	42.1	47.8
Diastat (Diazepam)	79	-	34	28	17	6	30	22	20	41	38	28	51	34	45
	47.0		47.2	47.5	54.8	37.5	54.5	44.0	47.6	47.1	46.9	41.8	50.5	44.7	48.9
Dilantin (Phenytoin)	162	6	68	57	31	16	54	48	39	86	76	64	98	73	89
	96.4	100.0	94.4	96.6	100.0	100.0	98.2	96.0	92.9	98.9	93.8	95.5	97.0	96.1	96.7
		C			C		i			k					
Felbatol (Felbamate)	53	-	27	14	12	6	18	18	10	25	28	15	38	20	33
	31.5		37.5	23.7	38.7	37.5	32.7	36.0	23.8	28.7	34.6	22.4	37.6	26.3	35.9
			d										L		

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 7
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Gabitril (Tiagabine hydrochloride)	52 31.0	-	23 31.9	14 23.7	15 48.4 D	3 18.8	16 29.1	18 36.0	14 33.3	19 21.8	33 40.7 J	17 25.4	35 34.7	24 31.6	28 30.4
Keppra (Levetiracetam)	167 99.4	6 100.0	71 98.6	59 100.0	31 100.0	16 100.0	55 100.0	49 98.0	42 100.0	87 100.0	80 98.8	67 100.0	100 99.0	76 100.0	91 98.9
Klonopin (Clonazepam)	83 49.4	-	36 50.0	29 49.2	18 58.1	6 37.5	31 56.4	24 48.0	21 50.0	41 47.1	42 51.9	30 44.8	53 52.5	37 48.7	46 50.0
Lamictal (Lamotrigine)	168 100.0	6 100.0	72 100.0	59 100.0	31 100.0	16 100.0	55 100.0	50 100.0	42 100.0	87 100.0	81 100.0	67 100.0	101 100.0	76 100.0	92 100.0
Lorazepam Intensol (Lorazepam)	73 43.5	-	34 47.2	25 42.4	14 45.2	6 37.5	26 47.3	21 42.0	19 45.2	34 39.1	39 48.1	22 32.8	51 50.5 L	34 44.7	39 42.4
Lyrica (Pregabalin)	83 49.4	-	37 51.4	29 49.2	17 54.8	6 37.5	31 56.4	24 48.0	21 50.0	42 48.3	41 50.6	31 46.3	52 51.5	36 47.4	47 51.1
Mebaral (Mephobarbital)	21 12.5	-	9 12.5	6 10.2	6 19.4	-	7 12.7	9 18.0	4 9.5	8 9.2	13 16.0	7 10.4	14 13.9	6 7.9	15 16.3 n
Mysoline (Primidone)	75 44.6	-	32 44.4	27 45.8	16 51.6	5 31.2	28 50.9	22 44.0	19 45.2	38 43.7	37 45.7	28 41.8	47 46.5	33 43.4	42 45.7
Neurontin (Gabapentin)	167 99.4	6 100.0	71 98.6	59 100.0	31 100.0	16 100.0	54 98.2	50 100.0	42 100.0	87 100.0	80 98.8	67 100.0	100 99.0	76 100.0	91 98.9
Peganone (Ethotoin)	21 12.5	-	11 15.3	7 11.9	3 9.7	-	10 18.2	6 12.0	5 11.9	7 8.0	14 17.3 j	7 10.4	14 13.9	7 9.2	14 15.2

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR7 Page 8
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S7: Please tell me all of the medicines, if any, for which you have written at least one prescription in the past 12 months. (Total Medications - physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Potiga (Ezogabine)	168 100.0	6 100.0	72 100.0	59 100.0	31 100.0	16 100.0	55 100.0	50 100.0	42 100.0	87 100.0	81 100.0	67 100.0	101 100.0	76 100.0	92 100.0
Tegretol/Tegretol XR (Carbamazepine)	83 49.4	- 50.0	36 49.2	29 49.2	18 58.1	6 37.5	31 56.4	24 48.0	21 50.0	41 47.1	42 51.9	30 44.8	53 52.5	37 48.7	46 50.0
Topamax (Topiramate)	157 93.5	5 83.3	66 91.7	56 94.9	30 96.8	15 93.8	52 94.5	47 94.0	39 92.9	79 90.8	78 96.3	62 92.5	95 94.1	70 92.1	87 94.6
Tranxene (Clorazepate dipotassium)	52 31.0	- 31.9	23 30.5	18 30.5	11 35.5	3 18.8	17 30.9	17 34.0	14 33.3	25 28.7	27 33.3	12 17.9	40 39.6 L	23 30.3	29 31.5
Trileptal (Oxcarbazepine)	82 48.8	- 48.6	35 48.6	29 49.2	18 58.1	6 37.5	30 54.5	23 46.0	22 52.4	41 47.1	41 50.6	29 43.3	53 52.5	36 47.4	46 50.0
Valium (Diazepam)	81 48.2	- 48.6	35 48.6	28 47.5	18 58.1	6 37.5	30 54.5	23 46.0	21 50.0	40 46.0	41 50.6	29 43.3	52 51.5	37 48.7	44 47.8
Zonegran (Zonisamide)	81 48.2	- 48.6	35 48.6	28 47.5	18 58.1	6 37.5	30 54.5	23 46.0	21 50.0	40 46.0	41 50.6	29 43.3	52 51.5	36 47.4	45 48.9
NONE OF THESE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	2569	47	1117	891	514	216	883	768	646	1281	1288	955	1614	1136	1433

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 9
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ativan (Lorazepam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Carbatrol (Carbamazepine)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Celontin (Methsuximide)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cerebyx (Fosphenytoin sodium)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depakote/Depakote ER/ Depakote Sprinkle (Divalproex Sodium)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depacon (Valproate sodium)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depakene (Valproic acid)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diastat (Diazepam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dilantin (Phenytoin)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Felbatol (Felbamate)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 10
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient	
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Gabitril (Tiagabine hydrochloride)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Keppra (Levetiracetam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Klonopin (Clonazepam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lamictal (Lamotrigine)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lorazepam Intensol (Lorazepam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lyrica (Pregabalin)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mebaral (Mephobarbital)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mysoline (Primidone)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Neurontin (Gabapentin)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Peganone (Ethotoin)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Potiga (Ezogabine)	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSCR8 Page 11
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

S8: Please tell me all of the medicines, if any, for which you have filled at least one prescription in the past 12 months. (Total Medications - pharmacist only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient	
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Tegretol/Tegretol XR (Carbamazepine)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Topamax (Topiramate)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tranxene (Clorazepate dipotassium)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trileptal (Oxcarbazepine)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Valium (Diazepam)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Zonegran (Zonisamide)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NONE OF THESE	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSA Page 12
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

SA: How would you classify your primary specialty?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Neurology	108	3	39	42	24	11	35	35	23	63	45	56	52	45	63
	64.3	50.0	54.2	71.2	77.4	68.8	63.6	70.0	54.8	72.4	55.6	83.6	51.5	59.2	68.5
				C	C					K		M			
Neurosurgery	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Epileptology	60	3	33	17	7	5	20	15	19	24	36	11	49	31	29
	35.7	50.0	45.8	28.8	22.6	31.2	36.4	30.0	45.2	27.6	44.4	16.4	48.5	40.8	31.5
			DE								J	L			
Pharmacy (Community/ Retail)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pharmacy (Hospital/ Clinical)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSB Page 13
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

SB: Approximately how many patients have you prescribed anti-epileptic drugs (AEDs) for in the past 12 months?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11-20	1 0.6	-	1 1.4	-	-	-	-	-	1 2.4	-	1 1.2	-	1 1.0	-	1 1.1
More than 20 patients	167 99.4	6 100.0	71 98.6	59 100.0	31 100.0	16 100.0	55 100.0	50 100.0	41 97.6	87 100.0	80 98.8	67 100.0	100 99.0	76 100.0	91 98.9
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSC Page 14
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

SC: Please confirm which of the following medicines, if any, you have written at least one prescription for in the past 12 months. (Multiple responses accepted - physicians only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Lamictal (Lamotrigine)	168 100.0	6 100.0	72 100.0	59 100.0	31 100.0	16 100.0	55 100.0	50 100.0	42 100.0	87 100.0	81 100.0	67 100.0	101 100.0	76 100.0	92 100.0
Lyrica (Pregabalin)	161 95.8	6 100.0	68 94.4	57 96.6	30 96.8	15 93.8	53 96.4	46 92.0	42 100.0	82 94.3	79 97.5	65 97.0	96 95.0	71 93.4	90 97.8
Potiga (Ezogabine)	168 100.0	6 100.0	72 100.0	59 100.0	31 100.0	16 100.0	55 100.0	50 100.0	42 100.0	87 100.0	81 100.0	67 100.0	101 100.0	76 100.0	92 100.0
Tegretol/Tegretol XR (Carbamazepine)	164 97.6	6 100.0	69 95.8	58 98.3	31 100.0	16 100.0	55 100.0	46 92.0	42 100.0	85 97.7	79 97.5	65 97.0	99 98.0	74 97.4	90 97.8
Topamax (Topiramate)	167 99.4	6 100.0	72 100.0	59 100.0	30 96.8	16 100.0	55 100.0	49 98.0	42 100.0	86 98.9	81 100.0	66 98.5	101 100.0	75 98.7	92 100.0
None of the above	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	828	30	353	292	153	79	273	241	210	427	401	330	498	372	456

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table QSD Page 15
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

SD: Approximately how many prescriptions for AEDs have you filled in the past 3 months? (pharmacist only)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11-20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 20 prescriptions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1 Page 16
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q1: According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Migraine	2 1.2	-	2 2.8	-	-	-	1 1.8	1 2.0	-	1 1.1	1 1.2	1 1.5	1 1.0	-	2 2.2
Partial-onset seizures	164 97.6	6 100.0	71 98.6	58 98.3	29 93.5	16 100.0	54 98.2	49 98.0	42 100.0	83 95.4	81 100.0	64 95.5	100 99.0	75 98.7	89 96.7
Generalized tonic clonic seizures	9 5.4	-	3 4.2	5 8.5	1 3.2	-	3 5.5	4 8.0	1 2.4	4 4.6	5 6.2	5 7.5	4 4.0	1 1.3	8 8.7 N
None of the above	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
I don't know	2 1.2	-	-	1 1.7	1 3.2	-	-	1 2.0	-	2 2.3	-	2 3.0	-	-	2 2.2
Total	177	6	76	64	31	16	58	55	43	90	87	72	105	76	101

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2 Page 17
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
True	8	-	3	3	2	-	2	3	2	4	4	3	5	1	7
	4.8		4.2	5.1	6.5		3.6	6.0	4.8	4.6	4.9	4.5	5.0	1.3	7.6
															N
False	153	6	65	55	27	15	52	45	38	80	73	60	93	72	81
	91.1	100.0	90.3	93.2	87.1	93.8	94.5	90.0	90.5	92.0	90.1	89.6	92.1	94.7	88.0
		CDE													
I don't know	7	-	4	1	2	1	1	2	2	3	4	4	3	3	4
	4.2		5.6	1.7	6.5	6.2	1.8	4.0	4.8	3.4	4.9	6.0	3.0	3.9	4.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3 Page 18
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q3: Urinary retention - According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Urinary retention	143	5	62	50	26	14	44	43	39	74	69	58	85	69	74
	85.1	83.3	86.1	84.7	83.9	87.5	80.0	86.0	92.9	85.1	85.2	86.6	84.2	90.8	80.4
									g					o	
Pancreatitis	9	-	4	4	1	2	5	1	1	6	3	1	8	2	7
	5.4		5.6	6.8	3.2	12.5	9.1	2.0	2.4	6.9	3.7	1.5	7.9	2.6	7.6
												L			
Ischemic colitis	3	-	2	1	-	1	2	-	-	3	-	1	2	2	1
	1.8		2.8	1.7		6.2	3.6			3.4		1.5	2.0	2.6	1.1
I don't know	19	1	8	6	4	1	8	6	2	10	9	8	11	6	13
	11.3	16.7	11.1	10.2	12.9	6.2	14.5	12.0	4.8	11.5	11.1	11.9	10.9	7.9	14.1
							i								
Total	174	6	76	61	31	18	59	50	42	93	81	68	106	79	95

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4 Page 19
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q4: According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
600mg	11 6.5	-	4 5.6	3 5.1	4 12.9	-	4 7.3	2 4.0	5 11.9	5 5.7	6 7.4	6 9.0	5 5.0	9 11.8	2 2.2
900mg	13 7.7	-	5 6.9	6 10.2	2 6.5	1 6.2	3 5.5	5 10.0	4 9.5	3 3.4	10 12.3 J	6 9.0	7 6.9	6 7.9	7 7.6
1200mg	114 67.9	5 83.3	52 72.2	39 66.1	18 58.1	8 50.0	37 67.3	35 70.0	31 73.8 f	55 63.2	59 72.8	43 64.2	71 70.3	53 69.7	61 66.3
2000mg	1 0.6	-	-	1 1.7	-	-	1 1.8	-	-	1 1.1	-	1 1.5	-	1 1.3	-
None of the above	4 2.4	-	3 4.2	-	1 3.2	-	2 3.6	1 2.0	1 2.4	4 4.6	-	2 3.0	2 2.0	-	4 4.3
I don't know	27 16.1	1 16.7	10 13.9	10 16.9	6 19.4	7 43.8 GHI	8 14.5	7 14.0	3 7.1	19 21.8 K	8 9.9	9 13.4	18 17.8	9 11.8	18 19.6
Total	170	6	74	59	31	16	55	50	44	87	83	67	103	78	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5 Page 20
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q5: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
The oldest age at which POTIGA can be used is 65	6 3.6	-	3 4.2	1 1.7	2 6.5	-	1 1.8	3 6.0	2 4.8	-	6 7.4	3 4.5	3 3.0	1 1.3	5 5.4
There are no lower age limits for POTIGA	11 6.5	1 16.7	4 5.6	3 5.1	3 9.7	1 6.2	3 5.5	5 10.0	2 4.8	4 4.6	7 8.6	3 4.5	8 7.9	4 5.3	7 7.6
The youngest age at which POTIGA can be used is 12	22 13.1	2 33.3	5 6.9	10 16.9	5 16.1	2 12.5	5 9.1	7 14.0	8 19.0	9 10.3	13 16.0	10 14.9	12 11.9	10 13.2	12 13.0
The youngest age at which POTIGA can be used is 18	104 61.9	3 50.0	45 62.5	36 61.0	20 64.5	8 50.0	36 65.5	33 66.0	24 57.1	54 62.1	50 61.7	43 64.2	61 60.4	44 57.9	60 65.2
None of the above	9 5.4	-	4 5.6	4 6.8	1 3.2	1 6.2	1 1.8	2 4.0	5 11.9	3 3.4	6 7.4	3 4.5	6 5.9	4 5.3	5 5.4
I don't know	25 14.9	-	14 19.4	8 13.6	3 9.7	4 25.0	10 18.2	5 10.0	4 9.5	17 19.5	8 9.9	10 14.9	15 14.9	14 18.4	11 12.0
Total	177	6	75	62	34	16	56	55	45	87	90	72	105	77	100

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6 Page 21
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q6: According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
POTIGA should always be taken with food	6 3.6	1 16.7	1 1.4	2 3.4	2 6.5	-	1 1.8	3 6.0	1 2.4	2 2.3	4 4.9	2 3.0	4 4.0	1 1.3	5 5.4
POTIGA should always be taken on its own, without food	2 1.2	-	-	2 3.4	-	-	1 1.8	1 2.0	-	1 1.1	1 1.2	-	2 2.0	-	2 2.2
POTIGA can be taken with or without food	116 69.0	3 50.0	53 73.6	40 67.8	20 64.5	10 62.5	34 61.8	34 68.0	37 88.1 FGH	53 60.9	63 77.8 J	46 68.7	70 69.3	57 75.0	59 64.1
None of the above	2 1.2	-	2 2.8	-	-	-	1 1.8	-	1 2.4	1 1.1	1 1.2	1 1.5	1 1.0	2 2.6	-
I don't know	42 25.0	2 33.3	16 22.2	15 25.4	9 29.0	6 37.5 I	18 32.7 I	12 24.0 I	3 7.1	30 34.5 K	12 14.8	18 26.9	24 23.8	16 21.1	26 28.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7 Page 22
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Pain when urinating	38 22.6	2 33.3	17 23.6	10 16.9	9 29.0	3 18.8	11 20.0	9 18.0	14 33.3	20 23.0	18 22.2	16 23.9	22 21.8	22 28.9	16 17.4
Difficulty starting urination	98 58.3	5 83.3	44 61.1	28 47.5	21 67.7	11 68.8	29 52.7	28 56.0	28 66.7	55 63.2	43 53.1	40 59.7	58 57.4	50 65.8	48 52.2
Renal colic	17 10.1	3 50.0	6 8.3	6 10.2	2 6.5	1 6.2	7 12.7	1 2.0	7 16.7	11 12.6	6 7.4	7 10.4	10 9.9	8 10.5	9 9.8
Inability to urinate	129 76.8	4 66.7	53 73.6	49 83.1	23 74.2	12 75.0	41 74.5	37 74.0	36 85.7	65 74.7	64 79.0	49 73.1	80 79.2	62 81.6	67 72.8
None of the above	1 0.6	-	1 1.4	-	-	-	-	1 2.0	-	1 1.1	-	1 1.5	-	1 1.3	-
I don't know	12 7.1	1 16.7	3 4.2	5 8.5	3 9.7	1 6.2	4 7.3	5 10.0	-	7 8.0	5 6.2	5 7.5	7 6.9	3 3.9	9 9.8
Total	295	15	124	98	58	28	92	81	85	159	136	118	177	146	149

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7NET Page 23
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q7: Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Correct response (1,2,4)	23	-	12	4	7	2	4	7	10	9	14	10	13	15	8
	13.7		16.7	6.8	22.6	12.5	7.3	14.0	23.8	10.3	17.3	14.9	12.9	19.7	8.7
			d		d				G					O	
Incorrect response	145	6	60	55	24	14	51	43	32	78	67	57	88	61	84
	86.3	100.0	83.3	93.2	77.4	87.5	92.7	86.0	76.2	89.7	82.7	85.1	87.1	80.3	91.3
		CDE		ce			I							N	
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8 Page 24
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q8: If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Report the issue at their next doctor's appointment	6 3.6	-	4 5.6	1 1.7	1 3.2	-	4 7.3	2 4.0	-	1 1.1	5 6.2 j	3 4.5	3 3.0	1 1.3	5 5.4
Drink more water	6 3.6	-	2 2.8	3 5.1	1 3.2	1 6.2	1 1.8	3 6.0	1 2.4	2 2.3	4 4.9	2 3.0	4 4.0	2 2.6	4 4.3
Seek immediate medical attention	139 82.7	6 100.0 CDE	58 80.6	51 86.4	24 77.4	14 87.5	45 81.8	39 78.0	37 88.1	73 83.9	66 81.5	54 80.6	85 84.2	68 89.5 O	71 77.2
Stop taking POTIGA	68 40.5	3 50.0	35 48.6 D	18 30.5	12 38.7	8 50.0	26 47.3 i	20 40.0	13 31.0	34 39.1	34 42.0	23 34.3	45 44.6	31 40.8	37 40.2
None of the above	2 1.2	-	-	-	2 6.5	-	-	1 2.0	1 2.4	1 1.1	1 1.2	2 3.0	-	1 1.3	1 1.1
I don't know	3 1.8	-	1 1.4	1 1.7	1 3.2	-	1 1.8	1 2.0	-	2 2.3	1 1.2	2 3.0	1 1.0	-	3 3.3
Total	224	9	100	74	41	23	77	66	52	113	111	86	138	103	121

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9 Page 25
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q9: According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Total daily dose increased by 50mg/day	21 12.5	-	11 15.3	7 11.9	3 9.7	2 12.5	11 20.0	2 4.0	4 9.5	14 16.1	7 8.6	8 11.9	13 12.9	8 10.5	13 14.1
							H								
Total daily dose increased by 150mg/day	100 59.5	4 66.7	47 65.3	31 52.5	18 58.1	8 50.0	32 58.2	34 68.0	25 59.5	46 52.9	54 66.7	39 58.2	61 60.4	54 71.1	46 50.0
											j			O	
Total daily dose increased by 200mg/day	8 4.8	-	5 6.9	1 1.7	2 6.5	1 6.2	-	4 8.0	3 7.1	4 4.6	4 4.9	4 6.0	4 4.0	4 5.3	4 4.3
Total daily dose increased by 300mg/day	13 7.7	1 16.7	2 2.8	8 13.6	2 6.5	2 12.5	4 7.3	3 6.0	4 9.5	9 10.3	4 4.9	8 11.9	5 5.0	3 3.9	10 10.9
				C										n	
None of the above	4 2.4	-	1 1.4	2 3.4	1 3.2	-	-	2 4.0	2 4.8	-	4 4.9	1 1.5	3 3.0	2 2.6	2 2.2
I don't know	22 13.1	1 16.7	6 8.3	10 16.9	5 16.1	3 18.8	8 14.5	5 10.0	4 9.5	14 16.1	8 9.9	7 10.4	15 14.9	5 6.6	17 18.5
														N	
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10 Page 26
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
True	54 32.1	1 16.7	18 25.0	25 42.4	10 32.3	5 31.2	16 29.1	19 38.0	13 31.0	27 31.0	27 33.3	19 28.4	35 34.7	21 27.6	33 35.9
False	92 54.8	4 66.7	46 63.9	27 45.8	15 48.4	7 43.8	32 58.2	24 48.0	27 64.3	44 50.6	48 59.3	39 58.2	53 52.5	47 61.8	45 48.9
I don't know	22 13.1	1 16.7	8 11.1	7 11.9	6 19.4	4 25.0	7 12.7	7 14.0	2 4.8	16 18.4	6 7.4	9 13.4	13 12.9	8 10.5	14 15.2
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R1 Page 27
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	147	5	66	51	25	14	51	43	37	78	69	57	90	66	81
	87.5	83.3	91.7	86.4	80.6	87.5	92.7	86.0	88.1	89.7	85.2	85.1	89.1	86.8	88.0
No	8	-	4	2	2	-	1	4	3	2	6	4	4	6	2
	4.8		5.6	3.4	6.5		1.8	8.0	7.1	2.3	7.4	6.0	4.0	7.9	2.2
Don't know	13	1	2	6	4	2	3	3	2	7	6	6	7	4	9
	7.7	16.7	2.8	10.2	12.9	12.5	5.5	6.0	4.8	8.0	7.4	9.0	6.9	5.3	9.8
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R2 Page 28
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	18 10.7	1 16.7	4 5.6	11 18.6 Ce	2 6.5	1 6.2	6 10.9	6 12.0	5 11.9	8 9.2	10 12.3	9 13.4	9 8.9	8 10.5	10 10.9
No	87 51.8	2 33.3	46 63.9 De	25 42.4	14 45.2	7 43.8	24 43.6	28 56.0	27 64.3 G	48 55.2	39 48.1	35 52.2	52 51.5	44 57.9	43 46.7
Don't know	63 37.5	3 50.0	22 30.6	23 39.0	15 48.4 c	8 50.0 i	25 45.5 I	16 32.0	10 23.8	31 35.6	32 39.5	23 34.3	40 39.6	24 31.6	39 42.4
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R3 Page 29
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	6 3.6	-	2 2.8	1 1.7	3 9.7	1 6.2	-	2 4.0	3 7.1	1 1.1	5 6.2 j	1 1.5	5 5.0	3 3.9	3 3.3
No	106 63.1	2 33.3	51 70.8 bE	38 64.4	15 48.4	8 50.0	32 58.2	36 72.0	29 69.0	52 59.8	54 66.7	41 61.2	65 64.4	55 72.4 O	51 55.4
Don't know	56 33.3	4 66.7 C	19 26.4	20 33.9	13 41.9	7 43.8	23 41.8 Hi	12 24.0	10 23.8	34 39.1 k	22 27.2	25 37.3	31 30.7	18 23.7	38 41.3 N
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R4 Page 30
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	93 55.4	6 100.0	36 50.0	35 59.3	16 51.6	11 68.8	25 45.5	30 60.0	25 59.5	49 56.3	44 54.3	32 47.8	61 60.4	48 63.2	45 48.9
No	39 23.2	-	20 27.8	12 20.3	7 22.6	1 6.2	14 25.5	12 24.0	12 28.6	17 19.5	22 27.2	20 29.9	19 18.8	16 21.1	23 25.0
Don't know	36 21.4	-	16 22.2	12 20.3	8 25.8	4 25.0	16 29.1	8 16.0	5 11.9	21 24.1	15 18.5	15 22.4	21 20.8	12 15.8	24 26.1
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11R5 Page 31
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	20 11.9	1 16.7	5 6.9	10 16.9	4 12.9	5 31.2 gi	5 9.1	6 12.0	4 9.5	10 11.5	10 12.3	7 10.4	13 12.9	11 14.5	9 9.8
No	79 47.0	3 50.0	38 52.8	25 42.4	13 41.9	4 25.0	21 38.2	26 52.0 F	27 64.3 FG	33 37.9	46 56.8 J	31 46.3	48 47.5	39 51.3	40 43.5
Don't know	69 41.1	2 33.3	29 40.3	24 40.7	14 45.2	7 43.8	29 52.7 hI	18 36.0	11 26.2	44 50.6 K	25 30.9	29 43.3	40 39.6	26 34.2	43 46.7 n
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12 Page 32
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
True	124	3	51	45	25	15	42	34	31	67	57	48	76	59	65
	73.8	50.0	70.8	76.3	80.6	93.8	76.4	68.0	73.8	77.0	70.4	71.6	75.2	77.6	70.7
						GHI									
False	8	1	2	4	1	-	2	4	1	5	3	6	2	1	7
	4.8	16.7	2.8	6.8	3.2		3.6	8.0	2.4	5.7	3.7	9.0	2.0	1.3	7.6
												m			N
I don't know	36	2	19	10	5	1	11	12	10	15	21	13	23	16	20
	21.4	33.3	26.4	16.9	16.1	6.2	20.0	24.0	23.8	17.2	25.9	19.4	22.8	21.1	21.7
							f	F	F						
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13 Page 33
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q13: Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Patients with benign prostatic hyperplasia (BPH)	144 85.7	5 83.3	62 86.1	52 88.1	25 80.6	16 100.0 GHI	47 85.5	41 82.0	37 88.1	79 90.8 k	65 80.2	59 88.1	85 84.2	65 85.5	79 85.9
Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	134 79.8	5 83.3	56 77.8	49 83.1	24 77.4	14 87.5	45 81.8	37 74.0	36 85.7	70 80.5	64 79.0	54 80.6	80 79.2	67 88.2 O	67 72.8
Patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics)	138 82.1	6 100.0 CDE	56 77.8	51 86.4	25 80.6	16 100.0 GHI	49 89.1 h	38 76.0	33 78.6	74 85.1	64 79.0	58 86.6	80 79.2	65 85.5	73 79.3
Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	13 7.7	1 16.7	4 5.6	7 11.9	1 3.2	4 25.0 h	6 10.9	3 6.0	-	10 11.5 k	3 3.7	4 6.0	9 8.9	6 7.9	7 7.6
Patients who are obese	4 2.4	-	1 1.4	3 5.1	-	-	3 5.5	1 2.0	-	3 3.4	1 1.2	1 1.5	3 3.0	-	4 4.3
None of the above	1 0.6	-	1 1.4	-	-	-	-	-	1 2.4	-	1 1.2	-	1 1.0	-	1 1.1
I don't know	11 6.5	-	6 8.3	2 3.4	3 9.7	-	1 1.8	7 14.0 GI	1 2.4	5 5.7	6 7.4	3 4.5	8 7.9	5 6.6	6 6.5
Total	445	17	186	164	78	50	151	127	108	241	204	179	266	208	237

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q14 Page 34
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q14: How long have you been practicing medicine?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precript AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Less than 5 years	8 4.8	5 83.3 CD	2 2.8	1 1.7	-	2 12.5	3 5.5	1 2.0	1 2.4	6 6.9	2 2.5	4 6.0	4 4.0	4 5.3	4 4.3
5-15 years	69 41.1	1 16.7	63 87.5 BD	5 8.5	-	4 25.0	22 40.0	26 52.0 F	16 38.1	31 35.6	38 46.9	23 34.3	46 45.5	40 52.6 O	29 31.5
16-25 years	61 36.3	-	6 8.3	51 86.4 CE	4 12.9	6 37.5	21 38.2	17 34.0	16 38.1	33 37.9	28 34.6	25 37.3	36 35.6	18 23.7	43 46.7 N
26-35 years	25 14.9	-	1 1.4	2 3.4	22 71.0 CD	4 25.0	8 14.5	5 10.0	7 16.7	13 14.9	12 14.8	10 14.9	15 14.9	11 14.5	14 15.2
More than 35 years	5 3.0	-	-	-	5 16.1	-	1 1.8	1 2.0	2 4.8	4 4.6	1 1.2	5 7.5	-	3 3.9	2 2.2
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q15 Page 35
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q15: How long have you been prescribing anti-epileptic drugs (AEDs)?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Less than 5 years	6	6	-	-	-	2	1	-	2	5	1	4	2	4	2
	3.6	100.0				12.5	1.8		4.8	5.7	1.2	6.0	2.0	5.3	2.2
5-15 years	72	-	72	-	-	5	25	25	16	33	39	24	48	40	32
	42.9		100.0			31.2	45.5	50.0	38.1	37.9	48.1	35.8	47.5	52.6	34.8
														0	
16-25 years	59	-	-	59	-	6	19	19	14	32	27	23	36	18	41
	35.1			100.0		37.5	34.5	38.0	33.3	36.8	33.3	34.3	35.6	23.7	44.6
															N
26-35 years	26	-	-	-	26	2	10	5	8	13	13	12	14	12	14
	15.5				83.9	12.5	18.2	10.0	19.0	14.9	16.0	17.9	13.9	15.8	15.2
More than 35 years	5	-	-	-	5	1	-	1	2	4	1	4	1	2	3
	3.0				16.1	6.2		2.0	4.8	4.6	1.2	6.0	1.0	2.6	3.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q16 Page 36
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q16: How many months have you been prescribing POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Less than 1	16	2	5	6	3	16	-	-	-	14	2	7	9	7	9
	9.5	33.3	6.9	10.2	9.7	100.0				16.1	2.5	10.4	8.9	9.2	9.8
										K					
1-3	55	1	25	19	10	-	55	-	-	39	16	23	32	25	30
	32.7	16.7	34.7	32.2	32.3		100.0			44.8	19.8	34.3	31.7	32.9	32.6
										K					
4-6	50	-	25	19	6	-	-	50	-	21	29	19	31	22	28
	29.8		34.7	32.2	19.4			100.0		24.1	35.8	28.4	30.7	28.9	30.4
			e								j				
7-9	19	1	9	5	4	-	-	-	19	4	15	8	11	10	9
	11.3	16.7	12.5	8.5	12.9				45.2	4.6	18.5	11.9	10.9	13.2	9.8
											J				
10-12	12	1	3	4	4	-	-	-	12	4	8	6	6	7	5
	7.1	16.7	4.2	6.8	12.9				28.6	4.6	9.9	9.0	5.9	9.2	5.4
More than 12 months	11	-	4	5	2	-	-	-	11	1	10	2	9	4	7
	6.5		5.6	8.5	6.5				26.2	1.1	12.3	3.0	8.9	5.3	7.6
											J		1		
I don't know/don't remember	5	1	1	1	2	-	-	-	-	4	1	2	3	1	4
	3.0	16.7	1.4	1.7	6.5					4.6	1.2	3.0	3.0	1.3	4.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q17 Page 37
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q17: Approximately how many patients have you prescribed POTIGA for in the past 12 months?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
1-2	87	5	33	32	17	14	39	21	9	87	-	46	41	40	47
	51.8	83.3	45.8	54.2	54.8	87.5	70.9	42.0	21.4	100.0		68.7	40.6	52.6	51.1
		Cd				HI	HI	I				M			
3-10	66	1	30	22	13	2	15	21	27	-	66	17	49	31	35
	39.3	16.7	41.7	37.3	41.9	12.5	27.3	42.0	64.3		81.5	25.4	48.5	40.8	38.0
							F	FGH				L			
11-20	12	-	8	3	1	-	-	7	5	-	12	4	8	5	7
	7.1		11.1	5.1	3.2			14.0	11.9		14.8	6.0	7.9	6.6	7.6
More than 20 patients	3	-	1	2	-	-	1	1	1	-	3	-	3	-	3
	1.8		1.4	3.4			1.8	2.0	2.4		3.7		3.0		3.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q18 Page 38
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q18: Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
1-10	5 3.0	1 16.7	1 1.4	2 3.4	1 3.2	-	2 3.6	1 2.0	1 2.4	4 4.6	1 1.2	5 7.5	-	3 3.9	2 2.2
11-30	24 14.3	1 16.7	8 11.1	8 13.6	7 22.6	3 18.8	8 14.5	6 12.0	6 14.3	19 21.8	5 6.2	24 35.8	-	13 17.1	11 12.0
31-50	38 22.6	2 33.3	15 20.8	13 22.0	8 25.8	4 25.0	13 23.6	12 24.0	9 21.4	23 26.4	15 18.5	38 56.7	-	16 21.1	22 23.9
More than 50	101 60.1	2 33.3	48 66.7	36 61.0	15 48.4	9 56.2	32 58.2	31 62.0	26 61.9	41 47.1	60 74.1	-	101 100.0	44 57.9	57 62.0
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q19 Page 39
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q19: What is the age range of your current patient population? Please select all categories that you treat.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Pediatric (Under 18)	53	1	23	17	12	4	20	14	15	24	29	14	39	20	33
	31.5	16.7	31.9	28.8	38.7	25.0	36.4	28.0	35.7	27.6	35.8	20.9	38.6	26.3	35.9
													L		
18-34	155	5	68	55	27	15	52	45	40	80	75	59	96	71	84
	92.3	83.3	94.4	93.2	87.1	93.8	94.5	90.0	95.2	92.0	92.6	88.1	95.0	93.4	91.3
35-64	157	6	69	55	27	15	50	47	41	80	77	61	96	72	85
	93.5	100.0	95.8	93.2	87.1	93.8	90.9	94.0	97.6	92.0	95.1	91.0	95.0	94.7	92.4
		CDE													
65 +	143	6	61	50	26	15	44	41	39	75	68	53	90	66	77
	85.1	100.0	84.7	84.7	83.9	93.8	80.0	82.0	92.9	86.2	84.0	79.1	89.1	86.8	83.7
		CDE				g			g				l		
Total	508	18	221	177	92	49	166	147	135	259	249	187	321	229	279

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q20 Page 40
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q20: Approximately what is the size of your current total patient population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Less than 100 patients	1 0.6	-	1 1.4	-	-	-	-	1 2.0	-	-	1 1.2	-	1 1.0	1 1.3	-
100 - 500 patients	19 11.3	-	10 13.9 E	8 13.6 e	1 3.2	2 12.5	5 9.1	8 16.0	4 9.5	12 13.8	7 8.6	8 11.9	11 10.9	19 25.0	-
501 - 1000 patients	56 33.3	4 66.7 D	29 40.3 D	10 16.9	13 41.9 D	5 31.2	20 36.4	13 26.0	17 40.5	28 32.2	28 34.6	24 35.8	32 31.7	56 73.7	-
More than 1000 patients	92 54.8	2 33.3	32 44.4	41 69.5 bC	17 54.8	9 56.2	30 54.5	28 56.0	21 50.0	47 54.0	45 55.6	35 52.2	57 56.4	-	92 100.0
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q21 Page 41
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q21: Approximately what is the size of your current epilepsy patient population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Less than 10 patients	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10 - 50 patients	3 1.8	-	3 4.2	-	-	-	1 1.8	1 2.0	1 2.4	2 2.3	1 1.2	3 4.5	-	3 3.9	-
51 - 100 patients	25 14.9	3 50.0	10 13.9	6 10.2	6 19.4	2 12.5	9 16.4	6 12.0	7 16.7	15 17.2	10 12.3	16 23.9	9 8.9	18 23.7	7 7.6
101+ patients	140 83.3	3 50.0	59 81.9	53 89.8	25 80.6	14 87.5	45 81.8	43 86.0	34 81.0	70 80.5	70 86.4	48 71.6	92 91.1	55 72.4	85 92.4
I do not treat patients with epilepsy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q22 Page 42
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q22: How long have you been a practicing pharmacist?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less than 5 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5-15 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16-25 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26-35 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 35 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q23 Page 43
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q23: How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less than 5 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5-15 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16-25 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26-35 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 35 years	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q24 Page 44
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q24: Have you answered any patient questions related to POTIGA in the past 12 months?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Yes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
No	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
I don't know/don't remember	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q25 Page 45
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q25: Have you dispensed POTIGA in the past 12 months?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Yes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
No	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
I don't know/don't remember	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q26 Page 46
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q26: How many months have you been dispensing POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less than 1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10-12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 12 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
I don't know/don't remember	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q27 Page 47
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q27: Approximately how many patients have you dispensed POTIGA for in the past 12 months?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3-10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11-20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 20 patients	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
I don't know/don't remember	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q28 Page 48
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q28: Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1 - 10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11 - 30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31 - 50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
More than 50 prescriptions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R1 Page 49
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: POTIGA Dear HCP Letter: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	14	-	8	3	3	1	4	3	6	6	8	6	8	7	7
	8.3		11.1	5.1	9.7	6.2	7.3	6.0	14.3	6.9	9.9	9.0	7.9	9.2	7.6
No	137	5	57	49	26	12	44	46	33	71	66	52	85	62	75
	81.5	83.3	79.2	83.1	83.9	75.0	80.0	92.0	78.6	81.6	81.5	77.6	84.2	81.6	81.5
Don't know	17	1	7	7	2	3	7	1	3	10	7	9	8	7	10
	10.1	16.7	9.7	11.9	6.5	18.8	12.7	2.0	7.1	11.5	8.6	13.4	7.9	9.2	10.9
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R2 Page 50
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: GlaxoSmithKline Medical Information: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	58	2	21	24	11	4	19	17	17	22	36	19	39	22	36
	34.5	33.3	29.2	40.7	35.5	25.0	34.5	34.0	40.5	25.3	44.4	28.4	38.6	28.9	39.1
										J					
No	98	4	45	31	18	9	33	30	24	57	41	41	57	46	52
	58.3	66.7	62.5	52.5	58.1	56.2	60.0	60.0	57.1	65.5	50.6	61.2	56.4	60.5	56.5
										K					
Don't know	12	-	6	4	2	3	3	3	1	8	4	7	5	8	4
	7.1		8.3	6.8	6.5	18.8	5.5	6.0	2.4	9.2	4.9	10.4	5.0	10.5	4.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R3 Page 51
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: GlaxoSmithKline Promotional Materials: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	67	-	26	30	11	3	22	21	21	26	41	26	41	26	41
	39.9		36.1	50.8	35.5	18.8	40.0	42.0	50.0	29.9	50.6	38.8	40.6	34.2	44.6
			c				f	f	F		J				
No	90	6	39	27	18	10	29	27	21	52	38	35	55	43	47
	53.6	100.0	54.2	45.8	58.1	62.5	52.7	54.0	50.0	59.8	46.9	52.2	54.5	56.6	51.1
		CDE								k					
Don't know	11	-	7	2	2	3	4	2	-	9	2	6	5	7	4
	6.5		9.7	3.4	6.5	18.8	7.3	4.0		10.3	2.5	9.0	5.0	9.2	4.3
										K					
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R4 Page 52
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: GSK Website: POTIGA.com: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	39 23.2	3 50.0	23 31.9	9 15.3	4 12.9	4 25.0	14 25.5	12 24.0	9 21.4	15 17.2	24 29.6	14 20.9	25 24.8	21 27.6	18 19.6
No	118 70.2	3 50.0	44 61.1	46 78.0	25 80.6	10 62.5	36 65.5	37 74.0	32 76.2	63 72.4	55 67.9	45 67.2	73 72.3	51 67.1	67 72.8
Don't know	11 6.5	-	5 6.9	4 6.8	2 6.5	2 12.5	5 9.1	1 2.0	1 2.4	9 10.3	2 2.5	8 11.9	3 3.0	4 5.3	7 7.6
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R5 Page 53
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: GlaxoSmithKline Sales Representatives: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	100	2	37	43	18	10	32	32	25	49	51	37	63	46	54
	59.5	33.3	51.4	72.9	58.1	62.5	58.2	64.0	59.5	56.3	63.0	55.2	62.4	60.5	58.7
				BC											
No	64	4	33	15	12	6	22	18	16	34	30	27	37	29	35
	38.1	66.7	45.8	25.4	38.7	37.5	40.0	36.0	38.1	39.1	37.0	40.3	36.6	38.2	38.0
		D	D												
Don't know	4	-	2	1	1	-	1	-	1	4	-	3	1	1	3
	2.4		2.8	1.7	3.2		1.8		2.4	4.6		4.5	1.0	1.3	3.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R6 Page 54
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: GlaxoSmithKline-sponsored Educational Meeting: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	30	2	11	13	4	3	8	6	12	10	20	8	22	12	18
	17.9	33.3	15.3	22.0	12.9	18.8	14.5	12.0	28.6	11.5	24.7	11.9	21.8	15.8	19.6
									gH		J		1		
No	130	4	56	44	26	12	44	43	29	72	58	54	76	60	70
	77.4	66.7	77.8	74.6	83.9	75.0	80.0	86.0	69.0	82.8	71.6	80.6	75.2	78.9	76.1
								i		k					
Don't know	8	-	5	2	1	1	3	1	1	5	3	5	3	4	4
	4.8		6.9	3.4	3.2	6.2	5.5	2.0	2.4	5.7	3.7	7.5	3.0	5.3	4.3
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R7 Page 55
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: POTIGA Product Labeling (including Prescribing Information, Medication Guide): Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	131	5	57	44	25	11	42	39	38	66	65	53	78	63	68
	78.0	83.3	79.2	74.6	80.6	68.8	76.4	78.0	90.5	75.9	80.2	79.1	77.2	82.9	73.9
									fgh						
No	30	1	12	12	5	3	11	10	4	16	14	10	20	11	19
	17.9	16.7	16.7	20.3	16.1	18.8	20.0	20.0	9.5	18.4	17.3	14.9	19.8	14.5	20.7
Don't know	7	-	3	3	1	2	2	1	-	5	2	4	3	2	5
	4.2		4.2	5.1	3.2	12.5	3.6	2.0		5.7	2.5	6.0	3.0	2.6	5.4
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q29R8 Page 56
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q29: Other Healthcare Professionals: Have you learned about the risks associated with the use of POTIGA from any of the following sources?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
Yes	74 44.0	5 83.3	35 48.6	21 35.6	13 41.9	4 25.0	23 41.8	18 36.0	28 66.7	30 34.5	44 54.3	28 41.8	46 45.5	37 48.7	37 40.2
No	85 50.6	1 16.7	31 43.1	36 61.0	17 54.8	10 62.5	30 54.5	30 60.0	13 31.0	50 57.5	35 43.2	34 50.7	51 50.5	36 47.4	49 53.3
Don't know	9 5.4	-	6 8.3	2 3.4	1 3.2	2 12.5	2 3.6	2 4.0	1 2.4	7 8.0	2 2.5	5 7.5	4 4.0	3 3.9	6 6.5
Total	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q30 Page 57
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q30: How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	168	6	72	59	31	16	55	50	42	87	81	67	101	76	92
POTIGA Dear HCP Letter	21 12.5	-	10 13.9	7 11.9	4 12.9	1 6.2	11 20.0	5 10.0	4 9.5	11 12.6	10 12.3	8 11.9	13 12.9	11 14.5	10 10.9
GlaxoSmithKline Medical Information	41 24.4	1 16.7	22 30.6	11 18.6	7 22.6	3 18.8	13 23.6	12 24.0	13 31.0	12 13.8	29 35.8	14 20.9	27 26.7	20 26.3	21 22.8
Other Healthcare Professionals	60 35.7	2 33.3	32 44.4	16 27.1	10 32.3	5 31.2	17 30.9	16 32.0	21 50.0	29 33.3	31 38.3	24 35.8	36 35.6	35 46.1	25 27.2
GlaxoSmithKline Promotional Materials	28 16.7	2 33.3	9 12.5	15 25.4	2 6.5	4 25.0	10 18.2	10 20.0	3 7.1	18 20.7	10 12.3	16 23.9	12 11.9	10 13.2	18 19.6
GSK Website: POTIGA.com	37 22.0	1 16.7	22 30.6	7 11.9	7 22.6	4 25.0	13 23.6	11 22.0	8 19.0	21 24.1	16 19.8	17 25.4	20 19.8	14 18.4	23 25.0
GlaxoSmithKline Sales Representatives	77 45.8	1 16.7	30 41.7	30 50.8	16 51.6	9 56.2	21 38.2	26 52.0	19 45.2	38 43.7	39 48.1	31 46.3	46 45.5	29 38.2	48 52.2
GlaxoSmithKline-sponsored Educational Meeting	92 54.8	5 83.3	32 44.4	38 64.4	17 54.8	8 50.0	33 60.0	27 54.0	23 54.8	46 52.9	46 56.8	34 50.7	58 57.4	40 52.6	52 56.5
POTIGA Product Labeling (including Prescribing Information, Medication Guide)	60 35.7	3 50.0	27 37.5	14 23.7	16 51.6	4 25.0	20 36.4	12 24.0	22 52.4	35 40.2	25 30.9	26 38.8	34 33.7	36 47.4	24 26.1
Total	416	15	184	138	79	38	138	119	113	210	206	170	246	195	221

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1_1CODE Page 58
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	11	-	4	6	1	-	3	6	1	5	6	6	5	1	10
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 9.1	-	-	1 16.7	-	-	-	-	-	1 20.0	-	1 16.7	-	-	1 10.0
FDA approved only for partial on-set seizures/ used for partial seizures	4 36.4	-	2 50.0	2 33.3	-	-	2 66.7	2 33.3	-	3 60.0	1 16.7	2 33.3	2 40.0	1 100.0	3 30.0
Used for all indications listed/aware of different uses for the med/med used for expanded indications in other countries	1 9.1	-	1 25.0	-	-	-	1 33.3	-	-	1 20.0	-	1 16.7	-	-	1 10.0
General recall/memory	1 9.1	-	-	1 16.7	-	-	1 33.3	-	-	-	1 16.7	-	1 20.0	-	1 10.0
Seizures/severe seizure disorder	1 9.1	-	1 25.0	-	-	-	-	-	1 100.0	-	1 16.7	1 16.7	-	-	1 10.0
Adjunctive therapy for CP seizures	1 9.1	-	-	-	1 100.0	-	-	1 16.7	-	1 20.0	-	1 16.7	-	-	1 10.0
Information provided from Pharmaceutical Representative	1 9.1	-	-	1 16.7	-	-	-	1 16.7	-	-	1 16.7	1 16.7	-	-	1 10.0

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q1_1CODE Page 59
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q1. According to U.S. prescribing information, what is the FDA-approved indication for POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
GTC could be partial with secondary or primary generalization (indicated)/this drug works well with partial seizure & also may work with generalized tonic clonic seizure	1 9.1	-	-	1 16.7	-	-	-	1 16.7	-	-	1 16.7	-	1 20.0	-	1 10.0
Misunderstood question/ Question is vague	2 18.2	-	1 25.0	1 16.7	-	-	-	2 33.3	-	-	2 33.3	-	2 40.0	-	2 20.0
Total	13	-	5	7	1	-	4	7	1	6	7	7	6	1	12

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 60
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	13	-	7	3	3	1	3	5	4	5	8	5	8	4	9
I believe so/I think it can be used for monotherapy	1 7.7	-	1 14.3	-	-	-	-	1 20.0	-	1 20.0	-	-	1 12.5	-	1 11.1
Using clinically/on-going trials for monotherapy use	2 15.4	-	-	1 33.3	1 33.3	-	-	1 20.0	1 25.0	1 20.0	1 12.5	-	2 25.0	-	2 22.2
Do not believe it is approved, but can be used as monotherapy	1 7.7	-	-	-	1 33.3	-	-	-	1 25.0	-	1 12.5	1 20.0	-	1 25.0	-
General recall/memory/best recall from PI/from clinical pharmacology reference literature/based on dosing directions	1 7.7	-	-	1 33.3	-	-	1 33.3	-	-	-	1 12.5	-	1 12.5	-	1 11.1
To be used as add-on therapy/approved as add-on to be treat seizures associated with epilepsy	1 7.7	-	-	-	1 33.3	-	-	1 20.0	-	1 20.0	-	1 20.0	-	1 25.0	-
Can be used as monotherapy/believe it can be used for monotherapy/have patients just using POTIGA/have seen it prescribed as a monotherapy/general mechanism lends itself to monotherapy	1 7.7	-	1 14.3	-	-	-	-	-	1 25.0	-	1 12.5	1 20.0	-	-	1 11.1

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q2_1CODE Page 61
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q2: True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Information provided from Pharmaceutical Representative	1 7.7	-	-	1 33.3	-	-	-	1 20.0	-	-	1 12.5	1 20.0	-	-	1 11.1
Not sure/not sure if it can be used as monotherapy	4 30.8	-	4 57.1	-	-	1 100.0 I	2 66.7	-	1 25.0	2 40.0	2 25.0	1 20.0	3 37.5	1 25.0	3 33.3
Don't know/Do not recall	1 7.7	-	1 14.3	-	-	-	-	1 20.0	-	-	1 12.5	-	1 12.5	1 25.0	-
Total	13	-	7	3	3	1	3	5	4	5	8	5	8	4	9

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 62
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	28	1	13	10	4	3	14	7	3	16	12	9	19	9	19
Lack of familiarity/ never heard of POTIGA, POTIGA risks or side effects/never dispensed POTIGA/no experience with POTIGA	1 3.6	-	-	1 10.0	-	-	-	-	-	1 6.2	-	1 11.1	-	-	1 5.3
Pancreatitis is common with AEDs	1 3.6	-	-	1 10.0	-	-	1 7.1	-	-	1 6.2	-	-	1 5.3	-	1 5.3
Ischemic colitis possible/may be reported	1 3.6	-	-	1 10.0	-	-	1 7.1	-	-	1 6.2	-	-	1 5.3	-	1 5.3
Risks reported in literature	1 3.6	-	1 7.7	-	-	-	1 7.1	-	-	1 6.2	-	1 11.1	-	1 11.1	-
General recall/memory/ best recall from PI/ clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data	3 10.7	-	1 7.7	2 20.0	-	1 33.3	1 7.1	1 14.3	-	1 6.2	2 16.7	-	3 15.8	1 11.1	2 10.5
Conditions can occur when stopping use of POTIGA	1 3.6	-	1 7.7	-	-	-	1 7.1	-	-	1 6.2	-	1 11.1	-	1 11.1	-
Aware of some risks associated with medicine, but not aware of all risks/aware of the major risks	2 7.1	-	1 7.7	-	1 25.0	-	1 7.1	1 14.3	-	-	2 16.7	1 11.1	1 5.3	1 11.1	1 5.3

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 63
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Aware of urinary issues/ problem with urinary function	2 7.1	- 7.7	1 7.7	- 7.7	1 25.0	1 33.3	- 14.3	1 14.3	- 14.3	2 12.5	- 12.5	- 10.5	2 10.5	1 11.1	1 5.3
Incorporated POTIGA into regimen, but not able to learn about the drug yet	1 3.6	- 7.7	1 7.7	- 7.7	- 7.7	- 7.7	- 14.3	1 14.3	- 14.3	- 8.3	1 8.3	- 5.3	1 5.3	- 5.3	1 5.3
Side effect/recall some of the side effects	2 7.1	- 15.4	2 15.4	- 15.4	- 15.4	- 14.3	2 14.3	- 14.3	- 14.3	1 6.2	1 8.3	- 10.5	2 10.5	- 10.5	2 10.5
Kidney, liver problems/ potentially toxic to kidneys	1 3.6	- 7.7	1 7.7	- 7.7	- 7.7	- 7.1	1 7.1	- 7.1	- 7.1	1 6.2	- 6.2	- 5.3	1 5.3	1 11.1	- 11.1
Never read the PI and not explained by pharmaceutical representative/never had a POTIGA representative visit/never fully read prescribing information	3 10.7	- 10.7	- 10.7	2 20.0	1 25.0	- 7.1	1 7.1	2 28.6	- 7.1	2 12.5	1 8.3	- 15.8	3 15.8	1 11.1	2 10.5
Known caution when using POTIGA	1 3.6	- 7.7	1 7.7	- 7.7	- 7.7	- 7.1	1 7.1	- 7.1	- 7.1	1 6.2	- 6.2	- 5.3	1 5.3	- 5.3	1 5.3
Mistaken POTIGA for another medicine/ mistaken in initial response	2 7.1	- 7.7	1 7.7	1 10.0	- 10.0	- 7.1	1 7.1	- 33.3	1 33.3	2 12.5	- 11.1	1 11.1	1 5.3	- 10.5	2 10.5
Not sure/not sure about the side effects, risks	3 10.7	- 7.7	1 7.7	1 10.0	1 25.0	- 7.1	1 7.1	1 14.3	1 33.3	- 25.0	3 25.0	1 11.1	2 10.5	- 10.5	3 15.8

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q3_1CODE Page 64
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q3. According to U.S. prescribing information, which of the following are potential risks associated with POTIGA?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Miscellaneous	2 7.1	-	1 7.7	1 10.0	-	-	1 7.1	-	1 33.3	-	2 16.7	2 22.2	-	2 22.2	-
Misunderstood question/ Question is vague	1 3.6	-	1 7.7	-	-	-	1 7.1	-	-	1 6.2	-	-	1 5.3	-	1 5.3
Don't know/Do not recall	3 10.7	1 100.0	1 7.7	1 10.0	-	1 33.3	2 14.3	-	-	3 18.8	-	2 22.2	1 5.3	1 11.1	2 10.5
Total	31	1	15	11	4	3	17	7	3	19	12	10	21	10	21

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 65
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	54	1	21	20	12	8	18	15	12	31	23	23	31	24	30
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.9	-	-	1 5.0	-	-	-	-	-	1 3.2	-	1 4.3	-	-	1 3.3
Not aware of the maximum dosage/uncertain of maximum dosage/not seen information on maximum dosing/not heard of maximum dosing	7 13.0	-	5 23.8	1 5.0	1 8.3	2 25.0	3 16.7	1 6.7	1 8.3	5 16.1	2 8.7	1 4.3	6 19.4	2 8.3	5 16.7
Recall maximum dose from pharmaceutical representative/ information from pharmaceutical representative	4 7.4	-	1 4.8	3 15.0	-	-	2 11.1	2 13.3	-	2 6.5	2 8.7	4 17.4	-	3 12.5	1 3.3
400mg three times a day/ 1200mg maximum dose	6 11.1	-	3 14.3	1 5.0	2 16.7	2 25.0	2 11.1	1 6.7	1 8.3	4 12.9	2 8.7	4 17.4	2 6.5	2 8.3	4 13.3
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	8 14.8	-	2 9.5	5 25.0	1 8.3	-	1 5.6	3 20.0	4 33.3	3 9.7	5 21.7	4 17.4	4 12.9	6 25.0	2 6.7

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 66
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Thought it was a different value	1 1.9	-	1 4.8	-	-	-	-	-	1 8.3	1 3.2	-	1 4.3	-	-	1 3.3
Representative said 1200mg, but being conservative	1 1.9	-	-	-	1 8.3	-	1 5.6	-	-	1 3.2	-	1 4.3	-	-	1 3.3
Clinical trials tested at 900mg-1200mg maximum dose	1 1.9	-	-	1 5.0	-	-	-	-	1 8.3	-	1 4.3	-	1 3.2	-	1 3.3
Personal experience/how currently prescribing	2 3.7	-	1 4.8	1 5.0	-	-	1 5.6	1 6.7	-	-	2 8.7	-	2 6.5	-	2 6.7
Previous studies indication a dose greater than 900mg offered no significant increased benefit, but greater side effects/1200mg not shown to be efficacious than 900mg/seizure frequency reduced at a lesser percent with higher dose	3 5.6	-	2 9.5	-	1 8.3	1 12.5	1 5.6	-	1 8.3	1 3.2	2 8.7	1 4.3	2 6.5	2 8.3	1 3.3
Never read the PI/never fully read the prescribing information	1 1.9	-	-	1 5.0	-	-	-	1 6.7	-	-	1 4.3	-	1 3.2	1 4.2	-
Never met with a pharmaceutical representative	1 1.9	-	-	-	1 8.3	-	-	1 6.7	-	1 3.2	-	-	1 3.2	-	1 3.3

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q4_1CODE Page 67
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q4. According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
150mg per day/per week that can be titrated	1 1.9	-	1 4.8	-	-	-	1 5.6	-	-	1 3.2	-	-	1 3.2	-	1 3.3
Incorrect suggested maximum dose stated	3 5.6	-	1 4.8	-	2 16.7	-	-	2 13.3	1 8.3	2 6.5	1 4.3	2 8.7	1 3.2	2 8.3	1 3.3
Refer/consult PI/would look up before dispensing	2 3.7	-	-	-	2 16.7	-	1 5.6	-	1 8.3	-	2 8.7	1 4.3	1 3.2	-	2 6.7
Rarely use POTIGA/only used POTIGA a few times	3 5.6	-	1 4.8	2 10.0	-	1 12.5	1 5.6	-	1 8.3	2 6.5	1 4.3	-	3 9.7	1 4.2	2 6.7
Not sure	1 1.9	-	1 4.8	-	-	-	-	-	1 8.3	-	1 4.3	1 4.3	-	1 4.2	-
Miscellaneous	2 3.7	-	1 4.8	1 5.0	-	-	1 5.6	1 6.7	-	1 3.2	1 4.3	1 4.3	1 3.2	1 4.2	1 3.3
Don't know/Do not recall	7 13.0	1 100.0 CDE	2 9.5	3 15.0	1 8.3	2 25.0	3 16.7	2 13.3	-	6 19.4 k	1 4.3	1 4.3	6 19.4 l	3 12.5	4 13.3
Total	55	1	22	20	12	8	18	15	13	31	24	23	32	24	31

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 68
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	67	2	29	25	11	7	20	20	19	31	36	26	41	32	35
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.5	-	-	1 4.0	-	-	-	-	-	1 3.2	-	1 3.8	-	-	1 2.9
Not aware of the minimum age/do not know lower age limit/have not heard about what the lower age limit is	7 10.4	-	5 17.2 d	1 4.0	1 9.1	1 14.3	1 5.0	3 15.0	2 10.5	5 16.1	2 5.6	4 15.4	3 7.3	5 15.6	2 5.7
Pharmaceutical representative unsure of the age limits	1 1.5	-	1 3.4	-	-	-	1 5.0	-	-	1 3.2	-	1 3.8	-	1 3.1	-
No known upper age limits	1 1.5	-	-	-	1 9.1	-	1 5.0	-	-	1 3.2	-	-	1 2.4	1 3.1	-
General recall/memory/ best recall from PI/from clinical pharmacology reference literature/ based on dosing directions/recall from clinical trial data/from prescriber information	6 9.0	1 50.0	2 6.9	2 8.0	1 9.1	1 14.3	1 5.0	2 10.0	2 10.5	3 9.7	3 8.3	1 3.8	5 12.2	2 6.2	4 11.4
Persons 12 years of age/ believe 12 years of age/ adolescents/most recently approved AEDs for age 12	8 11.9	1 50.0	3 10.3	2 8.0	2 18.2	1 14.3	2 10.0	2 10.0	3 15.8	3 9.7	5 13.9	2 7.7	6 14.6	3 9.4	5 14.3

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 69
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrip AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Adults/only approved for adults/approved for 18+	4 6.0	-	-	3 12.0	1 9.1	-	1 5.0	2 10.0	1 5.3	2 6.5	2 5.6	3 11.5	1 2.4	1 3.1	3 8.6
Clinical trials/studies did not include children/not established data in children	2 3.0	1 50.0	-	-	1 9.1	1 14.3	-	-	1 5.3	-	2 5.6	1 3.8	1 2.4	1 3.1	1 2.9
Incorrect label reference/indications	1 1.5	-	-	1 4.0	-	-	-	1 5.0	-	-	1 2.8	1 3.8	-	-	1 2.9
Data does not provide/indicate/cannot recall from clinical trials/information not available	2 3.0	-	1 3.4	1 4.0	-	1 14.3	1 5.0	-	-	2 6.5	-	-	2 4.9	2 6.2	-
Used for medically refractory seizures	1 1.5	-	-	1 4.0	-	-	-	-	1 5.3	1 3.2	-	-	1 2.4	-	1 2.9
Not approved for children/do not use in the pediatric population/new anticonvulsants do not have pediatric dosing	4 6.0	-	1 3.4	2 8.0	1 9.1	1 14.3	2 10.0	1 5.0	-	2 6.5	2 5.6	-	4 9.8	2 6.2	2 5.7
Information from pharmaceutical representative	1 1.5	-	-	1 4.0	-	-	-	1 5.0	-	-	1 2.8	-	1 2.4	1 3.1	-
Do not use POTIGA enough to have this experience	1 1.5	-	-	1 4.0	-	-	1 5.0	-	-	1 3.2	-	-	1 2.4	-	1 2.9

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 70
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
No lower age limit/safe for infants and children/AEDs do not have a lower age limit	2 3.0	-	2 6.9	-	-	-	1	-	1 5.3	1 3.2	1 2.8	1 3.8	1 2.4	2 6.2	-
Uncertain whether lower age limit is 12 or 18/uncertain if age limit is 18 years	5 7.5	-	3 10.3	2 8.0	-	1 14.3	1 5.0	3 15.0	-	1 3.2	4 11.1	-	5 12.2	3 9.4	2 5.7
Used with caution for those 65+/over 65 could have urination problems, immune system problems, weakness/65 is age limit/not sure if contraindicated for patients over 65	5 7.5	-	3 10.3	2 8.0	-	-	-	5 25.0	-	1 3.2	4 11.1	3 11.5	2 4.9	2 6.2	3 8.6
No indication in the prescribing information	3 4.5	-	1 3.4	1 4.0	1 9.1	-	1 5.0	2 10.0	-	1 3.2	2 5.6	1 3.8	2 4.9	-	3 8.6
Would refer to the package insert/have to research the drug/not studied drug yet	1 1.5	-	-	-	1 9.1	-	-	-	1 5.3	-	1 2.8	-	1 2.4	-	1 2.9
Based on FDA labeling	1 1.5	-	-	1 4.0	-	-	-	1 5.0	-	-	1 2.8	1 3.8	-	-	1 2.9
Do not treat pediatrics/patients are over age 18	2 3.0	-	2 6.9	-	-	-	-	-	10.5	-	2 5.6	-	2 4.9	1 3.1	1 2.9
Age 17 and above	1 1.5	-	1 3.4	-	-	-	-	-	1 5.3	-	1 2.8	-	1 2.4	-	1 2.9

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q5_1CODE Page 71
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q5. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Have used it in patients over 65 and under 12 years	1 1.5	-	-	1 4.0	-	-	-	-	1 5.3	1 3.2	-	1 3.8	-	1 3.1	-
Not sure of age limit / best guess from PI	2 3.0	-	1 3.4	-	1 9.1	-	1 5.0	-	1 5.3	1 3.2	1 2.8	-	2 4.9	1 3.1	1 2.9
Miscellaneous	5 7.5	-	2 6.9	2 8.0	1 9.1	-	3 15.0	-	2 10.5	2 6.5	3 8.3	5 19.2	-	3 9.4	2 5.7
Don't know/Do not recall	6 9.0	-	3 10.3	3 12.0	-	2 28.6	3 15.0	-	1 5.3	4 12.9	2 5.6	2 7.7	4 9.8	4 12.5	2 5.7
Total	74	3	31	28	12	9	21	23	20	34	40	28	46	36	38

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 72
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	51	3	19	19	10	6	21	16	5	33	18	20	31	19	32
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	4 7.8	- 10.5	2 10.5	2	-	-	2 9.5	-	-	4 12.1	-	1 5.0	3 9.7	1 5.3	3 9.4
POTIGA can be taken with or without food/pretty sure can be taken with or without food	3 5.9	- 5.3	1 5.3	1 5.3	1 10.0	-	2 9.5	-	1 20.0	1 3.0	2 11.1	1 5.0	2 6.5	-	3 9.4
POTIGA should be taken with food/think it should be taken with food	2 3.9	- 10.5	2 10.5	-	-	-	1 4.8	1 6.2	-	2 6.1	-	-	2 6.5	1 5.3	1 3.1
POTIGA should be taken without food/believe absorption is better with an empty stomach	1 2.0	-	-	-	1 10.0	-	1 4.8	-	-	-	1 5.6	1 5.0	-	-	1 3.1
Not sure about the absorption of this medication/unaware how food effects absorption of product	1 2.0	- 5.3	1 5.3	-	-	1 16.7	-	-	-	1 3.0	-	1 5.0	-	-	1 3.1
Not aware of any need to specify that it should be taken with or without food	1 2.0	-	-	1 5.3	-	1 16.7	-	-	-	1 3.0	-	1 5.0	-	-	1 3.1

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 73
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
General recall/believe to be true	1 2.0	-	-	1 5.3	-	-	1 4.8	-	-	-	1 5.6	-	1 3.2	-	1 3.1
Taken with food due to stomach side effects	1 2.0	-	-	1 5.3	-	-	-	1 6.2	-	-	1 5.6	-	1 3.2	-	1 3.1
Food slows the absorption but not area under the curve	1 2.0	-	-	-	1 10.0	-	-	-	1 20.0	-	1 5.6	-	1 3.2	1 5.3	-
Minimize nonspecific neurocognitive side effects on multiple AEDs	1 2.0	1 33.3	-	-	-	-	-	-	-	1 3.0	-	-	1 3.2	-	1 3.1
From the prescribing literature/from pharmaceutical representative/from the information	2 3.9	-	-	2 10.5	-	-	-	2 12.5	-	1 3.0	1 5.6	1 5.0	1 3.2	-	2 6.2
Never met with a pharmaceutical representative	1 2.0	-	-	-	1 10.0	-	-	1 6.2	-	1 3.0	-	-	1 3.2	-	1 3.1
Refer/consult PI/would look up before dispensing	1 2.0	-	-	-	1 10.0	-	1 4.8	-	-	-	1 5.6	1 5.0	-	-	1 3.1
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	4 7.8	-	4 21.1	-	-	1 16.7	1 4.8	2 12.5	-	3 9.1	1 5.6	2 10.0	2 6.5	1 5.3	3 9.4

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q6_1CODE Page 74
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q6. According to U.S. prescribing information, which of the following statements, if any, is true?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Not sure/uncertain/ unaware	7 13.7	2 66.7 CD	2 10.5	1 5.3	2 20.0	1 16.7	3 14.3	3 18.8	-	5 15.2	2 11.1	4 20.0	3 9.7	7 36.8	-
Miscellaneous	1 2.0	-	1 5.3	-	-	-	1 4.8	-	-	1 3.0	-	-	1 3.2	-	1 3.1
Don't know/Do not recall	20 39.2	-	7 36.8	10 52.6	3 30.0	3 50.0	8 38.1	6 37.5	3 60.0	13 39.4	7 38.9	8 40.0	12 38.7	8 42.1	12 37.5
Total	52	3	20	19	10	7	21	16	5	34	18	21	31	19	33

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 75
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	143	6	60	55	22	14	50	43	32	77	66	55	88	61	82
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	2 1.4	-	-	2 3.6	-	-	-	1 2.3	-	1 1.3	1 1.5	1 1.8	1 1.1	1 1.6	1 1.2
Unique side effect/side effects reported by patients/side effects/ symptom/potential complication	22 15.4	1 16.7	9 15.0	10 18.2	2 9.1	2 14.3	9 18.0	9 i 20.9	2 6.2	11 14.3	11 16.7	8 14.5	14 15.9	7 11.5	15 18.3
Unaware of the urinary symptoms/unaware of side effects, symptoms when taking POTIGA	1 0.7	-	1 1.7	-	-	-	1 2.0	-	-	1 1.3	-	1 1.8	-	1 1.6	-
Urinary retention is a symptom or AE/watch for urinary retention/ urinary retention/ urinary retention potential side effect/ urinary retention has been reported	51 35.7	3 50.0	25 41.7	17 30.9	6 27.3	5 35.7	17 34.0	14 32.6	15 46.9	29 37.7	22 33.3	24 43.6	27 30.7	25 41.0	26 31.7
POTIGA may make symptoms worse	1 0.7	-	1 1.7	-	-	-	-	1 2.3	-	-	1 1.5	-	1 1.1	-	1 1.2
Affect urinary flow/ difficulty starting urination/voiding dysfunction/difficulty urinating/urinary problems/pain with urination	6 4.2	-	3 5.0	1 1.8	2 9.1	2 14.3	3 6.0	1 2.3	-	6 7.8	-	2 3.6	4 4.5	4 6.6	2 2.4

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.

Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 76
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
General recall/memory/ knowledge	10 7.0	-	3 5.0	6 10.9	1 4.5	1 7.1	4 8.0	2 4.7	3 9.4	6 7.8	4 6.1	4 7.3	6 6.8	4 6.6	6 7.3
Forgot, but did know about urinary symptoms/ forgot about these risks	1 0.7	1 16.7	-	-	-	1 7.1	-	-	-	1 1.3	-	1 1.8	-	1 1.6	-
Warning from package insert/from package insert and patient info materials/warning for the drug/drug info/main warning	12 8.4	-	6 10.0	4 7.3	2 9.1	2 14.3	7 14.0	-	3 9.4	7 9.1	5 7.6	4 7.3	8 9.1	6 9.8	6 7.3
Read/heard about it (non- specific)	3 2.1	-	2 3.3	-	1 4.5	-	-	1 2.3	2 6.2	-	3 4.5	-	3 3.4	1 1.6	2 2.4
Clinical trials/results of clinical trials	8 5.6	1 16.7	4 6.7	3 5.5	-	-	3 6.0	3 7.0	1 3.1	4 5.2	4 6.1	1 1.8	7 8.0	4 6.6	4 4.9
From the prescribing literature/from pharmaceutical representative/from the information, medication inserts/drug company/ online pamphlet, REMS literature	18 12.6	-	5 8.3	9 16.4	4 18.2	1 7.1	6 12.0	5 11.6	6 18.8	10 13.0	8 12.1	6 10.9	12 13.6	6 9.8	12 14.6
Indications and label/ label	1 0.7	-	-	1 1.8	-	-	-	1 2.3	-	-	1 1.5	1 1.8	-	-	1 1.2

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q7_1CODE Page 77
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q7. Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
From internet/Google	1 0.7	-	1 1.7	-	-	-	-	-	-	1 1.3	-	-	1 1.1	-	1 1.2
From past experience with patients/personal experience	6 4.2	-	4 6.7	1 1.8	1 4.5	-	3 6.0	1 2.3	2 6.2	1 1.3	5 7.6 j	1 1.8	5 5.7	4 6.6	2 2.4
Never discussed/seen POTIGA representative	1 0.7	-	-	-	1 4.5	-	-	1 2.3	-	1 1.3	-	-	1 1.1	-	1 1.2
Easiest to tell patients to look out for/discuss with patients/advise patients	3 2.1	-	2 3.3	-	1 4.5	-	-	2 4.7	-	-	3 4.5	-	3 3.4	1 1.6	2 2.4
Bladder hypotonia can occur	1 0.7	-	-	-	1 4.5	-	-	-	1 3.1	-	1 1.5	-	1 1.1	1 1.6	-
Miscellaneous	4 2.8	-	3 5.0	1 1.8	-	-	1 2.0	2 4.7	1 3.1	2 2.6	2 3.0	2 3.6	2 2.3	3 4.9	1 1.2
Don't know/Do not recall	2 1.4	-	-	2 3.6	-	-	1 2.0	1 2.3	-	1 1.3	1 1.5	-	2 2.3	-	2 2.4
Total	154	6	69	57	22	14	55	45	36	82	72	56	98	69	85

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 78
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	80	3	38	22	17	9	29	26	14	39	41	30	50	34	46
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.2	-	-	1 4.5	-	-	-	-	-	1 2.6	-	1 3.3	-	-	1 2.2
Stop use and seek immediate medical attention	9 11.2	-	5 13.2	2 9.1	2 11.8	2 22.2	4 13.8	1 3.8	2 14.3	5 12.8	4 9.8	4 13.3	5 10.0	2 5.9	7 15.2
Medical emergency/seek medical care/seek medical attention right away	12 15.0	1 33.3	5 13.2	2 9.1	4 23.5	2 22.2	3 10.3	5 19.2	2 14.3	6 15.4	6 14.6	4 13.3	8 16.0	6 17.6	6 13.0
Stop use/stop use, cause of the problem	7 8.8	-	3 7.9	2 9.1	2 11.8	1 11.1	1 3.4	4 15.4	1 7.1	6 15.4 K	1 2.4	2 6.7	5 10.0	2 5.9	5 10.9
Prudent action to take with urinary retention/ prudent response	1 1.2	-	-	1 4.5	-	-	-	1 3.8	-	1 2.6	-	-	1 2.0	-	1 2.2
Advise given to my patients/recommendation	5 6.2	-	4 10.5	-	1 5.9	1 11.1	-	2 7.7	1 7.1	2 5.1	3 7.3	1 3.3	4 8.0	4 11.8	1 2.2
Correct course of action/ best possible action, advice/most logical action/best next steps/ right thing to do	7 8.8	2 66.7 Cd	2 5.3	3 13.6	-	2 22.2	2 6.9	2 7.7	1 7.1	5 12.8	2 4.9	4 13.3	3 6.0	4 11.8	3 6.5

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 79
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precript AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Information found in studies	1 1.2	-	-	-	1 5.9	-	1 3.4	-	-	-	1 2.4	1 3.3	-	-	1 2.2
POTIGA causes urinary retention	4 5.0	-	2 5.3	1 4.5	1 5.9	-	3 10.3	1 3.8	-	2 5.1	2 4.9	1 3.3	3 6.0	2 5.9	2 4.3
Urinary retention may be reversible	4 5.0	-	2 5.3	1 4.5	1 5.9	-	-	2 7.7	2 14.3	2 5.1	2 4.9	1 3.3	3 6.0	3 8.8	1 2.2
Information from the PI	2 2.5	-	1 2.6	-	1 5.9	-	-	1 3.8	1 7.1	-	2 4.9	-	2 4.0	1 2.9	1 2.2
Label/label indications	1 1.2	-	-	1 4.5	-	-	-	1 3.8	-	-	1 2.4	1 3.3	-	-	1 2.2
Side effects/serious side effect/dangerous issue	7 8.8	-	2 5.3	4 18.2	1 5.9	-	2 6.9	3 11.5	2 14.3	3 7.7	4 9.8	3 10.0	4 8.0	4 11.8	3 6.5
General recall/general knowledge	6 7.5	-	3 7.9	2 9.1	1 5.9	-	3 10.3	1 3.8	2 14.3	-	6 14.6	-	6 12.0	3 8.8	3 6.5
Information from pharmaceutical representative/drug company	3 3.8	-	1 2.6	2 9.1	-	-	2 6.9	1 3.8	-	1 2.6	2 4.9	2 6.7	1 2.0	-	3 6.5
Titrate down the dose	1 1.2	-	1 2.6	-	-	-	1 3.4	-	-	1 2.6	-	-	1 2.0	-	1 2.2
Helps with urination	1 1.2	-	-	1 4.5	-	-	-	1 3.8	-	-	1 2.4	-	1 2.0	-	1 2.2
Common sense	5 6.2	-	3 7.9	1 4.5	1 5.9	-	5 17.2	-	-	3 7.7	2 4.9	1 3.3	4 8.0	2 5.9	3 6.5

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q8_1CODE Page 80
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q8. If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? ?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Not familiar with urinary dysfunction	1 1.2	-	1 2.6	-	-	-	-	1 3.8	-	-	1 2.4	-	1 2.0	-	1 2.2
Further research necessary	1 1.2	-	1 2.6	-	-	-	-	1 3.8	-	-	1 2.4	-	1 2.0	-	1 2.2
Urinary retention is acute issue that needs to be treated	2 2.5	-	2 5.3	-	-	1 11.1	-	-	1 7.1	1 2.6	1 2.4	1 3.3	1 2.0	-	2 4.3
Miscellaneous	2 2.5	-	2 5.3	-	-	-	2 6.9	-	-	1 2.6	1 2.4	1 3.3	1 2.0	2 5.9	-
Don't know/Do not recall	2 2.5	-	1 2.6	-	1 5.9	-	2 6.9	-	-	2 5.1	-	2 6.7	-	1 2.9	1 2.2
Total	85	3	41	24	17	9	31	28	15	42	43	30	55	36	49

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 81
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	65	2	25	27	11	8	22	16	16	40	25	25	40	21	44
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.5	-	-	1 3.7	-	-	-	-	-	1 2.5	-	1 4.0	-	-	1 2.3
Uncertain of maximum weekly dosage	5 7.7	-	3 12.0	1 3.7	1 9.1	-	3 13.6	1 6.2	1 6.2	2 5.0	3 12.0	3 12.0	2 5.0	2 9.5	3 6.8
Start at a lower dosage/ conservative when adjusting dosage	2 3.1	-	1 4.0	1 3.7	-	1 12.5	1 4.5	-	-	2 5.0	-	1 4.0	1 2.5	-	2 4.5
Thought answer provided was correct response	2 3.1	-	1 4.0	1 3.7	-	-	2 9.1	-	-	2 5.0	-	1 4.0	1 2.5	-	2 4.5
From internet/Google	1 1.5	-	1 4.0	-	-	-	-	-	-	1 2.5	-	-	1 2.5	-	1 2.3
50mg per day is minimal increased dosage/ recalled 50mg	1 1.5	-	1 4.0	-	-	-	-	-	1 6.2	-	1 4.0	1 4.0	-	-	1 2.3
General recall/recall from reading	5 7.7	-	3 12.0	1 3.7	1 9.1	1 12.5	3 13.6	-	1 6.2	2 5.0	3 12.0	-	5 12.5	3 14.3	2 4.5
150mg per day/do not exceed 150 mg per day150mg per day/do not exceed 150 mg per day	8 12.3	-	4 16.0	3 11.1	1 9.1	1 12.5	3 13.6	2 12.5	2 12.5	4 10.0	4 16.0	3 12.0	5 12.5	1 4.8	7 15.9

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 82
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
1200mg/maximum dose is 1200mg	1 1.5	-	-	1 3.7	-	-	1 4.5	-	-	1 2.5	-	-	1 2.5	-	1 2.3
Have not titrated patient to maximum dosage	1 1.5	-	-	1 3.7	-	-	1 4.5	-	-	1 2.5	-	-	1 2.5	-	1 2.3
Titrate slowly/titrate patient 50mg weekly/titration scale/dosing charts	5 7.7	-	3 12.0	1 3.7	1 9.1	1 12.5	2 9.1	1 6.2	1 6.2	2 5.0	3 12.0	2 8.0	3 7.5	-	5 11.4
From label/indications/samples to patients/package insert/the prescribing literature/from the information	11 16.9	-	1 4.0	8 29.6	2 18.2	2 25.0	3 13.6	4 25.0	2 12.5	7 17.5	4 16.0	7 28.0	4 10.0	4 19.0	7 15.9
From manufacturer's recommendation/pharmaceutical representative	4 6.2	-	1 4.0	2 7.4	1 9.1	1 12.5	1 4.5	1 6.2	-	2 5.0	2 8.0	2 8.0	2 5.0	4 19.0	-
No adverse effects/adverse effects limitations	1 1.5	-	1 4.0	-	-	-	-	-	1 6.2	1 2.5	-	1 4.0	-	-	1 2.3
Depends on patient/based on patient's tolerability and frequency of seizures	2 3.1	-	-	2 7.4	-	-	-	1 6.2	1 6.2	1 2.5	1 4.0	1 4.0	1 2.5	-	2 4.5
Past experience	2 3.1	-	-	1 3.7	1 9.1	-	-	-	2 12.5	1 2.5	1 4.0	-	2 5.0	1 4.8	1 2.3

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 83
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Titration should not be more than 300mg per week/300mg would be the reasonable maximum	2 3.1	1 50.0	1 4.0	-	-	-	-	-	2 12.5	1 2.5	1 4.0	1 4.0	1 2.5	2 9.5	-
Can increase by one pill per week	2 3.1	-	1 4.0	1 3.7	-	-	-	2 12.5	-	1 2.5	1 4.0	2 8.0	-	1 4.8	1 2.3
Not had a chance to look up the dosing recommendations/research of the drug/need further information/never researched the drug/would need to look up drug/not aware of this detail/never read prescribing information	1 1.5	-	1 4.0	-	-	1 12.5	-	-	-	1 2.5	-	-	1 2.5	-	1 2.3
No pediatric dosing recommendations	1 1.5	-	-	1 3.7	-	1 12.5	-	-	-	1 2.5	-	-	1 2.5	-	1 2.3
Not sure	2 3.1	1 50.0	1 4.0	-	-	1 12.5	1 4.5	-	-	2 5.0	-	1 4.0	1 2.5	2 9.5	-
Miscellaneous	1 1.5	-	-	-	1 9.1	-	-	-	1 6.2	-	1 4.0	-	1 2.5	1 4.8	-
Misunderstood question/Question is vague	1 1.5	-	-	1 3.7	-	-	-	1 6.2	-	1 2.5	-	-	1 2.5	-	1 2.3
Nothing	2 3.1	-	1 4.0	-	1 9.1	-	1 4.5	1 6.2	-	2 5.0	-	1 4.0	1 2.5	-	2 4.5

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q9_1CODE Page 84
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q9. According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Don't know/Do not recall	6	-	1	3	2	-	3	2	1	5	1	-	6	2	4
	9.2		4.0	11.1	18.2		13.6	12.5	6.2	12.5	4.0		15.0	9.5	9.1
Total	70	2	26	30	12	10	25	16	16	44	26	28	42	23	47

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 85
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	75	2	26	32	15	9	23	26	15	42	33	27	48	29	46
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.3	-	-	1 3.1	-	-	-	-	-	1 2.4	-	1 3.7	-	-	1 2.2
300mg per day is initial dose/100mg TID	7 9.3	-	4 15.4	2 6.2	1 6.7	1 11.1	1 4.3	3 11.5	2 13.3	3 7.1	4 12.1	1 3.7	6 12.5	3 10.3	4 8.7
Do not know initial dose/ unsure of initial dose/ unsure of initial dose for general population	7 9.3	-	3 11.5	2 6.2	2 13.3	2 22.2	3 13.0	2 7.7	-	4 9.5	3 9.1	3 11.1	4 8.3	3 10.3	4 8.7
200mg per day is initial dose	1 1.3	-	1 3.8	-	-	-	-	1 3.8	-	-	1 3.0	1 3.7	-	1 3.4	-
150mg per day is minimal dose for efficacy	2 2.7	-	2 7.7	-	-	-	-	1 3.8	1 6.7	2 4.8	-	1 3.7	1 2.1	1 3.4	1 2.2
150mg is for geriatric population/renal population	1 1.3	-	-	-	1 6.7	-	1 4.3	-	-	-	1 3.0	1 3.7	-	-	1 2.2
General recall/recall from reading	12 16.0	-	3 11.5	7 21.9	2 13.3	-	3 13.0	6 23.1	2 13.3	7 16.7	5 15.2	3 11.1	9 18.8	5 17.2	7 15.2
Titrate slowly/start low/ start low and go slow	6 8.0	-	-	4 12.5	2 13.3	-	3 13.0	2 7.7	1 6.7	2 4.8	4 12.1	3 11.1	3 6.2	2 6.9	4 8.7
150mg is initial dosage increase/not to exceed 150mg dosage increase per week	2 2.7	-	-	-	2 13.3	-	-	2 7.7	-	2 4.8	-	2 7.4	-	1 3.4	1 2.2

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 86
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
150mg is dose for general population/start patients with 150mg initially	3 4.0	-	-	3 9.4	-	-	-	2 7.7	1 6.7	1 2.4	2 6.1	1 3.7	2 4.2	-	3 6.5
Conservative response/initially conservative when prescribing	1 1.3	-	-	1 3.1	-	-	-	1 3.8	-	-	1 3.0	1 3.7	-	-	1 2.2
From label/indications/samples to patients/pkg insert/prescribing literature/ from the info/representative starter kits	15 20.0	-	7 26.9	4 12.5	4 26.7	2 22.2	6 26.1	2 7.7	5 33.3	8 19.0	7 21.2	6 22.2	9 18.8	7 24.1	8 17.4
300mg three times a day	1 1.3	-	-	1 3.1	-	-	1 4.3	-	-	-	1 3.0	-	1 2.1	-	1 2.2
Clinical trials/studies	1 1.3	-	-	-	1 6.7	1 11.1	-	-	-	1 2.4	-	1 3.7	-	1 3.4	-
Depends on patient/titrate based on patient's tolerability	1 1.3	-	-	1 3.1	-	-	1 4.3	-	-	1 2.4	-	-	1 2.1	-	1 2.2
Recommended dosing of POTIGA	3 4.0	-	3 11.5	-	-	-	1 4.3	1 3.8	1 6.7	-	3 9.1	-	3 6.2	1 3.4	2 4.3
Past prescribing experience	3 4.0	-	1 3.8	2 6.2	-	-	-	3 11.5	-	-	3 9.1	-	3 6.2	2 6.9	1 2.2
Wrong response provided/selected	2 2.7	1 50.0	-	1 3.1	-	-	1 4.3	-	1 6.7	2 4.8	-	2 7.4	-	1 3.4	1 2.2

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q10_1CODE Page 87
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q10: True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Not sure/uncertain/ unaware	4 5.3	1 50.0	3 11.5	-	-	2 22.2	-	1	1 7.1	3 7.1	1 3.0	2 7.4	2 4.2	1 3.4	3 6.5
Miscellaneous	3 4.0	-	1 3.8	-	2 13.3	1 11.1	1 4.3	-	1 6.7	2 4.8	1 3.0	-	3 6.2	2 6.9	1 2.2
Don't know/Do not recall	3 4.0	-	-	3 9.4	-	-	2 8.7	1 3.8	-	3 7.1	-	-	3 6.2	1 3.4	2 4.3
Total	79	2	28	32	17	9	24	28	16	42	37	29	50	32	47

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 88
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	20	1	6	8	5	2	4	7	5	8	12	9	11	10	10
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	1 5.0	-	-	1 12.5	-	-	-	-	-	1 12.5	-	1 11.1	-	-	1 10.0
General recall/recall from reading/general understanding	2 10.0	-	-	1 12.5	1 20.0	-	-	1 14.3	1 20.0	1 12.5	1 8.3	1 11.1	1 9.1	2 20.0	-
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	2 10.0	-	-	1 12.5	1 20.0	-	1 25.0	1 14.3	-	-	2 16.7	2 22.2	-	-	2 20.0
A safe dose can be found for patients	1 5.0	-	1 16.7	-	-	-	1 25.0	-	-	-	1 8.3	-	1 9.1	1 10.0	-
Unaware of precautions/ problems/issues/ contraindications	2 10.0	-	1 16.7	-	1 20.0	-	-	1 14.3	1 20.0	1 12.5	1 8.3	1 11.1	1 9.1	1 10.0	1 10.0
Unaware of renal/hepatic issues/not aware of specific renal/hepatic issues	2 10.0	-	2 33.3	-	-	1 50.0	-	-	1 20.0	1 12.5	1 8.3	1 11.1	1 9.1	2 20.0	-

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ACODE Page 89
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11A: Moderate to severe renal or hepatic impairment: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Not sure/uncertain/ unaware	2 10.0	1 100.0	-	1 12.5	-	1 50.0	-	1 14.3	-	1 12.5	1 8.3	2 22.2	-	1 10.0	1 10.0
Miscellaneous	1 5.0	-	-	-	1 20.0	-	-	-	1 20.0	-	1 8.3	-	1 9.1	-	1 10.0
Don't know/Do not recall	7 35.0	-	2 33.3	4 50.0	1 20.0	-	2 50.0	3 42.9	1 20.0	3 37.5	4 33.3	1 11.1	6 54.5	3 30.0	4 40.0
Total	20	1	6	8	5	2	4	7	5	8	12	9	11	10	10

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 90
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	78	3	26	33	16	7	31	22	15	37	41	29	49	30	48
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	1 1.3	-	-	1 3.0	-	-	-	-	-	1 2.7	-	1 3.4	-	-	1 2.1
General recall/recall from reading/general understanding	3 3.8	-	-	3 9.1	-	-	1 3.2	2 9.1	-	-	3 7.3	-	3 6.1	1 3.3	2 4.2
Worsen the condition/ because of side effects/ might cause problems with condition	1 1.3	-	-	1 3.0	-	-	1 3.2	-	-	1 2.7	-	1 3.4	-	1 3.3	-
Conservative response/ initially conservative when prescribing/lower starting dose	1 1.3	-	-	1 3.0	-	-	1 3.2	-	-	1 2.7	-	-	1 2.0	-	1 2.1
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	5 6.4	-	-	3 9.1	2 12.5	-	2 6.5	1 4.5	2 13.3	2 5.4	3 7.3	4 13.8 m	1 2.0	1 3.3	4 8.3
No information available/ could not find the information	2 2.6	-	-	-	2 12.5	1 14.3	-	-	1 6.7	1 2.7	1 2.4	-	2 4.1	1 3.3	1 2.1

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1BCODE Page 91
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11B: Moderate to severe Crohn's disease: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Never heard about this/ never heard one way or the other	7 9.0	2 66.7	3 11.5	2 6.1	-	1 14.3	3 9.7	2 9.1	1 6.7	2 5.4	5 12.2	2 6.9	5 10.2	3 10.0	4 8.3
Urinary contraindications/ contraindicated	3 3.8	-	2 7.7	1 3.0	-	-	-	1 4.5	2 13.3	-	3 7.3	1 3.4	2 4.1	3 10.0	-
Unaware of precautions/ problems/issues/ contraindications	15 19.2	1 33.3	3 11.5	5 15.2	6 37.5 c	1 14.3	5 16.1	5 22.7	3 20.0	7 18.9	8 19.5	8 27.6	7 14.3	7 23.3	8 16.7
Not sure/uncertain/ unaware	12 15.4	-	5 19.2	5 15.2	2 12.5	-	5 16.1	5 22.7	2 13.3	4 10.8	8 19.5	4 13.8	8 16.3	4 13.3	8 16.7
Miscellaneous	7 9.0	-	3 11.5	2 6.1	2 12.5	-	4 12.9	2 9.1	1 6.7	4 10.8	3 7.3	1 3.4	6 12.2	3 10.0	4 8.3
Misunderstood question/ Question is vague	1 1.3	-	1 3.8	-	-	-	-	-	-	1 2.7	-	-	1 2.0	-	1 2.1
Don't know/Do not recall	20 25.6	-	9 34.6	9 27.3	2 12.5	4 57.1 hi	9 29.0	4 18.2	3 20.0	13 35.1 k	7 17.1	7 24.1	13 26.5	6 20.0	14 29.2
Total	78	3	26	33	16	7	31	22	15	37	41	29	49	30	48

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 92
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	60	3	21	21	15	7	23	14	13	33	27	24	36	20	40
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	1 1.7	-	-	1 4.8	-	-	-	-	-	1 3.0	-	1 4.2	-	-	1 2.5
Patients need to be monitored	1 1.7	-	1 4.8	-	-	-	-	-	1 7.7	-	1 3.7	1 4.2	-	-	1 2.5
Use with caution/a precaution	1 1.7	-	1 4.8	-	-	-	-	-	1 7.7	-	1 3.7	-	1 2.8	1 5.0	-
Worsen the condition/ because of side effects/ might cause problems with condition	1 1.7	-	-	1 4.8	-	-	1 4.3	-	-	1 3.0	-	1 4.2	-	1 5.0	-
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	3 5.0	-	-	2 9.5	1 6.7	-	2 8.7	1 7.1	-	1 3.0	2 7.4	3 12.5	-	1 5.0	2 5.0
No information available/ could not find the information	1 1.7	-	-	-	1 6.7	1 14.3	-	-	-	1 3.0	-	-	1 2.8	-	1 2.5
Never heard about this/ never heard one way or the other	2 3.3	-	1 4.8	-	1 6.7	-	-	1 7.1	1 7.7	-	2 7.4	-	2 5.6	1 5.0	1 2.5

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1CCODE Page 93
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11C: Moderate to severe asthma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Unaware of precautions/ problems/issues/ contraindications	8 13.3	1 33.3	2 9.5	3 14.3	2 13.3	1 14.3	2 8.7	-	4 30.8	3 9.1	5 18.5	4 16.7	4 11.1	2 10.0	6 15.0
Wrong response provided/ selected	2 3.3	-	2 9.5	-	-	-	-	1 7.1	1 7.7	-	2 7.4	-	2 5.6	1 5.0	1 2.5
Answer should be "yes"	1 1.7	-	-	-	1 6.7	-	-	-	1 7.7	-	1 3.7	-	1 2.8	1 5.0	-
Not sure/uncertain/ unaware	7 11.7	1 33.3	3 14.3	3 14.3	-	-	4 17.4	2 14.3	1 7.7	3 9.1	4 14.8	3 12.5	4 11.1	2 10.0	5 12.5
Miscellaneous	11 18.3	-	5 23.8	3 14.3	3 20.0	3 42.9	4 17.4	2 14.3	2 15.4	6 18.2	5 18.5	1 4.2	10 27.8	4 20.0	7 17.5
Don't know/Do not recall	23 38.3	1 33.3	7 33.3	9 42.9	6 40.0	2 28.6	11 47.8	7 50.0	2 15.4	18 54.5	5 18.5	11 45.8	12 33.3	8 40.0	15 37.5
Total	62	3	22	22	15	7	24	14	14	34	28	25	37	22	40

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 94
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	74	-	36	24	14	5	30	20	17	37	37	34	40	28	46
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA/never read literature on POTIGA	1 1.4	-	-	1 4.2	-	-	-	-	-	1 2.7	-	1 2.9	-	-	1 2.2
Depends on the patient	1 1.4	-	-	1 4.2	-	-	-	1 5.0	-	1 2.7	-	1 2.9	-	-	1 2.2
Odds of BPH/urinary retention increase after age 65/higher rate of renal problems	3 4.1	-	1 2.8	1 4.2	1 7.1	-	-	3 15.0	-	2 5.4	1 2.7	2 5.9	1 2.5	2 7.1	1 2.2
Personal prescribing history	1 1.4	-	1 2.8	-	-	-	-	1 5.0	-	-	1 2.7	-	1 2.5	-	1 2.2
No upper age limit/ unaware of upper age limit/no age limit	9 12.2	-	5 13.9	3 12.5	1 7.1	-	4 13.3	1 5.0	4 23.5	5 13.5	4 10.8	4 11.8	5 12.5	4 14.3	5 10.9
Data from past research/ studies/clinical trials	1 1.4	-	1 2.8	-	-	-	1 3.3	-	-	1 2.7	-	-	1 2.5	1 3.6	-
Patients need to be monitored	1 1.4	-	-	-	1 7.1	1 20.0	-	-	-	1 2.7	-	1 2.9	-	1 3.6	-
Use with caution/a precaution	4 5.4	-	1 2.8	2 8.3	1 7.1	-	1 3.3	1 5.0	2 11.8	2 5.4	2 5.4	2 5.9	2 5.0	1 3.6	3 6.5

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 95
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Worsen the condition/ because of side effects/ might cause problems with condition	2 2.7	-	-	1 4.2	1 7.1	-	1 3.3	1 5.0	-	1 2.7	1 2.7	-	2 5.0	1 3.6	1 2.2
From label/indications/ samples to patients/ package insert/the prescribing literature/ from the information/ representative starter kits/pharmaceutical rep	8 10.8	-	3 8.3	1 4.2	4 28.6 d	-	4 13.3	2 10.0	2 11.8	3 8.1	5 13.5	5 14.7	3 7.5	2 7.1	6 13.0
A safe dose can be found for patients	1 1.4	-	1 2.8	-	-	-	1 3.3	-	-	-	1 2.7	-	1 2.5	1 3.6	-
Unaware of precautions/ problems/issues/ contraindications	8 10.8	-	5 13.9	2 8.3	1 7.1	1 20.0	3 10.0	-	4 23.5	5 13.5	3 8.1	3 8.8	5 12.5	3 10.7	5 10.9
Caution when using in patients 65+/not recommended for 65+ patients	2 2.7	-	1 2.8	1 4.2	-	-	-	2 10.0	-	-	2 5.4	2 5.9	-	1 3.6	1 2.2
Treat pediatric patients only/do not treat adult populations	2 2.7	-	-	2 8.3	-	1 20.0	-	1 5.0	-	1 2.7	1 2.7	1 2.9	1 2.5	-	2 4.3
Not sure/uncertain/ unaware	8 10.8	-	5 13.9	2 8.3	1 7.1	-	4 13.3	2 10.0	2 11.8	1 2.7	7 18.9 J	4 11.8	4 10.0	1 3.6	7 15.2 n

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1DCODE Page 96
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11D: Patients over the age of 65 years: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	
Miscellaneous	13 17.6	-	7 19.4	3 12.5	3 21.4	-	8 26.7 H	1 5.0	3 17.6	7 18.9	6 16.2	3 8.8	10 25.0 1	6 21.4	7 15.2
Don't know/Do not recall	9 12.2	-	5 13.9	4 16.7	-	2 40.0	3 10.0	4 20.0	-	6 16.2	3 8.1	5 14.7	4 10.0	4 14.3	5 10.9
Total	74	-	36	24	14	5	30	20	17	37	37	34	40	28	46

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q11_1ECODEA Page 97
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q11E: Moderate to severe glaucoma: The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient	
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 98
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	44	3	21	14	6	1	13	16	11	20	24	19	25	17	27
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	4 9.1	-	2 9.5	2 14.3	-	-	-	2 12.5	1 9.1	1 5.0	3 12.5	1 5.3	3 12.0	1 5.9	3 11.1
Unaware of AE time frame/ never heard of the timeframe/unsure of the timeframe/did not recall specific timeframe	8 18.2	2 66.7 C	1 4.8	3 21.4	2 33.3	-	5 38.5	-	3 27.3	6 30.0 k	2 8.3	5 26.3	3 12.0	5 29.4	3 11.1
Not familiar with studies referenced in statement	3 6.8	-	1 4.8	2 14.3	-	-	1 7.7	1 6.2	1 9.1	1 5.0	2 8.3	1 5.3	2 8.0	1 5.9	2 7.4
Do not recall any data on this/do not recall this fact	3 6.8	-	-	2 14.3	1 16.7	-	2 15.4	-	1 9.1	1 5.0	2 8.3	2 10.5	1 4.0	2 11.8	1 3.7
Timing is usual for most side effects	1 2.3	-	-	-	1 16.7	-	-	-	1 9.1	-	1 4.2	1 5.3	-	1 5.9	-
AE's can occur at any time/soon after starting medicine	1 2.3	-	-	1 7.1	-	-	1 7.7	-	-	1 5.0	-	1 5.3	-	1 5.9	-
General recall	1 2.3	-	1 4.8	-	-	-	-	1 6.2	-	-	1 4.2	-	1 4.0	-	1 3.7
AE's may not be reported within 6 mos/can occur after 6 mos	2 4.5	-	1 4.8	1 7.1	-	-	-	1 6.2	1 9.1	-	2 8.3	2 10.5	-	-	2 7.4

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q12_1CODE Page 99
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q12: True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Clinical trials still pending/will require post-market data/research	2 4.5	1 33.3	1 4.8	- -	- -	- -	1 7.7	- -	- -	2 10.0	- -	- -	2 8.0	- -	2 7.4
AE's should be reported immediately/earlier than 6 mos	1 2.3	- -	- -	1 7.1	- -	- -	- -	1 6.2	- -	- -	1 4.2	1 5.3	- -	- -	1 3.7
Label/PI/resources do not mention	2 4.5	- -	- -	1 7.1	1 16.7	- -	1 7.7	1 6.2	- -	- -	2 8.3	- -	2 8.0	- -	2 7.4
From label/indications/samples to patients/package insert/the prescribing literature/from the information/representative starter kits/pharmaceutical rep/internet research	2 4.5	- -	1 4.8	1 7.1	- -	- -	- -	1 6.2	- -	1 5.0	1 4.2	1 5.3	1 4.0	- -	2 7.4
Should have answered "yes"/true statement	2 4.5	- -	1 4.8	- -	1 16.7	- -	- -	2 12.5	- -	1 5.0	1 4.2	1 5.3	1 4.0	- -	2 7.4
Not sure/uncertain/unaware	1 2.3	- -	1 4.8	- -	- -	- -	1 7.7	- -	- -	1 5.0	- -	- -	1 4.0	1 5.9	- -
Miscellaneous	3 6.8	- -	1 4.8	1 7.1	1 16.7	- -	- -	2 12.5	1 9.1	2 10.0	1 4.2	2 10.5	1 4.0	2 11.8	1 3.7
Don't know/Do not recall	11 25.0	- -	10 47.6	1 7.1	- -	1 100.0	1 7.7	5 31.2	4 36.4	3 15.0	8 33.3	3 15.8	8 32.0	5 29.4	6 22.2
Total	47	3	21	16	7	1	13	17	13	20	27	21	26	19	28

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 100
May 15, 2013

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Total Answering	60	2	26	21	11	6	23	19	10	30	30	22	38	24	36
Lack of familiarity/ never heard of POTIGA/ never dispensed POTIGA/ no experience with POTIGA	1 1.7	-	-	1 4.8	-	-	-	-	-	1 3.3	-	1 4.5	-	-	1 2.8
All are high risk groups/ need to be monitored	2 3.3	-	-	1 4.8	1 9.1	1 16.7	1 4.3	-	-	2 6.7	-	-	2 5.3	1 4.2	1 2.8
Patients cannot report symptoms/problems	8 13.3	-	3 11.5	3 14.3	2 18.2	-	3 13.0	3 15.8	2 20.0	1 3.3	7 23.3 J	3 13.6	5 13.2	6 25.0 O	2 5.6
Patients are at higher risk for BPH/voiding difficulty/urinary retention/underlying urinary retention concerns	23 38.3	1 50.0	9 34.6	7 33.3	6 54.5	2 33.3	9 39.1	6 31.6	6 60.0	12 40.0	11 36.7	13 59.1 M	10 26.3	8 33.3	15 41.7
Side effects/known side effect(s) of urinary retention	3 5.0	-	2 7.7	-	1 9.1	-	1 4.3	2 10.5	-	1 3.3	2 6.7	1 4.5	2 5.3	-	3 8.3
Approach on a patient by patient basis	1 1.7	-	1 3.8	-	-	-	-	-	1 10.0	-	1 3.3	-	1 2.6	-	1 2.8
General recall	2 3.3	-	-	2 9.5	-	-	1 4.3	1 5.3	-	1 3.3	1 3.3	1 4.5	1 2.6	1 4.2	1 2.8
Previous knowledge/past experience	2 3.3	-	-	2 9.5	-	-	2 8.7	-	-	2 6.7	-	-	2 5.3	1 4.2	1 2.8

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.

Table Q13_1CODEA Page 101
May 15, 2013
(Continued)

WEUKBRE5993 ARISTOTLE YR 1
Concentrics Research LLC
Confidential and Proprietary
Physician's Banner

Q13. Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention?

Phys	Years Prescribing AED Drugs				Months Prescribing POTIGA				# Pats Presb		# Precrpt AEDs		Tot Patient		
	< 5	5-15	16-25	16+	< 1	1-3	4-6	7+	1-2	3+	<= 50	> 50	<=1000	> 1000	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)
Understanding of product labeling	1 1.7	-	1 3.8	-	-	-	1 4.3	-	-	1 3.3	-	-	1 2.6	1 4.2	-
Patients with kidney/stomach issues monitored closely/NSAIDS patients/effect kidney	1 1.7	-	1 3.8	-	-	-	1 4.3	-	-	1 3.3	-	-	1 2.6	1 4.2	-
From label/indications/samples to patients/package insert/the prescribing literature/from the information/representative starter kits/pharmaceutical rep/internet research, past clinical research	4 6.7	-	3 11.5	1 4.8	-	-	2 8.7	1 5.3	-	2 6.7	2 6.7	2 9.1	2 5.3	1 4.2	3 8.3
Make situation worse	1 1.7	-	1 3.8	-	-	1 16.7	-	-	-	1 3.3	-	1 4.5	-	-	1 2.8
Not sure/uncertain/unaware	2 3.3	-	1 3.8	1 4.8	-	-	2 8.7	-	-	2 6.7	-	-	2 5.3	1 4.2	1 2.8
Miscellaneous	11 18.3	1 50.0	4 15.4	4 19.0	2 18.2	2 33.3	2 8.7	6 31.6	1 10.0	4 13.3	7 23.3	3 13.6	8 21.1	5 20.8	6 16.7
Don't know/Do not recall	3 5.0	-	2 7.7	-	1 9.1	-	-	2 10.5	1 10.0	-	3 10.0	-	3 7.9	2 8.3	1 2.8
Total	65	2	28	22	13	6	25	21	11	31	34	25	40	28	37

Comparison Groups: BCDE/FGHI/JK/LM/NO
Independent T-Test for Means, Independent Z-Test for Percentages (unpooled proportions)
Uppercase letters indicate significance at the 95% level.
Lowercase letters indicate significance at the 90% level.